Altria (MO) 10-Q 30 Apr 20 2020 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2020	Apr. 21, 2020
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2020
Document Transition Report	false
Entity File Number	1-08940
Entity Registrant Name	Altria Group, Inc.
Entity Incorporation, State or Country Code	VA
Entity Tax Identification Number	13-3260245
Entity Address, Address Line One	6601 West Broad Street,
Entity Address, City or Town	Richmond,
Entity Address, State or Province	VA
Entity Address, Postal Zip Code	23230
City Area Code	804
Local Phone Number	274-2200
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		1,858,368,058
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Entity Central Index Key	0000764180
Current Fiscal Year End Date	--12-31
Common Stock, $0.33 1/3 par value [Member]
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, $0.33 1/3 par value
Trading Symbol	MO
Security Exchange Name	NYSE
1.000% Notes due 2023 [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.000% Notes due 2023
Trading Symbol	MO23A
Security Exchange Name	NYSE
1.700% Notes due 2025 [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.700% Notes due 2025
Trading Symbol	MO25
Security Exchange Name	NYSE
2.200% Notes due 2027 [Member]
Entity Information [Line Items]
Title of 12(b) Security	2.200% Notes due 2027
Trading Symbol	MO27
Security Exchange Name	NYSE
3.125% Notes due 2031 [Member]
Entity Information [Line Items]
Title of 12(b) Security	3.125% Notes due 2031
Trading Symbol	MO31
Security Exchange Name	NYSE

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018
Assets
Cash and cash equivalents	$ 5,616,000,000	$ 2,117,000,000
Receivables	147,000,000	152,000,000
Inventories:
Leaf tobacco	895,000,000	874,000,000
Other raw materials	193,000,000	192,000,000
Work in process	467,000,000	696,000,000
Finished product	451,000,000	531,000,000
Inventory, net	2,006,000,000	2,293,000,000
Other current assets	166,000,000	262,000,000
Total current assets	7,935,000,000	4,824,000,000
Property, plant and equipment, at cost	5,103,000,000	5,074,000,000
Less accumulated depreciation	3,106,000,000	3,075,000,000
Property, plant and equipment, net	1,997,000,000	1,999,000,000
Goodwill	5,177,000,000	5,177,000,000
Other intangible assets, net	12,668,000,000	12,687,000,000
Investments in equity securities	23,861,000,000	23,581,000,000
Other assets	980,000,000	1,003,000,000
Total Assets	52,618,000,000	49,271,000,000
Liabilities
Short-term borrowings	3,000,000,000	0
Current portion of long-term debt	0	1,000,000,000
Accounts payable	278,000,000	325,000,000
Accrued liabilities:
Marketing	467,000,000	393,000,000
Settlement charges	4,419,000,000	3,346,000,000
Other	1,032,000,000	1,533,000,000
Income taxes	393,000,000	12,000,000
Dividends payable	1,565,000,000	1,565,000,000
Total current liabilities	11,154,000,000	8,174,000,000
Long-term debt	26,971,000,000	27,042,000,000
Deferred income taxes	5,191,000,000	5,083,000,000
Accrued pension costs	427,000,000	473,000,000
Accrued postretirement health care costs	1,798,000,000	1,797,000,000
Other liabilities	402,000,000	345,000,000
Total liabilities	45,943,000,000	42,914,000,000
Contingencies (Note 11)
Redeemable noncontrolling interest	38,000,000	38,000,000
Stockholders’ Equity
Common stock, par value $0.33 1/3 per share (2,805,961,317 shares issued)	935,000,000	935,000,000
Additional paid-in capital	5,959,000,000	5,970,000,000
Earnings reinvested in the business	36,528,000,000	36,539,000,000
Accumulated other comprehensive losses	(2,533,000,000)	(2,864,000,000)
Cost of repurchased stock (947,593,259 shares at March 31, 2020 and 947,979,763 shares at December 31, 2019)	(34,346,000,000)	(34,358,000,000)
Total stockholders’ equity attributable to Altria	6,543,000,000	6,222,000,000
Noncontrolling interests	94,000,000	97,000,000
Total stockholders’ equity	6,637,000,000	6,319,000,000	$ 14,081,000,000	$ 14,789,000,000
Total Liabilities and Stockholders’ Equity	$ 52,618,000,000	$ 49,271,000,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common stock, par value (usd per share)	$ 0.3333	$ 0.3333
Common stock, shares issued (shares)	2,805,961,317	2,805,961,317
Shares repurchased (shares)	947,593,259	947,979,763

Condensed Consolidated Statemen

Condensed Consolidated Statements of Earnings - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Net revenues	$ 6,359	$ 5,628
Cost of sales	2,173	1,578
Excise taxes on products	1,313	1,239
Gross profit	2,873	2,811
Marketing, administration and research costs	537	533
Asset impairment and exit costs	0	40
Operating income (expense)	2,336	2,238
Interest and other debt expense, net	275	384
Net periodic benefit income, excluding service cost	(27)	(1)
Earnings from equity investments	(157)	(86)
Loss on Cronos-related financial instruments	137	425
Earnings (losses) before income taxes and equity earnings of subsidiaries	2,108	1,516
Provision for income taxes	558	395
Net earnings	1,550	1,121
Net (earnings) losses attributable to noncontrolling interests	2	(1)
Net earnings attributable to Altria	$ 1,552	$ 1,120
Per share data:
Basic and diluted earnings per share attributable to Altria (in usd per share)	$ 0.83	$ 0.60

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Earnings - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement of Comprehensive Income [Abstract]
Net earnings	$ 1,550	$ 1,121
Other comprehensive earnings (losses), net of deferred income taxes:
Benefit plans	21	29
ABI	298	(199)
Currency translation adjustments and other	12	0
Other comprehensive earnings (losses), net of deferred income taxes	331	(170)
Comprehensive earnings	1,881	951
Comprehensive (earnings) losses attributable to noncontrolling interests	2	(1)
Comprehensive earnings attributable to Altria	$ 1,883	$ 950

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Millions		Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Earnings Reinvested in the Business [Member]	Accumulated Other Comprehensive Losses [Member]	Cost of Repurchased Stock [Member]	Non-controlling Interests [Member]
Beginning balance at Dec. 31, 2018		$ 14,789	$ 935	$ 5,961	$ 43,962	$ (2,547)	$ (33,524)	$ 2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	[1]	1,120			1,120
Other comprehensive earnings (losses), net of deferred income taxes		(170)				(170)
Stock award activity		(7)		(18)			11
Cash dividends declared		(1,500)			(1,500)
Repurchases of common stock		(151)					(151)
Ending balance at Mar. 31, 2019		14,081	935	5,943	43,582	(2,717)	(33,664)	2
Beginning balance at Dec. 31, 2019		6,319	935	5,970	36,539	(2,864)	(34,358)	97
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	[1]	1,549			1,552			(3)
Other comprehensive earnings (losses), net of deferred income taxes		331				331
Stock award activity		1		(11)			12
Cash dividends declared		(1,563)			(1,563)
Ending balance at Mar. 31, 2020		$ 6,637	$ 935	$ 5,959	$ 36,528	$ (2,533)	$ (34,346)	$ 94
[1]	Amounts attributable to noncontrolling interests for the three months ended March 31, 2020 and 2019 exclude net earnings of $1 million due to the redeemable noncontrolling interest related to Stag’s Leap Wine Cellars , which is reported in the mezzanine equity section on the condensed consolidated balance sheets.

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement of Stockholders' Equity [Abstract]
Net earnings attributable to noncontrolling interests	$ 1	$ 1
Dividends declared (usd per share)	$ 0.84	$ 0.80

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash Provided by (Used in) Operating Activities
Net earnings	$ 1,550	$ 1,121
Adjustments to reconcile net earnings to operating cash flows:
Depreciation and amortization	65	53
Deferred income tax provision (benefit)	26	(72)
Earnings from equity investments	(157)	(86)
Loss on Cronos-related financial instruments	137	425
Asset impairment and exit costs, net of cash paid	(23)	17
Cash effects of changes:
Receivables	5	(16)
Inventories	(5)	(25)
Accounts payable	(45)	(189)
Income taxes	495	471
Accrued liabilities and other current assets	(421)	(513)
Accrued settlement charges	1,073	913
Pension plan contributions	(4)	(3)
Pension provisions and postretirement, net	(20)	(8)
Other, net	453	201
Net cash provided by (used in) operating activities	3,129	2,289
Cash Provided by (Used in) Investing Activities
Capital expenditures	(52)	(38)
Investment in Cronos	0	(1,831)
Other, net	0	(81)
Net cash provided by (used in) investing activities	(52)	(1,950)
Cash Provided by (Used in) Financing Activities
Proceeds from short-term borrowings	3,000	0
Repayment of short-term borrowings	0	(12,800)
Long-term debt issued	0	16,265
Long-term debt repaid	(1,000)	0
Repurchases of common stock	0	(151)
Dividends paid on common stock	(1,563)	(1,502)
Other, net	(10)	(129)
Net cash provided by (used in) financing activities	427	1,683
Cash, cash equivalents and restricted cash:
Increase (decrease)	3,504	2,022
Balance at beginning of period	2,160	1,433
Balance at end of period	5,664	3,455
Cash, cash equivalents and restricted cash	$ 5,664	$ 3,455

Background and Basis of Present

Background and Basis of Presentation	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background and Basis of Presentation	Background and Basis of Presentation: Background When used in these notes, the term "Altria” refers to Altria Group, Inc. and its subsidiaries, unless otherwise specified or unless otherwise required. At March 31, 2020 , Altria Group, Inc.’s wholly-owned subsidiaries included Philip Morris USA Inc. (“PM USA”), which is engaged in the manufacture and sale of cigarettes in the United States; John Middleton Co. (“Middleton”), which is engaged in the manufacture and sale of machine-made large cigars and pipe tobacco and is a wholly-owned subsidiary of PM USA; Sherman Group Holdings, LLC and its subsidiaries (“Nat Sherman”), which are engaged in the manufacture and sale of super premium cigarettes and the sale of premium cigars; UST LLC (“UST”), which through its wholly-owned subsidiaries, including U.S. Smokeless Tobacco Company LLC (“USSTC”) and Ste. Michelle Wine Estates Ltd. (“Ste. Michelle”), is engaged in the manufacture and sale of moist smokeless tobacco (“MST”) and snus products and wine; and Philip Morris Capital Corporation (“PMCC”), which maintains a portfolio of finance assets, substantially all of which are leveraged leases. In addition, Altria owned an 80% interest in Helix Innovations LLC (“Helix”), which is engaged in the manufacture and sale of oral nicotine pouches. Other Altria wholly-owned subsidiaries included Altria Group Distribution Company, which provides sales and distribution services to certain Altria operating subsidiaries, and Altria Client Services LLC, which provides various support services in areas such as legal, regulatory, consumer engagement, finance, human resources and external affairs to Altria and its subsidiaries. Altria’s access to the operating cash flows of its wholly-owned subsidiaries consists of cash received from the payment of dividends and distributions, and the payment of interest on intercompany loans by its subsidiaries. At March 31, 2020 , Altria’s significant wholly-owned subsidiaries were not limited by long-term debt or other agreements in their ability to pay cash dividends or make other distributions with respect to their equity interests. At March 31, 2020 , Altria had a 10.1% ownership in Anheuser-Busch InBev SA/NV (“ABI”), which Altria accounts for under the equity method of accounting using a one-quarter lag. Altria receives cash dividends on its interest in ABI and will continue to do so as long as ABI pays dividends. At March 31, 2020 , Altria had a 35% economic interest in JUUL Labs, Inc. (“JUUL”), which Altria accounts for as an investment in an equity security. JUUL is engaged in the manufacture and sale of e-vapor products globally and is the U.S. leader in e-vapor. During the third quarter of 2019, Helix acquired Burger Söhne Holding and its subsidiaries as well as certain affiliated companies (the “Burger Group”) that are engaged in the manufacture and sale of on! oral nicotine pouches. At closing, Altria indirectly owned an 80% interest in Helix, for which Altria paid $353 million in third quarter of 2019. The financial results of Helix are included in Altria’s condensed consolidated financial statements as part of its oral tobacco products segment (formerly smokeless products segment), with the 20% minority ownership interest in Helix (held by the former shareholders of the Burger Group) included as a noncontrolling interest. The final purchase price allocation, which is subject to post-closing adjustments, will be completed by the third quarter of 2020. In March 2019, Altria completed its acquisition of a 45% ownership in Cronos Group Inc. (“Cronos”), a global cannabinoid company headquartered in Toronto, Canada. At March 31, 2020 , Altria had a 45% ownership in Cronos, which Altria accounts for under the equity method of accounting using a one-quarter lag. For further discussion of Altria’s investments in equity securities, see Note 4 . Investments in Equity Securities . Share Repurchases In January 2018, Altria’s Board of Directors (the “Board of Directors”) authorized a new $1.0 billion share repurchase program that it expanded to $2.0 billion in May 2018 (as expanded, the “January 2018 share repurchase program”). In June 2019, Altria completed the January 2018 share repurchase program, under which it purchased a total of 34.0 million shares of its common stock at an average price of $58.86 per share. In July 2019, the Board of Directors authorized a new $1.0 billion share repurchase program (the “July 2019 share repurchase program”). During the first quarter of 2020, there were no share repurchases made under the July 2019 share repurchase program. In April 2020, the Board of Directors rescinded the $500 million remaining in the July 2019 share repurchase program to strengthen Altria’s liquidity position amidst the COVID-19 pandemic. Altria’s share repurchase activity for the three months ended March 31, 2019 was as follows: (in millions, except per share data) 2019 Total number of shares repurchased 2.7 Aggregate cost of shares repurchased $ 151 Average price per share of shares repurchased $ 56.34 Basis of Presentation The interim condensed consolidated financial statements of Altria are unaudited. It is the opinion of Altria’s management that all adjustments necessary for a fair statement of the interim results presented have been reflected in the interim condensed consolidated financial statements. All such adjustments were of a normal recurring nature. Net revenues and net earnings for any interim period are not necessarily indicative of results that may be expected for the entire year. In the first quarter of 2020, Altria renamed its smokeless products segment as the oral tobacco products segment. These statements should be read in conjunction with the audited consolidated financial statements and related notes, which appear in Altria’s Annual Report on Form 10-K for the year ended December 31, 2019. On January 1, 2020, Altria adopted Accounting Standards Update (“ASU”) No. 2016-13, Measurement of Credit Losses on Financial Instruments and all related ASU amendments (collectively “ASU No. 2016-13”). This guidance replaces the current incurred loss impairment methodology for recognizing credit losses for financial assets with a methodology that reflects the entity’s current estimate of all expected credit losses and requires consideration of a broader range of reasonable and supportable information for estimating credit losses. The adoption of ASU No. 2016-13 did not have a material impact on Altria’s condensed consolidated financial statements. Additionally, on January 1, 2020, Altria adopted ASU No. 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (“ASU No. 2018-15”). This guidance aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The adoption of ASU No. 2018-15 did not have a material impact on Altria’s condensed consolidated financial statements. For a description of issued accounting guidance applicable to, but not yet adopted by, Altria, see Note 13 . New Accounting Guidance Not Yet Adopted . Certain immaterial prior year amounts have been reclassified to conform with the current year’s presentation.

Revenues from Contracts with Cu

Revenues from Contracts with Customers	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Revenues from Contracts with Customers	Revenues from Contracts with Customers: Altria disaggregates net revenues based on product type. For further discussion, see Note 9 . Segment Reporting . Altria’s businesses offer cash discounts to customers for prompt payment and calculate cash discounts as a percentage of the list price based on historical experience and agreed-upon payment terms. Altria’s businesses record an allowance for cash discounts, which is included as a contra-asset against receivables on Altria’s condensed consolidated balance sheets. Cash discounts at March 31, 2020 and December 31, 2019 were de minimis, and there were no differences between amounts recorded as an allowance for cash discounts and cash discounts subsequently given to customers. Altria’s businesses that receive payments in advance of product shipment record such payments as deferred revenue. These payments are included in other accrued liabilities on Altria’s condensed consolidated balance sheets until control of such products is obtained by the customer. Deferred revenue was $219 million and $362 million at March 31, 2020 and December 31, 2019 , respectively. When cash is received in advance of product shipment, Altria’s businesses satisfy their performance obligations within three days of receiving payment. At March 31, 2020 and December 31, 2019 , there were no differences between amounts recorded as deferred revenue and amounts subsequently recognized as revenue. Receivables, which primarily reflect sales of wine produced and/or distributed by Ste. Michelle, were $147 million and $152 million at March 31, 2020 and December 31, 2019 , respectively. At March 31, 2020 and December 31, 2019 , there were no expected differences between amounts recorded and subsequently received, and Altria’s businesses did not record an allowance for doubtful accounts against these receivables. Altria’s businesses record an allowance for returned goods, which is included in other accrued liabilities on Altria’s condensed consolidated balance sheets. While all of Altria’s tobacco operating companies sell tobacco products with dates relative to freshness as printed on product packaging, it is USSTC’s policy to accept authorized sales returns from its customers for products that have passed such dates due to the limited shelf life of USSTC’s MST and snus products. Altria’s businesses record estimated sales returns, which are based principally on historical volume and return rates, as a reduction to revenues. Actual sales returns will differ from estimated sales returns to the extent actual results differ from estimated assumptions. Altria’s businesses reflect differences between actual and estimated sales returns in the period in which the actual amounts become known. These differences, if any, have not had a material impact on Altria’s condensed consolidated financial statements. All returned goods are destroyed upon return and not included in inventory. Consequently, Altria’s businesses do not record an asset for their right to recover goods from customers upon return. Sales incentives include variable payments related to goods sold by Altria’s businesses. Altria’s businesses include estimates of variable consideration as a reduction to revenues upon shipment of goods to customers. The sales incentives that require significant estimates and judgments are as follows: Price promotion payments- Altria’s businesses make price promotion payments, substantially all of which are made to their retail partners, to incent the promotion of certain product offerings in select geographic areas. Wholesale and retail participation payments- Altria’s businesses make payments to their wholesale and retail partners to incent merchandising and sharing of sales data in accordance with each business’s trade agreements. These estimates primarily include estimated wholesale to retail sales volume and historical acceptance rates. Actual payments will differ from estimated payments to the extent actual results differ from estimated assumptions. Differences between actual and estimated payments are reflected in the period such information becomes available. These differences, if any, have not had a material impact on Altria’s condensed consolidated financial statements.

Asset Impairment, Exit and Impl

Asset Impairment, Exit and Implementation Costs	3 Months Ended
	Mar. 31, 2020
Restructuring and Related Activities [Abstract]
Asset Impairment, Exit and Implementation Costs	Asset Impairment, Exit and Implementation Costs: Pre-tax asset impairment, exit and implementation costs consisted of the following: For the Three Months Ended March 31, 2020 2019 Implementation Costs (1) Total Asset Impairment and Exit Costs Implementation Costs (1) Total (in millions) Smokeable products $ — $ — $ 36 $ 8 $ 44 Oral tobacco products — — 8 1 9 Wine 392 392 — — — All other — — (5 ) — (5 ) General corporate — — 1 — 1 Total 392 392 40 9 49 Plus amounts included in net periodic benefit income, excluding service cost (2) — — 12 — 12 Total $ 392 $ 392 $ 52 $ 9 $ 61 (1) Included in cost of sales for 2020 and marketing, administration and research costs for 2019 in Altria’s condensed consolidated statements of earnings. (2) Represents curtailment costs. See Note 6 . Benefit Plans . Implementation costs for 2020 were related to Ste. Michelle’s inventory-related charges, as discussed below. The 2019 pre-tax asset impairment, exit and implementation costs were related to the cost reduction program, which was completed in 2019. The movement in the restructuring liabilities, substantially all of which were severance liabilities, related to the cost reduction program was as follows: (in millions) Balances at December 31, 2019 $ 67 Charges — Cash spent (23 ) Balances at March 31, 2020 $ 44 Wine Business Strategic Reset Evolving adult consumer preferences have posed strategic challenges for Ste. Michelle, which has seen slowing growth in the wine category and increased inventory levels in recent periods. Against a backdrop of product volume demand uncertainty and long-term non-cancelable grape purchase commitments, which have been further negatively impacted by the economic uncertainty surrounding the COVID-19 pandemic, Ste. Michelle has experienced additional increases in inventory levels that at March 31, 2020 significantly exceed long-term forecasted demand. As a result, in connection with the preparation of Altria’s first quarter financial statements, Ste. Michelle recorded pre-tax charges of $392 million , which were included in cost of sales in Altria’s condensed consolidated statement of earnings for the three months ended March 31, 2020. The charges consisted of the following: (i) write-off of inventory ( $292 million ) as Ste. Michelle no longer believes that the benefit of the blending and production plans for its inventory outweighs inventory carrying cost given the reduced product volume demand; and (ii) estimated losses on future non-cancelable grape purchase commitments that Ste. Michelle believes no longer have a future economic benefit ( $100 million ). Such commitments will continue to require cash payments as grape commitments are fulfilled over the next five years . Given such uncertainty in economic conditions and product volume demand, as well as long-term supply-side contractual challenges, Altria and Ste. Michelle undertook a review of the wine business. As a result, Altria and Ste. Michelle implemented a strategic reset in order to maximize Ste. Michelle’s profitability and achieve improved long-term cash-flow generation. This strategic reset includes: (i) an updated approach to forecasting demand; (ii) supply chain optimization; (iii) SKU rationalization to reduce the number of products and eliminate underperforming brands; and (iv) streamlining operations by reducing future capital expenditures, working capital requirements and ongoing operating costs. Additionally, Ste. Michelle expects to record additional charges of approximately $25 million

Investments in Equity Securitie

Investments in Equity Securities	3 Months Ended
	Mar. 31, 2020
Investments [Abstract]
Investments in Equity Securities	Investments in Equity Securities: Altria’s investments consisted of the following: Carrying Amount March 31, 2020 December 31, 2019 (in millions) ABI $ 18,453 $ 18,071 JUUL 4,205 4,205 Cronos (1) 1,203 1,305 Total $ 23,861 $ 23,581 (1) March 31, 2020 includes Altria’s equity method investment in Cronos ( $1,037 million ), the Cronos warrant ( $132 million ) and the Fixed-price Preemptive Rights ( $34 million ) and December 31, 2019 includes Altria’s equity method investment in Cronos ( $1,002 million ), the Cronos warrant ( $234 million ) and the Fixed -price Preemptive Rights ( $69 million ), as discussed further below. Earnings from equity investments accounted for under the equity method of accounting consisted of the following: For the Three Months Ended March 31, 2020 2019 (in millions) ABI $ 134 $ 86 Cronos (1) 23 — Total $ 157 $ 86 (1) Represents Altria’s share of Cronos’s earnings, which includes the change in fair value of Cronos’s derivative financial instruments associated with the issuance of additional shares. As a result of the acquisition of Cronos in March 2019 and Altria reporting its share of Cronos’s results using a one-quarter lag, no equity earnings from Altria’s investment in Cronos were recorded for the three months ended March 31, 2019. Altria reviews its equity investments accounted for under the equity method of accounting (ABI and Cronos) for impairment on a quarterly basis in connection with the preparation of its financial statements by comparing the fair value of each of its investments to its respective carrying value. If the carrying value of an investment exceeds its fair value and the loss in value is other than temporary, the investment is considered impaired and reduced to fair value, and the impairment is recognized in the period identified. For further discussion, see Investment in ABI and Investment in Cronos below. Investment in ABI At March 31, 2020 , Altria had a 10.1% ownership in ABI, consisting of 185 million restricted shares of ABI (the “Restricted Shares”) and 12 million ordinary shares of ABI. Altria accounts for its investment in ABI under the equity method of accounting because Altria has the ability to exercise significant influence over the operating and financial policies of ABI, including having active representation on ABI’s board of directors (“ABI Board”) and certain ABI Board committees. Through this representation, Altria participates in ABI policy making processes. Altria reports its share of ABI’s results using a one-quarter lag because ABI’s results are not available in time for Altria to record them in the concurrent period. The fair value of Altria’s equity investment in ABI is based on (i) unadjusted quoted prices in active markets for ABI’s ordinary shares and was classified in Level 1 of the fair value hierarchy and (ii) observable inputs other than Level 1 prices, such as quoted prices for similar assets for the Restricted Shares, and was classified in Level 2 of the fair value hierarchy. Altria may, in certain instances, pledge or otherwise grant a security interest in all or part of its Restricted Shares. In the event the pledgee or security interest holder forecloses on the Restricted Shares, the relevant Restricted Shares will be automatically converted, one-for-one, into ordinary shares. Therefore, the fair value of each Restricted Share is based on the value of an ordinary share. The fair value of Altria’s equity investment in ABI at March 31, 2020 and December 31, 2019 was $8.8 billion (carrying value of $18.5 billion ) and $16.1 billion (carrying value of $18.1 billion ), respectively, which was less than its carrying by approximately 52% and 11% , respectively. As recently as September 30, 2019, the fair value of Altria’s equity investment in ABI exceeded its carrying value. In October 2019, the fair value of Altria’s equity investment in ABI declined below its carrying value and has not recovered. Altria has evaluated the factors related to the fair value decline, including the recent impact on the fair value of ABI’s shares amidst the COVID-19 pandemic, which has impacted the equity markets. Altria has also evaluated ABI’s financial condition and near-term prospects, and Altria’s intent and ability to hold its investment in ABI until recovery. Altria concluded at March 31, 2020 and December 31, 2019, the decline in fair value of its investment in ABI below its carrying value was temporary and, therefore, no impairment was recorded. Consistent with the one-quarter lag for reporting ABI’s results in Altria’s financial results, in the second quarter of 2020 Altria will record its share of ABI’s first quarter 2020 net mark-to-market losses on certain ABI financial instruments associated with ABI’s share commitments, primarily related to ABI’s derivative financial instruments used to hedge exposure to approximately 100 million shares of ABI common stock. Such activity is primarily driven by the change in ABI’s share price, which decreased from €72.71 to €40.47 at December 31, 2019 and March 31, 2020 Investment in JUUL In December 2018, Altria made a minority investment in JUUL for $12.8 billion . In exchange for the investment, Altria received a 35% economic interest in JUUL through non-voting shares, which are convertible at Altria’s election into voting shares (“Share Conversion”), and for no additional payment, a security convertible into additional non-voting or voting shares, as applicable, upon settlement or exercise of certain JUUL convertible securities (the “JUUL Transaction”). During 2019, Altria recorded total pre-tax impairment charges of $ 8.6 billion related to its investment in JUUL resulting in a $4.2 billion carrying value of its investment in JUUL at December 31, 2019. Altria received a broad preemptive right to purchase JUUL shares, exercisable each quarter upon dilution, to maintain its ownership percentage and is subject to a standstill restriction under which it may not acquire additional JUUL shares above its 35% interest. Furthermore, Altria agreed not to sell or transfer any of its JUUL shares until December 20, 2024. On January 28, 2020, Altria and JUUL amended certain JUUL Transaction agreements and entered into a new cooperation agreement, which included the following provisions: ▪ Altria will continue to provide regulatory affairs support for JUUL’s pursuit of its pre-market tobacco applications (PMTA) and/or its modified risk tobacco products authorization (MRTP) and discontinued all other services as of March 31, 2020; ▪ Altria will have the option to be released from its non-compete obligation (i) in the event JUUL is prohibited by federal law from selling e-vapor products in the U.S. for a continuous period of at least 12 months (subject to tolling of this period in certain circumstances) or (ii) if the carrying value of Altria’s investment in JUUL is not more than 10% of its initial carrying value of $12.8 billion ; ▪ Altria and JUUL agreed that for a period of one year they will not pursue any litigation against each other in connection with any conduct that occurred prior to the date of such cooperation agreement, with statutes of limitation being tolled during the one-year period; ▪ with respect to certain litigation in which Altria and JUUL are both defendants against third-party plaintiffs, Altria will not pursue any claims against JUUL for indemnification or reimbursement except for any non-contractual claims for contribution or indemnity where a judgment has been entered against Altria and JUUL; and ▪ upon Share Conversion, JUUL will: ▪ restructure JUUL’s current seven -member Board of Directors to a nine -member board that will include independent board members. The new structure will include: (i) three independent directors ( one of whom will be designated by Altria and two of whom will be designated by JUUL stockholders other than Altria) unanimously certified as independent by a nominating committee, which will include at least one Altria designee, (ii) two directors designated by Altria, (iii) three directors designated by JUUL stockholders other than Altria, and (iv) the JUUL Chief Executive Officer; and ▪ create a Litigation Oversight Committee, which will include two Altria designated directors ( one of whom will chair the Litigation Oversight Committee) that will have oversight authority and review of litigation management for matters in which JUUL and Altria are co-defendants and have or reasonably could have a written joint defense agreement in effect between them. Subject to certain limitations, the Litigation Oversight Committee will recommend to JUUL changes to outside counsel and litigation strategy by majority vote, with disagreements by JUUL’s management being resolved by majority vote of JUUL’s Board of Directors. On April 1, 2020, the U.S. Federal Trade Commission (“FTC”) issued an administrative complaint challenging Altria’s investment in JUUL. The FTC has not sought to preliminarily enjoin Altria from converting its non-voting JUUL shares to voting shares. Altria has not converted its non-voting JUUL shares to voting shares and is considering whether to do so. For further discussion on the FTC litigation, see Note 11. Contingencies - Antitrust Litigation . At March 31, 2020 and December 31, 2019 , Altria had a 35% economic interest in JUUL. Altria accounted for its investment in JUUL as an investment in an equity security as of March 31, 2020 . Since the JUUL shares do not have a readily determinable fair value, Altria has elected to measure its investment in JUUL at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. There have been no upward or downward adjustments to the carrying value of Altria’s investment in JUUL resulting from observable price changes in orderly transactions since the JUUL Transaction through March 31, 2020. Altria reviews its investment in JUUL for impairment by performing a qualitative assessment of impairment indicators on a quarterly basis in connection with the preparation of its financial statements. If this qualitative assessment indicates that Altria’s investment in JUUL may be impaired, a quantitative assessment is performed. If the quantitative assessment indicates the fair value of the investment is less than its carrying value, the investment is written down to its fair value. Altria performed its qualitative assessment of potential impairment indicators for its investment in JUUL, which included the consideration of potential impacts of COVID-19 on JUUL’s business, as part of the preparation of its financial statements for the period ended March 31, 2020 . Altria’s assessment did not result in impairment at March 31, 2020 . The carrying value of Altria’s investment in JUUL was $4.2 billion at March 31, 2020 and December 31, 2019 . Investment in Cronos In March 2019, Altria completed its acquisition of: ▪ 149.8 million newly issued common shares of Cronos (“Acquired Common Shares”), which represented a 45% economic and voting interest and is accounted for under the equity method of accounting; ▪ anti-dilution protections to purchase Cronos common shares, exercisable each quarter upon dilution, to maintain its ownership percentage. Certain of the anti-dilution protections provide Altria the ability to purchase additional Cronos common shares at a per share exercise price of Canadian dollar (“CAD”) $16.25 upon the occurrence of specified events (“Fixed-price Preemptive Rights”). Based on Altria’s assumptions as of March 31, 2020, Altria estimates the Fixed-price Preemptive Rights allows Altria to purchase up to an additional approximately 37 million common shares of Cronos; and ▪ a warrant providing Altria the ability to purchase up to an additional 10% of common shares of Cronos (approximately 78 million common shares at March 31, 2020) at a per share exercise price of CAD $19.00 , which expires on March 8, 2023. The total purchase price for the Acquired Common Shares, Fixed-price Preemptive Rights and warrant (collectively, “Investment in Cronos”) was CAD $2.4 billion (U.S. dollar (“USD”) $1.8 billion ). Upon full exercise of the Fixed-price Preemptive Rights, to the extent such rights become available, and the warrant, Altria would own a maximum of 55% of the outstanding common shares of Cronos. In accounting for the acquisition of these assets as of the date of closing, the Fixed-price Preemptive Rights and warrant were recorded at each of their fair values using Black-Scholes option-pricing models, based on the assumptions described in Note 5 . Financial Instruments . In addition, a deferred tax liability related to the Fixed-price Preemptive Rights and warrant was recorded. The residual of the purchase price was allocated to the Acquired Common Shares. Accordingly, the CAD $2.4 billion (USD $1.8 billion ) purchase price was recorded in USD as follows: ▪ $1.2 billion to the warrant; ▪ $0.5 billion to the Fixed-price Preemptive Rights; ▪ $0.4 billion to the Acquired Common Shares; and ▪ $0.3 billion to a deferred tax liability. If exercised in full, the exercise prices for the warrant and Fixed-price Preemptive Rights are approximately CAD $ 1.5 billion and CAD $0.6 billion (approximately USD $1.1 billion and $0.4 billion , respectively, based on the CAD to USD exchange rate on April 27, 2020). For a discussion of derivatives related to Altria’s investment in Cronos, including Altria’s accounting for changes in the fair value of these derivatives, see Note 5 . Financial Instruments . At March 31, 2020 , Altria had a 45% ownership in Cronos, which Altria accounts for under the equity method of accounting. Altria reports its share of Cronos’s results using a one-quarter lag because Cronos’s results are not available in time for Altria to record them in the concurrent period. Altria nominated four directors, including one director who is independent from Altria, who serve on Cronos’s seven -member Board of Directors. The fair value of Altria’s equity method investment in Cronos is based on unadjusted quoted prices in active markets for Cronos’s common shares and was classified in Level 1 of the fair value hierarchy. The fair value of Altria’s equity method investment in Cronos at March 31, 2020 and December 31, 2019 was $0.9 billion and $1.2 billion , respectively, compared with its carrying value of $1.0 billion at March 31, 2020 and December 31, 2019 . At March 31, 2020 , the fair value of Altria’s equity method investment in Cronos was less than its carrying value by approximately 14% . Based on Altria’s evaluation of the duration and magnitude of the fair value decline, Altria’s evaluation of Cronos’s financial condition (including its strong cash position) and near-term prospects, and Altria’s intent and ability to hold its investment in Cronos until recovery, Altria concluded that the decline in fair value of its equity method investment in Cronos below its carrying value is temporary and, therefore, no

Financial Instruments

Financial Instruments	3 Months Ended
	Mar. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments	Financial Instruments: Altria enters into derivative financial instruments to mitigate the potential impact of certain market risks, including foreign currency exchange rate risk. Altria uses various types of derivative financial instruments, including forward contracts, options and swaps. Altria does not enter into or hold derivative financial instruments for trading or speculative purposes. Altria’s investment in ABI, whose functional currency is the Euro, exposes Altria to foreign currency exchange risk on the carrying value of its investment. To manage this risk, Altria designates certain foreign exchange contracts, including cross-currency swap contracts and forward contracts (collectively “foreign currency contracts”), and Euro denominated unsecured long-term notes (“foreign currency denominated debt”) as net investment hedges of Altria’s investment in ABI. At both March 31, 2020 and December 31, 2019 , Altria had foreign currency contracts with aggregate notional amounts of $2,246 million . At March 31, 2020 , Altria had foreign currency denominated debt with an aggregate fair value and carrying value of $4,595 million and $4,666 million , respectively. At December 31, 2019 , Altria had foreign currency denominated debt with an aggregate fair value and carrying value of $5,057 million and $4,741 million , respectively. Altria’s estimates of the fair values of its foreign currency contracts are determined using valuation models with significant inputs that are readily available in public markets, or can be derived from observable market transactions, and therefore are classified in Level 2 of the fair value hierarchy. An adjustment for credit risk and nonperformance risk is included in the fair values of foreign currency contracts. Altria’s estimate of the fair value of its short-term borrowings is derived from discounted future cash flows based on the contractual terms of the Credit Agreement (see Note 10 . Debt ) and observable interest rates and is classified in Level 2 of the fair value hierarchy. The fair value of Altria’s short-term borrowings at March 31, 2020 approximated its carrying value. Altria had no short-term borrowings at December 31, 2019. Altria’s estimate of the fair value of its total long-term debt is based on observable market information derived from a third-party pricing source and is classified in Level 2 of the fair value hierarchy. The aggregate fair value of Altria’s total long-term debt at March 31, 2020 and December 31, 2019 was $28.3 billion and $30.7 billion , respectively, as compared with its carrying value of $27.0 billion and $28.0 billion , respectively. Altria’s Fixed-price Preemptive Rights and warrant related to its investment in Cronos, which is further discussed in Note 4 . Investments in Equity Securities , are derivative financial instruments, which are required to be recorded at fair value. The fair values of the Fixed-price Preemptive Rights and Cronos warrant are estimated using Black-Scholes option-pricing models, adjusted for observable inputs (which are classified in Level 1 of the fair value hierarchy), including share price, and unobservable inputs, including probability factors and weighting of expected life, volatility levels and risk-free interest rates (which are classified in Level 3 of the fair value hierarchy) based on the following assumptions at: March 31, 2020 December 31, 2019 March 31, 2020 December 31, 2019 Fixed-price Preemptive Rights Cronos Warrant Share price (1) C$7.99 C$9.97 C$7.99 C$9.97 Expected life (2) 1.60 years 1.67 years 2.93 years 3.18 years Expected volatility (3) 79.97% 81.61% 79.97% 81.61% Risk-free interest rate (4)(5) 0.38% 1.71% 0.49% 1.69% Expected dividend yield (6) —% —% —% —% (1) Based on the closing market price for Cronos common stock on the Toronto Stock Exchange on the date indicated. (2) Based on the weighted-average expected life of the Fixed-price Preemptive Rights (with a range from approximately 0.25 year to 6 years at March 31, 2020 and December 31, 2019) and the March 8, 2023 expiration date of the Cronos warrant. (3) Based on a blend of historical volatility levels of the underlying equity security and peer companies. (4) Based on the implied yield currently available on Canadian Treasury zero coupon issues (with a range from approximately 0.21% to 0.62% at March 31, 2020 and 1.66% to 1.74% at December 31, 2019) weighted for the remaining expected life of the Fixed-price Preemptive Rights. (5) Based on the implied yield currently available on Canadian Treasury zero coupon issues and the expected life of the Cronos warrant. (6) Based on Cronos’s expected dividend payments. The following table provides a reconciliation of the beginning and ending balance of the Fixed-price Preemptive Rights and Cronos warrant, which are classified in Level 3 of the fair value hierarchy: (in millions) Balance at December 31, 2019 $ 303 Pre-tax earnings (losses) recognized in net earnings (137 ) Balance at March 31, 2020 $ 166 Altria elects to record the gross assets and liabilities of derivative financial instruments executed with the same counterparty on its condensed consolidated balance sheets. The fair values of Altria’s derivative financial instruments on a gross basis included on the condensed consolidated balance sheets were as follows: Fair Value of Assets Fair Value of Liabilities Balance Sheet Classification March 31, 2020 December 31, 2019 Balance Sheet Classification March 31, 2020 December 31, 2019 Derivatives designated as hedging instruments: (in millions) Foreign currency contracts Other current assets $ 55 $ 46 Other accrued liabilities $ — $ 7 Foreign currency contracts Other assets 19 — Other liabilities — 21 Total $ 74 $ 46 $ — $ 28 Derivatives not designated as hedging instruments: Cronos warrant Investments in equity securities $ 132 $ 234 Fixed-price Preemptive Rights Investments in equity securities 34 69 Total $ 166 $ 303 Total derivatives $ 240 $ 349 $ — $ 28 Altria records in its condensed consolidated statements of earnings any changes in the fair values of the Fixed-price Preemptive Rights and Cronos warrant as gains or losses on Cronos-related financial instruments in the periods in which the changes occur. For the three months ended March 31, 2020 and 2019 , Altria recognized pre-tax unrealized losses, representing the changes in the fair values of the Fixed-price Preemptive Rights and Cronos warrant, as follows: For the Three Months Ended March 31, 2020 2019 (in millions) Fixed-price Preemptive Rights $ (35 ) $ (132 ) Cronos warrant (102 ) (262 ) (137 ) (394 ) Additionally, in January and February 2019, Altria entered into derivative financial instruments in the form of forward contracts, which were settled on March 7, 2019, to hedge Altria’s exposure to CAD to USD foreign currency exchange rate movements, in relation to the CAD $2.4 billion purchase price for the Cronos transaction. The aggregate notional amounts of the forward contracts were USD $1.8 billion (CAD $2.4 billion ). The forward contracts did not qualify for hedge accounting; therefore, in the first quarter of 2019, pre-tax losses of USD $31 million representing changes in the fair values of the forward contracts were recorded in loss on Cronos-related financial instruments in Altria’s condensed consolidated statement of earnings. Counterparties to Altria’s foreign currency contracts are domestic and international financial institutions. Altria is exposed to potential losses due to non-performance by these counterparties. Altria manages its credit risk by entering into transactions with counterparties with investment grade credit ratings, limiting the amount of exposure Altria has with each counterparty and monitoring the financial condition of each counterparty. The counterparty agreements also contain provisions that require Altria to maintain an investment grade credit rating. In the event Altria’s credit rating falls below investment grade, counterparties to Altria’s foreign currency contracts can require Altria to post collateral. No collateral was received or posted related to derivative assets and liabilities at March 31, 2020 and December 31, 2019 . Net Investment Hedging The pre-tax effects of Altria’s net investment hedges on accumulated other comprehensive losses and the condensed consolidated statements of earnings were as follows: Gain (Loss) Recognized in Accumulated Other Comprehensive Losses Gain (Loss) Recognized in Net Earnings (1) For the Three Months Ended March 31, 2020 2019 2020 2019 (in millions) Foreign currency contracts $ 56 $ 23 $ 14 $ 9 Foreign currency denominated debt 77 33 — — Total $ 133 $ 56 $ 14 $ 9 (1) Related to amounts excluded from effectiveness testing. The changes in the fair value of the foreign currency contracts and in the carrying value of the foreign currency denominated debt due to changes in the Euro to USD exchange rate were recognized in accumulated other comprehensive losses related to ABI. Gains on the foreign currency contracts arising from components excluded from effectiveness testing were recognized in interest and other debt expense, net in the condensed consolidated statements of earnings based on an amortization approach.

Benefit Plans

Benefit Plans	3 Months Ended
	Mar. 31, 2020
Retirement Benefits [Abstract]
Benefit Plans	Benefit Plans: Components of Net Periodic Benefit (Income) Cost Net periodic benefit (income) cost consisted of the following: For the Three Months Ended March 31, Pension Postretirement 2020 2019 2020 2019 (in millions) Service cost $ 19 $ 17 $ 4 $ 4 Interest cost 63 77 15 20 Expected return on plan assets (126 ) (145 ) (3 ) (4 ) Amortization: Net loss 27 42 3 3 Prior service cost (credit) 1 1 (7 ) (7 ) Curtailment — 7 — 5 Net periodic benefit (income) cost $ (16 ) $ (1 ) $ 12 $ 21 Curtailment costs shown in the table above were related to the cost reduction program discussed in Note 3 . Asset Impairment, Exit and Implementation Costs . Employer Contributions Altria makes contributions to the pension plans to the extent that the contributions are tax deductible and pays benefits that relate to plans for salaried employees that cannot be funded under Internal Revenue Service regulations. Altria made employer contributions of $4 million to its pension plans during the three months ended March 31, 2020 . Currently, Altria anticipates making additional employer contributions to its pension plans during the remainder of 2020 of up to approximately $25 million based on current tax law. Altria did no t make any employer contributions to its postretirement plans during the three months ended March 31, 2020 . Currently, Altria anticipates making employer contributions to its postretirement plans of up to approximately $60 million in 2020 . However, these estimates may be subject to change as a result of changes in tax and other benefit laws, as well as asset performance significantly above or below the assumed long-term rate of return on assets, changes in interest rates or other considerations.

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share: Basic and diluted earnings per share (“EPS”) were calculated using the following: For the Three Months Ended March 31, 2020 2019 (in millions) Net earnings attributable to Altria $ 1,552 $ 1,120 Less: Distributed and undistributed earnings attributable to share-based awards (2 ) (2 ) Earnings for basic and diluted EPS $ 1,550 $ 1,118 Weighted-average shares for basic and diluted EPS 1,858 1,874

Other Comprehensive Earnings_Lo

Other Comprehensive Earnings/Losses	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Other Comprehensive Earnings/Losses	Other Comprehensive Earnings/Losses: The following tables set forth the changes in each component of accumulated other comprehensive losses, net of deferred income taxes, attributable to Altria: For the Three Months Ended March 31, 2020 Benefit Plans ABI Currency Translation Adjustments and Other Accumulated Other Comprehensive Losses (in millions) Balances, December 31, 2019 $ (2,192 ) $ (693 ) $ 21 $ (2,864 ) Other comprehensive earnings (losses) before reclassifications — 388 12 400 Deferred income taxes — (85 ) — (85 ) Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes — 303 12 315 Amounts reclassified to net earnings 28 (7 ) — 21 Deferred income taxes (7 ) 2 — (5 ) Amounts reclassified to net earnings, net of deferred income taxes 21 (5 ) — 16 Other comprehensive earnings (losses), net of deferred income taxes 21 298 (1) 12 331 Balances, March 31, 2020 $ (2,171 ) $ (395 ) $ 33 $ (2,533 ) For the Three Months Ended March 31, 2019 Benefit Plans ABI Currency Translation Adjustments and Other Accumulated Other Comprehensive Losses (in millions) Balances, December 31, 2018 $ (2,168 ) $ (374 ) $ (5 ) $ (2,547 ) Other comprehensive earnings (losses) before reclassifications — (238 ) — (238 ) Deferred income taxes — 49 — 49 Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes — (189 ) — (189 ) Amounts reclassified to net earnings 39 (12 ) — 27 Deferred income taxes (10 ) 2 — (8 ) Amounts reclassified to net earnings, net of deferred income taxes 29 (10 ) — 19 Other comprehensive earnings (losses), net of deferred income taxes 29 (199 ) (1) — (170 ) Balances, March 31, 2019 $ (2,139 ) $ (573 ) $ (5 ) $ (2,717 ) (1) Primarily reflects Altria’s share of ABI’s currency translation adjustments and the impact of Altria’s designated net investment hedges. For further discussion of designated net investment hedges, see Note 5 . Financial Instruments. The following table sets forth pre-tax amounts by component, reclassified from accumulated other comprehensive losses to net earnings: For the Three Months Ended March 31, 2020 2019 (in millions) Benefit Plans: (1) Net loss $ 34 $ 49 Prior service cost/credit (6 ) (10 ) 28 39 ABI (2) (7 ) (12 ) Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings $ 21 $ 27 (1) Amounts are included in net defined benefit plan costs. For further details, see Note 6 . Benefit Plans. (2) Amounts are included in earnings from equity investments. For further information, see Note 4 . Investments in Equity Securities.

Segment Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Segment Reporting	Segment Reporting: In the first quarter of 2020, Altria renamed its smokeless products segment as the oral tobacco products segment. The products of Altria’s subsidiaries include smokeable tobacco products, consisting of combustible cigarettes manufactured and sold by PM USA and Nat Sherman, machine-made large cigars and pipe tobacco manufactured and sold by Middleton and premium cigars sold by Nat Sherman; oral tobacco products, consisting of MST and snus products manufactured and sold by USSTC and oral nicotine pouches manufactured and sold by Helix; and wine produced and/or distributed by Ste. Michelle. The products and services of these subsidiaries constitute Altria’s reportable segments of smokeable products, oral tobacco products (formerly smokeless products) and wine. The financial services and the innovative tobacco products businesses are included in all other. Altria’s chief operating decision maker (the “CODM”) reviews operating companies income to evaluate the performance of, and allocate resources to, the segments. Operating companies income for the segments is defined as operating income before general corporate expenses and amortization of intangibles. Interest and other debt expense, net, net periodic benefit income/cost, excluding service cost, and provision for income taxes are centrally managed at the corporate level and, accordingly, such items are not presented by segment since they are excluded from the measure of segment profitability reviewed by the CODM. Segment data were as follows: For the Three Months Ended March 31, 2020 2019 (in millions) Net revenues: Smokeable products $ 5,606 $ 4,935 Oral tobacco products 601 540 Wine 146 151 All other 6 2 Net revenues $ 6,359 $ 5,628 Earnings before income taxes: Operating companies income (loss): Smokeable products $ 2,370 $ 1,932 Oral tobacco products 414 358 Wine (379 ) 15 All other (5 ) (12 ) Amortization of intangibles (19 ) (8 ) General corporate expenses (45 ) (46 ) Corporate asset impairment and exit costs — (1 ) Operating income 2,336 2,238 Interest and other debt expense, net (275 ) (384 ) Net periodic benefit income, excluding service cost 27 1 Earnings from equity investments 157 86 Loss on Cronos-related financial instruments (137 ) (425 ) Earnings before income taxes $ 2,108 $ 1,516 The comparability of operating companies income for the reportable segments was affected by the following: Tobacco and Health Litigation Items - Pre-tax charges related to certain tobacco and health litigation items were recorded in Altria’s condensed consolidated statements of earnings as follows: For the Three Months Ended March 31, 2020 2019 (in millions) Smokeable products segment $ 22 $ 15 Interest and other debt expense, net 2 2 Total $ 24 $ 17 The amounts shown in the table above for the smokeable products segment were recorded in marketing, administration and research costs. For further discussion, see Note 11 . Contingencies . Asset Impairment, Exit and Implementation Costs - See Note 3 . Asset Impairment, Exit and Implementation Costs for a breakdown of these costs by segment.

Debt

Debt	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Debt	Debt: Short-term Borrowings and Borrowing Arrangements Altria had $3.0 billion and no short-term borrowings at March 31, 2020 and December 31, 2019 , respectively. At March 31, 2020, Altria had a senior unsecured 5 -year revolving credit agreement, dated August 1, 2018 (as amended, the “Credit Agreement”), that provides for borrowings up to an aggregate principal amount of $3.0 billion . On March 23, 2020, Altria provided notice to JPMorgan Chase Bank, N.A., as administrative agent under the Credit Agreement, to borrow the entire available amount ( $3.0 billion ) under the Credit Agreement and, as of March 31, 2020, $3.0 billion was outstanding under the Credit Agreement. Altria typically accesses the commercial paper market early in the second quarter to help fund payments related to the 1998 Master Settlement Agreement (the “MSA”) and shareholder dividends. In light of the current uncertainty in the global capital markets, including the commercial paper markets, resulting from the COVID-19 pandemic, Altria elected to borrow the entire amount available under the Credit Agreement as a precautionary measure to increase its cash position and preserve financial flexibility. Altria used a portion of the proceeds from the borrowing under the Credit Agreement to help fund these payments and for other general corporate purposes. All borrowings under the Credit Agreement mature on August 1, 2023, unless extended pursuant to the terms of the Credit Agreement. The Credit Agreement includes an option, subject to certain conditions, for Altria to extend the expiration date for two additional one -year periods. Altria may repay the borrowings under the Credit Agreement at any time without penalty. Altria has the intent and ability to repay the entire outstanding balance under the Credit Agreement within one year and believes it has adequate liquidity and access to financial resources to meet its anticipated obligations in the foreseeable future. As a result, Altria has classified the full amount of the borrowings as a current liability on its condensed consolidated balance sheet at March 31, 2020. Interest on the outstanding borrowings at March 31, 2020 was based on the three -month London Interbank Offered Rate (“LIBOR”) plus an applicable percentage based on the higher of the ratings of Altria’s long-term senior unsecured debt from Moody’s Investors Service, Inc. and Standard & Poor’s Ratings Services. The applicable percentage based on Altria’s long-term senior unsecured debt ratings at March 31, 2020 for borrowings under the Credit Agreement was 1.0% . At March 31, 2020, the interest rate for Altria’s current borrowings under the Credit Agreement was 2.23% . The Credit Agreement does not include any other rating triggers or any provisions that could require the posting of collateral. The Credit Agreement includes various covenants, one of which requires Altria to maintain a ratio of consolidated earnings before interest, taxes, depreciation and amortization (“EBITDA”) to Consolidated Interest Expense of not less than 4.0 to 1.0, calculated as of the end of the applicable quarter on a rolling four quarters basis. At March 31, 2020, the ratio of consolidated EBITDA to Consolidated Interest Expense, calculated in accordance with the Credit Agreement, was 9.0 to 1.0. At March 31, 2020, Altria was in compliance with its covenants in the Credit Agreement. The terms “Consolidated EBITDA” and “Consolidated Interest Expense,” each as defined in the Credit Agreement, include certain adjustments. At March 31, 2020, accrued interest on short-term borrowings under the Credit Agreement of $1 million was included in other accrued liabilities on Altria’s condensed consolidated balance sheet. Any commercial paper issued by Altria and borrowings under the Credit Agreement are guaranteed by PM USA as further discussed in Note 12 . Condensed Consolidating Financial Information. For discussion of the fair value of Altria’s short-term borrowings, see Note 5 . Financial Instruments . Long-term Debt During the first quarter of 2020, Altria repaid in full at maturity senior unsecured notes in the aggregate principal amount of $1,000 million . At March 31, 2020 and December 31, 2019 , accrued interest on long-term debt of $270 million and $470 million , respectively, was included in other accrued liabilities on Altria’s condensed consolidated balance sheets. Altria designated its Euro denominated senior unsecured notes as a net investment hedge of its investment in ABI. For discussion of Altria’s net investment hedge and the fair value of Altria’s long-term debt, see Note 5 . Financial Instruments .

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies Legal proceedings covering a wide range of matters are pending or threatened in various U.S. and foreign jurisdictions against Altria and its subsidiaries, including PM USA and USSTC, as well as their respective indemnitees and Altria’s investees. Various types of claims may be raised in these proceedings, including product liability, unfair trade practices, antitrust, tax, contraband shipments, patent infringement, employment matters, claims for contribution and claims of competitors, shareholders or distributors. Litigation is subject to uncertainty and it is possible that there could be adverse developments in pending or future cases. An unfavorable outcome or settlement of pending tobacco-related or other litigation could encourage the commencement of additional litigation. Damages claimed in some tobacco-related and other litigation are or can be significant and, in certain cases, have ranged in the billions of dollars. The variability in pleadings in multiple jurisdictions, together with the actual experience of management in litigating claims, demonstrate that the monetary relief that may be specified in a lawsuit bears little relevance to the ultimate outcome. In certain cases, plaintiffs claim that defendants’ liability is joint and several. In such cases, Altria or its subsidiaries may face the risk that one or more co-defendants decline or otherwise fail to participate in the bonding required for an appeal or to pay their proportionate or jury-allocated share of a judgment. As a result, Altria or its subsidiaries under certain circumstances may have to pay more than their proportionate share of any bonding- or judgment-related amounts. Furthermore, in those cases where plaintiffs are successful, Altria or its subsidiaries may also be required to pay interest and attorneys’ fees. Although PM USA has historically been able to obtain required bonds or relief from bonding requirements in order to prevent plaintiffs from seeking to collect judgments while adverse verdicts have been appealed, there remains a risk that such relief may not be obtainable in all cases. This risk has been substantially reduced given that 47 states and Puerto Rico limit the dollar amount of bonds or require no bond at all. As discussed below, however, tobacco litigation plaintiffs have challenged the constitutionality of Florida’s bond cap statute in several cases and plaintiffs may challenge state bond cap statutes in other jurisdictions as well. Such challenges may include the applicability of state bond caps in federal court. States, including Florida, may also seek to repeal or alter bond cap statutes through legislation. Although Altria cannot predict the outcome of such challenges, it is possible that the consolidated results of operations, cash flows or financial position of Altria, or one or more of its subsidiaries, could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome of one or more such challenges. Altria and its subsidiaries record provisions in the condensed consolidated financial statements for pending litigation when they determine that an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. At the present time, while it is reasonably possible that an unfavorable outcome in a case may occur, except to the extent discussed elsewhere in this Note 11 . Contingencies : (i) management has concluded that it is not probable that a loss has been incurred in any of the pending cases; (ii) management is unable to estimate the possible loss or range of loss that could result from an unfavorable outcome in any of the pending cases; and (iii) accordingly, management has not provided any amounts in the condensed consolidated financial statements for unfavorable outcomes, if any. Litigation defense costs are expensed as incurred. Altria and its subsidiaries have achieved substantial success in managing litigation. Nevertheless, litigation is subject to uncertainty and significant challenges remain. It is possible that the consolidated results of operations, cash flows or financial position of Altria, or one or more of its subsidiaries, could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome or settlement of certain pending litigation. Altria and each of its subsidiaries named as a defendant believe, and each has been so advised by counsel handling the respective cases, that it has valid defenses to the litigation pending against it, as well as valid bases for appeal of adverse verdicts. Each of the companies has defended, and will continue to defend, vigorously against litigation challenges. However, Altria and its subsidiaries may enter into settlement discussions in particular cases if they believe it is in the best interests of Altria to do so. Overview of Altria and/or PM USA Tobacco-Related Litigation Types and Number of U.S. Cases Claims related to tobacco products generally fall within the following categories: (i) smoking and health cases alleging personal injury brought on behalf of individual plaintiffs; (ii) health care cost recovery cases brought by governmental (both domestic and foreign) plaintiffs seeking reimbursement for health care expenditures allegedly caused by cigarette smoking and/or disgorgement of profits; (iii) e-vapor cases alleging violation of the Racketeer Influenced and Corrupt Organizations Act (“RICO”), fraud, failure to warn, design defect, negligence and unfair trade practices; and (iv) other tobacco-related litigation described below. Plaintiffs’ theories of recovery and the defenses raised in tobacco-related litigation are discussed below. The table below lists the number of certain tobacco-related cases pending in the U.S. against PM USA and, in some instances, Altria as of April 27, 2020, April 22, 2019 and April 23, 2018: April 27, 2020 April 22, 2019 April 23, 2018 Individual Smoking and Health Cases (1) 109 98 102 Health Care Cost Recovery Actions (2) — 1 1 E-vapor Cases (3) 202 2 3 Other Tobacco-Related Cases (4) 4 — — (1) Includes 22 cases filed in Massachusetts and 46 non- Engle cases filed in Florida. Does not include individual smoking and health cases brought by or on behalf of plaintiffs in Florida state and federal courts following the decertification of the Engle case (these Engle progeny cases are discussed below in Smoking and Health Litigation - Engle Class Action ). Also does not include 1,472 cases brought by flight attendants seeking compensatory damages for personal injuries allegedly caused by exposure to environmental tobacco smoke (“ETS”). The flight attendants allege that they are members of an ETS smoking and health class action in Florida, which was settled in 1997 ( Broin ). The terms of the court-approved settlement in that case allowed class members to file individual lawsuits seeking compensatory damages, but prohibited them from seeking punitive damages. In March 2018, 923 of these cases were voluntarily dismissed without prejudice. (2) See Health Care Cost Recovery Litigation - Federal Government’s Lawsuit below. (3) Includes 24 class action lawsuits, 170 individual lawsuits, five state or local government lawsuits and three lawsuits filed by school districts relating to JUUL e-vapor products. JUUL is an additional named defendant in each of these lawsuits. (4) For 2019 and 2020, includes two inactive smoking and health cases alleging personal injury or seeking court-supervised programs or ongoing medical monitoring and purporting to be brought on behalf of a class of individual plaintiffs, including one case in which the aggregated claims of a number of individual plaintiffs are to be tried in a single proceeding, and two inactive class action lawsuits alleging that use of the terms “Lights” and “Ultra Lights” constitute deceptive and unfair trade practices, common law or statutory fraud, unjust enrichment, breach of warranty or violations of RICO. International Tobacco-Related Cases As of April 27, 2020, PM USA is a named defendant in 10 health care cost recovery actions in Canada, eight of which also name Altria as a defendant. PM USA and Altria are also named defendants in seven smoking and health class actions filed in various Canadian provinces. See Guarantees and Other Similar Matters below for a discussion of the Distribution Agreement between Altria and Philip Morris International Inc. (“PMI”) that provides for indemnities for certain liabilities concerning tobacco products. Tobacco-Related Cases Set for Trial As of April 27, 2020, two Engle progeny cases are set for trial through June 30, 2020. In addition, there are no individual smoking and health cases against PM USA set for trial during this period. Cases against other companies in the tobacco industry may be scheduled for trial during this period. Trial dates are subject to change and some trials have been postponed due to the COVID-19 pandemic. Trial Results Since January 1999, excluding the Engle progeny cases (separately discussed below), verdicts have been returned in 69 tobacco-related cases in which PM USA was a defendant. Verdicts in favor of PM USA and other defendants were returned in 44 of the 69 cases. These 44 cases were tried in Alaska ( 1 ), California ( 7 ), Connecticut ( 1 ), Florida ( 10 ), Louisiana ( 1 ), Massachusetts ( 4 ), Mississippi ( 1 ), Missouri ( 4 ), New Hampshire ( 1 ), New Jersey ( 1 ), New York ( 5 ), Ohio ( 2 ), Pennsylvania ( 1 ), Rhode Island ( 1 ), Tennessee ( 2 ) and West Virginia ( 2 ). Of the 25 non- Engle progeny cases in which verdicts were returned in favor of plaintiffs, 20 have reached final resolution, and one case ( Gentile ) that was initially returned in favor of plaintiff was reversed post-trial and remains pending. See Smoking and Health Litigation - Engle Progeny Trial Results below for a discussion of verdicts in state and federal Engle progeny cases involving PM USA as of April 27, 2020. Judgments Paid and Provisions for Tobacco and Health Litigation Items (Including Engle Progeny Litigation) After exhausting all appeals in those cases resulting in adverse verdicts associated with tobacco-related litigation, since October 2004, PM USA has paid judgments and settlements (including related costs and fees) totaling approximately $748 million and interest totaling approximately $216 million as of March 31, 2020. These amounts include payments for Engle progeny judgments (and related costs and fees) totaling approximately $327 million and related interest totaling approximately $54 million . The changes in Altria’s accrued liability for tobacco and health litigation items, including related interest costs, for the periods specified below are as follows: For the Three Months Ended March 31, (in millions) 2020 2019 Accrued liability for tobacco and health litigation items at beginning of period (1) $ 14 $ 112 Pre-tax charges for: Tobacco and health litigation 22 (2) 15 Related interest costs 2 2 Payments (1) (28 ) (3) (109 ) Accrued liability for tobacco and health litigation items at end of period (1) $ 10 $ 20 (1) Includes amounts related to the costs of implementing the corrective communications remedy related to the Federal Government’s Lawsuit discussed below. (2) Includes approximately $7 million related to pre-trial resolution of approximately 100 tobacco and health cases. (3) Includes approximately $7 million in payments related to above-mentioned pre-trial resolution of approximately 100 tobacco and health cases and $2 million for pre-trial resolution of other tobacco and health cases that was accrued in 2019 but not paid until 2020 . The accrued liability for tobacco and health litigation items, including related interest costs, was included in accrued liabilities on Altria’s condensed consolidated balance sheets. Pre-tax charges for tobacco and health litigation were included in marketing, administration and research costs on Altria’s condensed consolidated statements of earnings (losses). Pre-tax charges for related interest costs were included in interest and other debt expense, net on Altria’s condensed consolidated statements of earnings (losses). Security for Judgments To obtain stays of judgments pending appeal, PM USA has posted various forms of security. As of March 31, 2020, PM USA has posted appeal bonds totaling approximately $48 million , which have been collateralized with restricted cash that are included in assets on the condensed consolidated balance sheet. Smoking and Health Litigation Overview Plaintiffs’ allegations of liability in smoking and health cases are based on various theories of recovery, including negligence, gross negligence, strict liability, fraud, misrepresentation, design defect, failure to warn, nuisance, breach of express and implied warranties, breach of special duty, conspiracy, concert of action, violations of unfair trade practice laws and consumer protection statutes, and claims under the federal and state anti-racketeering statutes. Plaintiffs in the smoking and health cases seek various forms of relief, including compensatory and punitive damages, treble/multiple damages and other statutory damages and penalties, creation of medical monitoring and smoking cessation funds, disgorgement of profits, and injunctive and equitable relief. Defenses raised in these cases include lack of proximate cause, assumption of the risk, comparative fault and/or contributory negligence, statutes of limitations and preemption by the Federal Cigarette Labeling and Advertising Act. Non-Engle Progeny Litigation Summarized below are the non- Engle progeny smoking and health cases pending during 2020 in which a verdict was returned in favor of plaintiff and against PM USA. Charts listing certain verdicts for plaintiffs in the Engle progeny cases can be found in Smoking and Health Litigation - Engle Progeny Trial Results below. Principe : In February 2020, a jury in a Florida state court returned a verdict in favor of plaintiff and against PM USA, awarding approximately $11 million in compensatory damages. There was no claim for punitive damages. PM USA’s post-trial motions are pending. Greene : In September 2019, a jury in a Massachusetts state court returned a verdict in favor of plaintiffs and against PM USA, awarding approximately $10 million in compensatory damages. An additional claim by plaintiffs remains pending. Laramie : In August 2019, a jury in a Massachusetts state court returned a verdict in favor of plaintiff, awarding $11 million in compensatory damages and $10 million in punitive damages. PM USA and plaintiff have appealed. Gentile : In October 2017, a jury in a Florida state court returned a verdict in favor of plaintiff, awarding approximately $7.1 million in compensatory damages and allocating 75% of the fault to PM USA (an amount of approximately $5.3 million ). PM USA appealed. In September 2019, the Florida Fourth District Court of Appeal reversed the judgment entered by the trial court, granted PM USA judgment on certain claims and remanded for a new trial on the remaining claims. Plaintiff has petitioned the Florida Supreme Court for further review. Federal Government’s Lawsuit : See Health Care Cost Recovery Litigation - Federal Government’s Lawsuit below for a discussion of the verdict and post-trial developments in the United States of America health care cost recovery case. Engle Class Action In July 2000, in the second phase of the Engle smoking and health class action in Florida, a jury returned a verdict assessing punitive damages totaling approximately $145 billion against various defendants, including $74 billion against PM USA. Following entry of judgment, PM USA appealed. In May 2003, the Florida Third District Court of Appeal reversed the judgment entered by the trial court and instructed the trial court to order the decertification of the class. Plaintiffs petitioned the Florida Supreme Court for further review. In July 2006, the Florida Supreme Court ordered that the punitive damages award be vacated, that the class approved by the trial court be decertified and that members of the decertified class could file individual actions against defendants within one year of issuance of the mandate. The court further declared the following Phase I findings are entitled to res judicata effect in such individual actions brought within one year of the issuance of the mandate: (i) that smoking causes various diseases; (ii) that nicotine in cigarettes is addictive; (iii) that defendants’ cigarettes were defective and unreasonably dangerous; (iv) that defendants concealed or omitted material information not otherwise known or available knowing that the material was false or misleading or failed to disclose a material fact concerning the health effects or addictive nature of smoking; (v) that defendants agreed to misrepresent information regarding the health effects or addictive nature of cigarettes with the intention of causing the public to rely on this information to their detriment; (vi) that defendants agreed to conceal or omit information regarding the health effects of cigarettes or their addictive nature with the intention that smokers would rely on the information to their detriment; (vii) that all defendants sold or supplied cigarettes that were defective; and (viii) that defendants were negligent. In August 2006, PM USA and plaintiffs sought rehearing from the Florida Supreme Court on parts of its July 2006 opinion. In December 2006, the Florida Supreme Court refused to revise its July 2006 ruling, except that it revised the set of Phase I findings entitled to res judicata effect by excluding finding (v) listed above (relating to agreement to misrepresent information), and added the finding that defendants sold or supplied cigarettes that, at the time of sale or supply, did not conform to the representations of fact made by defendants. In February 2008, the trial court decertified the class. Pending Engle Progeny Cases The deadline for filing Engle progeny cases expired in January 2008, at which point a total of approximately 9,300 federal and state claims were pending. As of April 27, 2020, approximately 1,500 state court cases were pending against PM USA or Altria asserting individual claims by or on behalf of approximately 1,900 state court plaintiffs. Because of a number of factors, including docketing delays, duplicated filings and overlapping dismissal orders, these numbers are estimates. While the Federal Engle Agreement (discussed below) resolved nearly all Engle progeny cases pending in federal court, as of April 27, 2020, four cases were pending against PM USA in federal court representing the cases excluded from that agreement. Engle Progeny Trial Results As of April 27, 2020, 134 federal and state Engle progeny cases involving PM USA have resulted in verdicts since the Florida Supreme Court Engle decision. Seventy-eight verdicts were returned in favor of plaintiffs and four verdicts ( Skolnick , Calloway , Oshinsky-Blacker and Freeman ) that were initially returned in favor of plaintiffs were reversed post-trial or on appeal and remain pending. Forty-seven verdicts were returned in favor of PM USA, of which 42 were state cases. In addition, there have been a number of mistrials, only some of which have resulted in new trials as of April 27, 2020. Four verdicts ( Pearson, D. Cohen , Collar and Chacon ) that were returned in favor of PM USA were subsequently reversed for new trials. Juries in two cases ( Reider and Banks ) returned zero damages verdicts in favor of PM USA . Juries in two other cases ( Weingart and Hancock ) returned verdicts against PM USA awarding no damages, but the trial court in each case decided to award plaintiffs damages. One case, Pollari, resulted in a verdict in favor of PM USA following a retrial of an initial verdict returned in favor of plaintiff. Appeals by plaintiff and defendants are pending. Three cases, Gloger, Rintoul ( Caprio ) and Duignan , resulted in verdicts in favor of plaintiffs following retrial of initial verdicts returned in favor of plaintiffs. Post-trial motions or appeals are pending. One case, Freeman , resulted in an appellate reversal of a jury verdict in favor of plaintiff and a judgment in favor of PM USA. The charts below list the verdicts and post-trial developments in certain Engle progeny cases in which verdicts were returned in favor of plaintiffs. The first chart lists such cases that are pending as of April 27, 2020 where PM USA has recorded a provision in its consolidated financial statements because PM USA has determined that an unfavorable outcome is probable and the amount of the loss can be reasonably estimated; the second chart lists other such cases that are pending as of April 27, 2020 but where PM USA has determined an unfavorable outcome is not probable and the amount of loss cannot be reasonably estimated; and the third chart lists other such cases that have concluded within the previous 12 months. Unless otherwise noted for a particular case, the jury’s award for compensatory damages will not be reduced by any finding of plaintiff’s comparative fault. Further, the damages noted reflect adjustments based on post-trial or appellate rulings. Currently Pending Engle Cases with Accrued Liabilities (rounded to nearest $ million) Plaintiff Verdict Date Defendant(s) Court Compensatory Damages (All Defendants) Punitive Damages (PM USA) Appeal Status Accrual (1) Berger ( Cote ) September 2014 PM USA Federal Court - Middle District of Florida $6 million $21 million The Eleventh Circuit Court of Appeals reinstated the punitive and compensatory damages awards and remanded the case to the district court. PM USA’s challenge to the punitive damages award was denied by the district court. PM USA’s appeal to the Eleventh Circuit Court of Appeals is pending. $6 million accrual in the fourth quarter of 2018 (1) Accrual amounts include interest and associated costs, if applicable. For cases with multiple defendants, if any, accrual amounts reflect the portion of compensatory damages PM USA believes it will have to pay if the case is ultimately decided in plaintiff’s favor after taking into account any portion potentially payable by the other defendant(s). Other Currently Pending Engle Cases with Verdicts Against PM USA (rounded to nearest $ million) Plaintiff Verdict Date Defendant(s) Court Compensatory Damages (1) Punitive Damages Appeal Status Duignan February 2020 (2 ) PM USA and (3) Pinellas $3 million $12 million Defendants’ post-trial motions pending. Cuddihee January 2020 PM USA Duval $3 million $0 Defendant’s post-trial motions pending. Rintoul (Caprio) November 2019 (2 ) PM USA and R.J. Reynolds Broward $9 million ($5 million PM USA) $74 million Defendants’ post-trial motion pending. Gloger November 2019 (2 ) PM USA and R.J. Reynolds Miami-Dade $15 million ($5 million PM USA) $11 million Appeal by defendants to Third District Court of Appeal pending. McCall March 2019 PM USA Broward <$1 million (<$1 million PM USA) <$1 million New trial ordered on punitive damages. Neff March 2019 PM USA and R.J. Reynolds Broward $4 million $2 million Appeals by plaintiff and defendants to Fourth District Court of Appeal pending. Frogel March 2019 PM USA Palm Beach <$1 million (<$1 million PM USA) $0 Appeals by plaintiff and defendant to Fourth District Court of Appeal pending. Other Currently Pending Engle Cases with Verdicts Against PM USA (rounded to nearest $ million) Plaintiff Verdict Date Defendant(s) Court Compensatory Damages (1) Punitive Damages Appeal Status Mahfuz February 2019 PM USA and R.J. Reynolds Broward $12 million $10 million Appeals by plaintiff and defendants to Fourth District Court of Appeal pending. Holliman February 2019 PM USA Miami-Dade $3 million $0 Defendant’s appeal to Third District Court of Appeal pending. Chadwell September 2018 PM USA Miami-Dade $2 million $0 Appeals by defendant and plaintiff to Third District Court of Appeal pending. Kaplan July 2018 PM USA and R.J. Reynolds Broward $2 million $2 million Appeals by defendants and plaintiff to Fourth District Court of Appeal pending. Landi June 2018 PM USA and R.J. Reynolds Broward $8 million $5 million Appeals by plaintiff and defendants to Fourth District Court of Appeal pending. R. Douglas November 2017 PM USA Duval <$1 million $0 Awaiting entry of final judgment by the trial court. Sommers April 2017 PM USA Miami-Dade $1 million $0 Third District Court of Appeal affirmed compensatory damages award and granted new trial on punitive damages. Defendant petitioned Florida Supreme Court for review. Santoro March 2017 PM USA, R.J. Reynolds and Liggett Group (3) Broward $2 million $0 Trial court set aside punitive damages award; appeals by plaintiff and defendants to Fourth District Court of Appeal pending. Cooper (Blackwood) September 2015 PM USA and R.J. Reynolds Broward $5 million $0 Fourth District Court of Appeal affirmed judgment and granted a new trial on punitive damages. D. Brown January 2015 PM USA Federal Court - Middle District of Florida $8 million $9 million Appeal by defendant to U.S. Court of Appeals for the Eleventh Circuit pending. Kerrivan October 2014 PM USA and R.J. Reynolds Federal Court - Middle District of Florida $16 million $16 million U.S. Court of Appeals for the Eleventh Circuit affirmed the judgment. Defendants’ motion for rehearing pending. Harris July 2014 PM USA, (3) Federal Court - Middle District of Florida $2 million (<$ 1 million PM USA) $0 Appeals by plaintiff and defendants to U.S. Court of Appeals for the Eleventh Circuit pending. (1) PM USA’s portion of the compensatory damages award is noted parenthetically where the court has ruled that comparative fault applies. (2) Plaintiff’s verdict following a retrial of an initial verdict in favor of plaintiff. (3) References to “R.J. Reynolds,” “Liggett Group” and “Lorillard” are to R.J. Reynolds Tobacco Company, Liggett Group, LLC and Lorillard Tobacco Company, respectively. Engle Cases Concluded Within Past 12 Months (1) (rounded to nearest $ million) Plaintiff Verdict Date Defendant(s) Court Accrual Date Payment Amount (if any) Payment Date Theis (2) May 2018 PM USA and Sarasota First quarter of 2020 $17 million February 2020 Alvarez Del Real September 2019 PM USA Miami-Dade Fourth quarter of 2019 <$1 million October 2019 Engle Cases Concluded Within Past 12 Months (1) (rounded to nearest $ million) Plaintiff Verdict Date Defendant(s) Court Accrual Date Payment Amount (if any) Payment Date Zingaro May 2019 PM USA and Broward Third quarter of 2019 <$1 million October 2019 Bryant December 2017 PM USA Escambia Second quarter of 2019 <$1 million July 2019 Wallace October 2017 PM USA and Brevard Second quarter of 2019 $26 million May 2019 J. Brown February 2017 PM USA and Pinellas First quarter of 2019 $4 million April 2019 L. Martin May 2017 PM USA Miami-Dade First quarter of 2019 $2 million April 2019 Danielson November 2015 PM USA Escambia First quarter of 2019 $3 million March 2019 S. Martin November 2016 PM USA and Broward First quarter of 2019 $5 million March 2019 Searcy April 2013 PM USA and Federal Court - Middle District of Florida Third quarter of 2018 $2 million March 2019 Boatright November 2014 PM USA and Liggett Group Polk Second quarter of 2018 $42 million March 2019 M. Brown (3) May 2015 PM USA Duval Second quarter of 2018 $8 million March 2019 Jordan (4) August 2015 PM USA Duval Second quarter of 2018 $11 million March 2019 Pardue December 2016 PM USA and Alachua Second and Third quarters of 2018 $11 million March 2019 McKeever February 2015 PM USA Broward Fourth quarter of 2017 $21 million March 2019 (1) In two cases in which PM USA paid the judgments more than a year ago, Naugle and Gore , plaintiffs were awarded approximately $8 million and approximately $2 million in fees and other costs, respectively. In both cases, PM USA has appealed. (2) In February 2020, the Florida Second District Court of Appeal denied PM USA’s petition for review. As a result, in the first quarter of 2020, PM USA recorded a pre-tax provision of approximately $17 million for the judgment plus interest, which was subsequently paid in the first quarter of 2020. (3) The trial court also awarded plaintiff approximately $9 million in fees, interest and costs. PM USA and plaintiff have appealed. (4) The trial court also awarded plaintiff approximately $4 million in fees and costs. PM USA and plaintiff have appealed. Florida Bond Statute In June 2009, Florida amended its existing bond cap statute by adding a $200 million bond cap that applies to all state Engle progeny lawsuits in the aggregate and establishes individual bond caps for individual Engle progeny cases in amounts that vary depending on the number of judgments in effect at a given time. Plaintiffs have been unsuccessful in various challenges to the bond cap statute in Florida state court. No federal court has yet addressed the constitutionality of the bond cap statute or the applicability of the bond cap to Engle progeny cases tried in federal court. From time to time, legislation has been presented to the Florida legislature that would repeal the bond cap statute; however to date, no legislation repealing the statute has passed. Other Smoking and Health Class Actions Since the dismissal in May 1996 of a purported nationwide class action brought on behalf of allegedly addicted smokers, plaintiffs have filed numerous putative smoking and health class action suits in various state and federal courts. In general, these cases purport to be brought on behalf of residents of a particular state or states (although a few cases purport to be nationwide in scope) and raise addiction claims and, in many cases, claims of physical injury as well. Class certification has been denied or reversed by courts in 61 smoking and health class actions involving PM USA in Arkansas ( 1 ), California ( 1 ), Delaware ( 1 ), the District of Columbia ( 2 ), Florida ( 2 ), Illinois ( 3 ), Iowa ( 1 ), Kansas ( 1 ), Louisiana ( 1 ), Maryland ( 1 ), Michigan ( 1 ), Minnesota ( 1 ), Nevada ( 29 ), New Jersey ( 6 ), New York ( 2 ), Ohio ( 1 ), Oklahoma ( 1 ), Oregon ( 1 ), Pennsylvania ( 1 ), Puerto Rico ( 1 ), South Carolina ( 1 ), Texas ( 1 ) and Wisconsin ( 1 ). See Certain Other Tobacco-Related Litigation below for a discussion of “Lights” and “Ultra Lights” class action cases and medical monitoring class action cases pending against PM USA. As of April 27, 2020, PM USA and Altria are named as defendants, along with other cigarette manufacturers, in seven class actions filed in the Canadian provinces of Alberta, Manitoba, Nova Scotia, Saskatchewan, British Columbia and Ontario. In Saskatchewan, British Columbia ( two separate cases) and Ontario, plaintiffs seek class certification on behalf of individuals who suffer or have suffered from various diseases, including chronic obstructive pulmonary disease, emphysema, heart disease or cancer, after smoking defendants’ cigarettes. In the actions filed in Alberta, Manitoba and Nova Scotia, plaintiffs seek certification of classes of all individuals who smoked defendants’ cigarettes. In March 2019, all of these class actions were stayed as a result of three Canadian tobacco manufacturers (none of which is related to Altria or its subsidiaries) seeking protection under Canada’s Companies’ Creditors Arrangement Act (which is similar to Chapter 11 bankruptcy in the U.S.). The companies entered into these proceedings following a Canadian appellate court upholding two smoking and health class action verdicts against those companies totaling approximately CAD $13 billion . See Guarantees and Other Similar Matters below for a discussion of the Distribution Agreement between Altria and PMI, which provides for indemnities for certain liabilities concerning tobacco products. Health Care Cost Recovery Litigation Overview In the health care cost recovery litigation, governmental entities seek reimbursement of health care cost expenditures allegedly caused by tobacco products and, in some cases, of future expenditures and damages. Relief sought by some but not all plaintiffs includes punitive damages, multiple damages and other statutory damages and penalties, injunctions prohibiting alleged marketing and sales to minors, disclosure of research, disgorgement of profits, funding of anti-smoking programs, additional disclosure of nicotine yields, and payment of attorney and expert witness fees. Although there have been some decisions to the contrary, most judicial decisions in the U.S. have dismissed all or most health care cost recovery claims against cigarette manufacturers. Nine federal circuit courts o

Condensed Consolidating Financi

Condensed Consolidating Financial Information	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Consolidating Financial Information	Condensed Consolidating Financial Information: PM USA, which is a 100% owned subsidiary of Altria Group, Inc., has guaranteed Altria Group, Inc.’s obligations under its outstanding debt securities, borrowings under its Credit Agreement and amounts outstanding under its commercial paper program (the “Guarantees”). Pursuant to the Guarantees, PM USA fully and unconditionally guarantees, as primary obligor, the payment and performance of Altria Group, Inc.’s obligations under the guaranteed debt instruments (the “Obligations”), subject to release under certain customary circumstances as noted below. The Guarantees provide that PM USA guarantees the punctual payment when due, whether at stated maturity, by acceleration or otherwise, of the Obligations. The liability of PM USA under the Guarantees is absolute and unconditional irrespective of: any lack of validity, enforceability or genuineness of any provision of any agreement or instrument relating thereto; any change in the time, manner or place of payment of, or in any other term of, all or any of the Obligations, or any other amendment or waiver of or any consent to departure from any agreement or instrument relating thereto; any exchange, release or non-perfection of any collateral, or any release or amendment or waiver of or consent to departure from any other guarantee, for all or any of the Obligations; or any other circumstance that might otherwise constitute a defense available to, or a discharge of, Altria Group, Inc. or PM USA. The obligations of PM USA under the Guarantees are limited to the maximum amount as will not result in PM USA’s obligations under the Guarantees constituting a fraudulent transfer or conveyance, after giving effect to such maximum amount and all other contingent and fixed liabilities of PM USA that are relevant under Bankruptcy Law, the Uniform Fraudulent Conveyance Act, the Uniform Fraudulent Transfer Act or any similar federal or state law to the extent applicable to the Guarantees. For this purpose, “Bankruptcy Law” means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors. PM USA will be unconditionally released and discharged from the Obligations upon the earliest to occur of: ▪ the date, if any, on which PM USA consolidates with or merges into Altria Group, Inc. or any successor; ▪ the date, if any, on which Altria Group, Inc. or any successor consolidates with or merges into PM USA; ▪ the payment in full of the Obligations pertaining to such Guarantees; and ▪ the rating of Altria Group, Inc.’s long-term senior unsecured debt by Standard & Poor’s Ratings Services of A or higher. At March 31, 2020 , the respective principal 100% owned subsidiaries of Altria Group, Inc. and PM USA were not limited by long-term debt or other agreements in their ability to pay cash dividends or make other distributions with respect to their equity interests. The following sets forth the condensed consolidating balance sheets as of March 31, 2020 and December 31, 2019 , condensed consolidating statements of earnings and comprehensive earnings for the three months ended March 31, 2020 and 2019 , and condensed consolidating statements of cash flows for the three months ended March 31, 2020 and 2019 for Altria Group, Inc., PM USA and, collectively, Altria Group, Inc.’s other subsidiaries that are not guarantors of Altria Group, Inc.’s debt instruments (the “Non-Guarantor Subsidiaries”). The financial information may not necessarily be indicative of results of operations or financial position had PM USA and the Non-Guarantor Subsidiaries operated as independent entities. Altria Group, Inc. and PM USA account for investments in their subsidiaries under the equity method of accounting. Condensed Consolidating Balance Sheets March 31, 2020 (in millions of dollars) Altria Group, Inc. PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Assets Cash and cash equivalents $ 5,548 $ 1 $ 67 $ — $ 5,616 Receivables — 17 130 — 147 Inventories: Leaf tobacco — 508 387 — 895 Other raw materials — 123 70 — 193 Work in process — 6 461 — 467 Finished product — 87 364 — 451 — 724 1,282 — 2,006 Due from Altria Group, Inc. and subsidiaries 91 5,660 1,361 (7,112 ) — Other current assets 301 23 68 (226 ) 166 Total current assets 5,940 6,425 2,908 (7,338 ) 7,935 Property, plant and equipment, at cost — 2,970 2,133 — 5,103 Less accumulated depreciation — 2,186 920 — 3,106 — 784 1,213 — 1,997 Goodwill — — 5,177 — 5,177 Other intangible assets, net — 2 12,666 — 12,668 Investments in equity securities 18,453 — 5,408 — 23,861 Investment in consolidated subsidiaries 18,905 2,867 — (21,772 ) — Due from Altria Group, Inc. and subsidiaries 4,790 — — (4,790 ) — Other assets 71 950 567 (608 ) 980 Total Assets $ 48,159 $ 11,028 $ 27,939 $ (34,508 ) $ 52,618 Condensed Consolidating Balance Sheets (Continued) March 31, 2020 (in millions of dollars) Altria Group, Inc. PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Liabilities Short-term borrowings $ 3,000 $ — $ — $ — $ 3,000 Accounts payable 1 136 141 — 278 Accrued liabilities: Marketing — 391 76 — 467 Settlement charges — 4,410 9 — 4,419 Other 312 343 377 — 1,032 Income taxes 6 508 105 (226 ) 393 Dividends payable 1,565 — — — 1,565 Due to Altria Group, Inc. and subsidiaries 6,278 587 247 (7,112 ) — Total current liabilities 11,162 6,375 955 (7,338 ) 11,154 Long-term debt 26,971 — — — 26,971 Deferred income taxes 3,228 — 2,571 (608 ) 5,191 Accrued pension costs 196 — 231 — 427 Accrued postretirement health care costs — 1,076 722 — 1,798 Due to Altria Group, Inc. and subsidiaries — — 4,790 (4,790 ) — Other liabilities 59 90 253 — 402 Total liabilities 41,616 7,541 9,522 (12,736 ) 45,943 Contingencies Redeemable noncontrolling interest — — 38 — 38 Stockholders’ Equity Common stock 935 — 9 (9 ) 935 Additional paid-in capital 5,959 3,310 27,566 (30,876 ) 5,959 Earnings reinvested in the business 36,528 393 (7,441 ) 7,048 36,528 Accumulated other comprehensive losses (2,533 ) (216 ) (1,849 ) 2,065 (2,533 ) Cost of repurchased stock (34,346 ) — — — (34,346 ) Total stockholders’ equity attributable to Altria Group, Inc. 6,543 3,487 18,285 (21,772 ) 6,543 Noncontrolling interests — — 94 — 94 Total stockholders’ equity 6,543 3,487 18,379 (21,772 ) 6,637 Total Liabilities and Stockholders’ Equity $ 48,159 $ 11,028 $ 27,939 $ (34,508 ) $ 52,618 Condensed Consolidating Balance Sheets December 31, 2019 (in millions of dollars) Altria Group, Inc. PM USA Non- Total Consolidated Assets Cash and cash equivalents $ 2,022 $ — $ 95 $ — $ 2,117 Receivables — 30 122 — 152 Inventories: Leaf tobacco — 494 380 — 874 Other raw materials — 120 72 — 192 Work in process — 4 692 — 696 Finished product — 119 412 — 531 — 737 1,556 — 2,293 Due from Altria Group, Inc. and subsidiaries 88 4,005 1,359 (5,452 ) — Other current assets 133 64 114 (49 ) 262 Total current assets 2,243 4,836 3,246 (5,501 ) 4,824 Property, plant and equipment, at cost — 2,956 2,118 — 5,074 Less accumulated depreciation — 2,166 909 — 3,075 — 790 1,209 — 1,999 Goodwill — — 5,177 — 5,177 Other intangible assets, net — 2 12,685 — 12,687 Investments in equity securities 18,071 — 5,510 — 23,581 Investment in consolidated subsidiaries 19,312 2,831 — (22,143 ) — Due from Altria Group, Inc. and subsidiaries 4,790 — — (4,790 ) — Other assets 58 951 603 (609 ) 1,003 Total Assets $ 44,474 $ 9,410 $ 28,430 $ (33,043 ) $ 49,271 Condensed Consolidating Balance Sheets (Continued) December 31, 2019 (in millions of dollars) Altria Group, Inc. PM USA Non- Total Consolidated Liabilities Current portion of long-term debt $ 1,000 $ — $ — $ — $ 1,000 Accounts payable — 146 179 — 325 Accrued liabilities: Marketing — 320 73 — 393 Settlement charges — 3,340 6 — 3,346 Other 570 482 481 — 1,533 Income taxes 6 — 55 (49 ) 12 Dividends payable 1,565 — — — 1,565 Due to Altria Group, Inc. and subsidiaries 4,693 514 245 (5,452 ) — Total current liabilities 7,834 4,802 1,039 (5,501 ) 8,174 Long-term debt 27,042 — — — 27,042 Deferred income taxes 3,099 — 2,593 (609 ) 5,083 Accrued pension costs 197 — 276 — 473 Accrued postretirement health care costs — 1,078 719 — 1,797 Due to Altria Group, Inc. and subsidiaries — — 4,790 (4,790 ) — Other liabilities 80 87 178 — 345 Total liabilities 38,252 5,967 9,595 (10,900 ) 42,914 Contingencies Redeemable noncontrolling interest — — 38 — 38 Stockholders’ Equity Common stock 935 — 9 (9 ) 935 Additional paid-in capital 5,970 3,310 27,565 (30,875 ) 5,970 Earnings reinvested in the business 36,539 352 (6,997 ) 6,645 36,539 Accumulated other comprehensive losses (2,864 ) (219 ) (1,877 ) 2,096 (2,864 ) Cost of repurchased stock (34,358 ) — — — (34,358 ) Total stockholders’ equity attributable to Altria Group, Inc. 6,222 3,443 18,700 (22,143 ) 6,222 Noncontrolling interests — — 97 — 97 Total stockholders’ equity 6,222 3,443 18,797 (22,143 ) 6,319 Total Liabilities and Stockholders’ Equity $ 44,474 $ 9,410 $ 28,430 $ (33,043 ) $ 49,271 Condensed Consolidating Statements of Earnings and Comprehensive Earnings For the Three Months Ended March 31, 2020 (in millions of dollars) Altria Group, Inc. PM USA Non- Total Consolidated Net revenues $ — $ 5,359 $ 1,008 $ (8 ) $ 6,359 Cost of sales — 1,532 649 (8 ) 2,173 Excise taxes on products — 1,267 46 — 1,313 Gross profit — 2,560 313 — 2,873 Marketing, administration and research costs 22 387 128 — 537 Operating income (expense) (22 ) 2,173 185 — 2,336 Interest and other debt expense (income), net 237 (18 ) 56 — 275 Net periodic benefit (income) cost, excluding service cost — (22 ) (5 ) — (27 ) Earnings from equity investments (134 ) — (23 ) — (157 ) Loss on Cronos-related financial instruments — — 137 — 137 Earnings (losses) before income taxes and equity earnings of subsidiaries (125 ) 2,213 20 — 2,108 Provision (benefit) for income taxes (32 ) 550 40 — 558 Equity earnings of subsidiaries 1,645 126 — (1,771 ) — Net earnings 1,552 1,789 (20 ) (1,771 ) 1,550 Net (earnings) losses attributable to noncontrolling interests — — 2 — 2 Net earnings attributable to Altria $ 1,552 $ 1,789 $ (18 ) $ (1,771 ) $ 1,552 Net earnings $ 1,552 $ 1,789 $ (20 ) $ (1,771 ) $ 1,550 Other comprehensive earnings (losses), net of deferred income taxes 331 3 28 (31 ) 331 Comprehensive earnings 1,883 1,792 8 (1,802 ) 1,881 Comprehensive (earnings) losses attributable to noncontrolling interests — — 2 — 2 Comprehensive earnings attributable to Altria $ 1,883 $ 1,792 $ 10 $ (1,802 ) $ 1,883 Condensed Consolidating Statements of Earnings and Comprehensive Earnings For the Three Months Ended March 31, 2019 (in millions of dollars) Altria Group, Inc. PM USA Non- Total Consolidated Net revenues $ — $ 4,725 $ 913 $ (10 ) $ 5,628 Cost of sales — 1,340 248 (10 ) 1,578 Excise taxes on products — 1,185 54 — 1,239 Gross profit — 2,200 611 — 2,811 Marketing, administration and research costs 35 384 114 — 533 Asset impairment and exit costs 1 35 4 — 40 Operating income (expense) (36 ) 1,781 493 — 2,238 Interest and other debt expense (income), net 355 (25 ) 54 — 384 Net periodic benefit (income) cost, excluding service cost 1 — (2 ) — (1 ) Earnings from equity investments (86 ) — — — (86 ) Loss on Cronos-related financial instruments — — 425 — 425 Earnings (losses) before income taxes and equity earnings of subsidiaries (306 ) 1,806 16 — 1,516 Provision (benefit) for income taxes (75 ) 459 11 — 395 Equity earnings of subsidiaries 1,351 95 — (1,446 ) — Net earnings 1,120 1,442 5 (1,446 ) 1,121 Net (earnings) losses attributable to noncontrolling interests — — (1 ) — (1 ) Net earnings attributable to Altria $ 1,120 $ 1,442 $ 4 $ (1,446 ) $ 1,120 Net earnings $ 1,120 $ 1,442 $ 5 $ (1,446 ) $ 1,121 Other comprehensive earnings (losses), net of deferred income taxes (170 ) 5 23 (28 ) (170 ) Comprehensive earnings 950 1,447 28 (1,474 ) 951 Comprehensive (earnings) losses attributable to noncontrolling interests — — (1 ) — (1 ) Comprehensive earnings attributable to Altria $ 950 $ 1,447 $ 27 $ (1,474 ) $ 950 Condensed Consolidating Statements of Cash Flows For the Three Months Ended March 31, 2020 (in millions of dollars) Altria Group, Inc. PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Cash Provided by (Used In) Operating Activities Net cash provided by (used in) operating activities $ 1,515 $ 3,351 $ 437 $ (2,174 ) $ 3,129 Cash Provided by (Used in) Investing Activities Capital expenditures — (15 ) (37 ) — (52 ) Investment in consolidated subsidiaries (1 ) — — 1 — Other, net — — — — — Net cash provided by (used in) investing activities (1 ) (15 ) (37 ) 1 (52 ) Cash Provided by (Used in) Financing Activities Proceeds from short-term borrowings 3,000 — — — 3,000 Long-term debt repaid (1,000 ) — — — (1,000 ) Dividends paid on common stock (1,563 ) — — — (1,563 ) Changes in amounts due to/from Altria Group, Inc. and subsidiaries 1,584 (1,582 ) (1 ) (1 ) — Cash dividends paid to parent — (1,748 ) (426 ) 2,174 — Other, net (9 ) — (1 ) — (10 ) Net cash provided by (used in) financing activities 2,012 (3,330 ) (428 ) 2,173 427 Cash, cash equivalents and restricted cash (1) : Increase (decrease) 3,526 6 (28 ) — 3,504 Balance at beginning of period 2,022 43 95 — 2,160 Balance at end of period $ 5,548 $ 49 $ 67 $ — $ 5,664 (1) Restricted cash consisted of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals. See Note 11 . Contingencies . Condensed Consolidating Statements of Cash Flows For the Three Months Ended March 31, 2019 (in millions of dollars) Altria Group, Inc. PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Cash Provided by (Used In) Operating Activities Net cash provided by (used in) operating activities $ 1,642 $ 2,520 $ 166 $ (2,039 ) $ 2,289 Cash Provided by (Used in) Investing Activities Capital expenditures — (9 ) (29 ) — (38 ) Investment in Cronos — — (1,831 ) — (1,831 ) Investment in consolidated subsidiaries (1,947 ) — — 1,947 — Other, net (3 ) — (78 ) — (81 ) Net cash provided by (used in) investing activities (1,950 ) (9 ) (1,938 ) 1,947 (1,950 ) Cash Provided by (Used in) Financing Activities Repayment of short-term borrowings (12,800 ) — — — (12,800 ) Long-term debt issued 16,265 — — — 16,265 Repurchases of common stock (151 ) — — — (151 ) Dividends paid on common stock (1,502 ) — — — (1,502 ) Changes in amounts due to/from Altria Group, Inc. and subsidiaries 657 (771 ) 2,061 (1,947 ) — Cash dividends paid to parent — (1,737 ) (302 ) 2,039 — Other (120 ) — (9 ) — (129 ) Net cash provided by (used in) financing activities 2,349 (2,508 ) 1,750 92 1,683 Cash, cash equivalents and restricted cash (1) : Increase (decrease) 2,041 3 (22 ) — 2,022 Balance at beginning of period 1,277 100 56 — 1,433 Balance at end of period $ 3,318 $ 103 $ 34 $ — $ 3,455 (1) Restricted cash consisted of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals. See Note 11 . Contingencies .

New Accounting Guidance Not Yet

New Accounting Guidance Not Yet Adopted	3 Months Ended
	Mar. 31, 2020
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Guidance Not Yet Adopted	New Accounting Guidance Not Yet Adopted: The following table provides a description of issued accounting guidance applicable to, but not yet adopted by, Altria: Standards Description Effective Date for Public Entity Effect on Financial Statements ASU 2019-12 Simplifying the Accounting for Income Taxes (Topic 740) The guidance removes certain exceptions for investments, intraperiod allocations and interim calculations, and adds guidance to reduce complexity in accounting for income taxes. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early application is permitted, including adoption in any interim period. Altria is in the process of evaluating the impact of this guidance on its consolidated financial statements and related disclosures. ASU 2020-01 Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 The guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early application is permitted, including adoption in any interim period. Altria is in the process of evaluating the impact of this guidance on its consolidated financial statements and related disclosures.

Background and Basis of Prese_2

Background and Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
New Accounting Pronouncements	On January 1, 2020, Altria adopted Accounting Standards Update (“ASU”) No. 2016-13, Measurement of Credit Losses on Financial Instruments and all related ASU amendments (collectively “ASU No. 2016-13”). This guidance replaces the current incurred loss impairment methodology for recognizing credit losses for financial assets with a methodology that reflects the entity’s current estimate of all expected credit losses and requires consideration of a broader range of reasonable and supportable information for estimating credit losses. The adoption of ASU No. 2016-13 did not have a material impact on Altria’s condensed consolidated financial statements. Additionally, on January 1, 2020, Altria adopted ASU No. 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (“ASU No. 2018-15”). This guidance aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The adoption of ASU No. 2018-15 did not have a material impact on Altria’s condensed consolidated financial statements. Standards Description Effective Date for Public Entity Effect on Financial Statements ASU 2019-12 Simplifying the Accounting for Income Taxes (Topic 740) The guidance removes certain exceptions for investments, intraperiod allocations and interim calculations, and adds guidance to reduce complexity in accounting for income taxes. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early application is permitted, including adoption in any interim period. Altria is in the process of evaluating the impact of this guidance on its consolidated financial statements and related disclosures. ASU 2020-01 Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 The guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early application is permitted, including adoption in any interim period. Altria is in the process of evaluating the impact of this guidance on its consolidated financial statements and related disclosures.
Equity Method Investments	The fair value of Altria’s equity investment in ABI is based on (i) unadjusted quoted prices in active markets for ABI’s ordinary shares and was classified in Level 1 of the fair value hierarchy and (ii) observable inputs other than Level 1 prices, such as quoted prices for similar assets for the Restricted Shares, and was classified in Level 2 of the fair value hierarchy. Altria may, in certain instances, pledge or otherwise grant a security interest in all or part of its Restricted Shares. In the event the pledgee or security interest holder forecloses on the Restricted Shares, the relevant Restricted Shares will be automatically converted, one-for-one, into ordinary shares. Therefore, the fair value of each Restricted Share is based on the value of an ordinary share. Altria reviews its equity investments accounted for under the equity method of accounting (ABI and Cronos) for impairment on a quarterly basis in connection with the preparation of its financial statements by comparing the fair value of each of its investments to its respective carrying value. If the carrying value of an investment exceeds its fair value and the loss in value is other than temporary, the investment is considered impaired and reduced to fair value, and the impairment is recognized in the period identified. For further discussion, see Investment in ABI and Investment in Cronos below.
Equity Securities Without Readily Determinable Fair Value	Altria accounted for its investment in JUUL as an investment in an equity security as of March 31, 2020 . Since the JUUL shares do not have a readily determinable fair value, Altria has elected to measure its investment in JUUL at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. There have been no upward or downward adjustments to the carrying value of Altria’s investment in JUUL resulting from observable price changes in orderly transactions since the JUUL Transaction through March 31, 2020. Altria reviews its investment in JUUL for impairment by performing a qualitative assessment of impairment indicators on a quarterly basis in connection with the preparation of its financial statements. If this qualitative assessment indicates that Altria’s investment in JUUL may be impaired, a quantitative assessment is performed. If the quantitative assessment indicates the fair value of the investment is less than its carrying value, the investment is written down to its fair value.

Background and Basis of Prese_3

Background and Basis of Presentation (Tables)	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Share Repurchase Activity	Altria’s share repurchase activity for the three months ended March 31, 2019 was as follows: (in millions, except per share data) 2019 Total number of shares repurchased 2.7 Aggregate cost of shares repurchased $ 151 Average price per share of shares repurchased $ 56.34

Asset Impairment, Exit and Im_2

Asset Impairment, Exit and Implementation Costs (Tables)	3 Months Ended
	Mar. 31, 2020
Restructuring and Related Activities [Abstract]
Restructuring and Related Costs	Pre-tax asset impairment, exit and implementation costs consisted of the following: For the Three Months Ended March 31, 2020 2019 Implementation Costs (1) Total Asset Impairment and Exit Costs Implementation Costs (1) Total (in millions) Smokeable products $ — $ — $ 36 $ 8 $ 44 Oral tobacco products — — 8 1 9 Wine 392 392 — — — All other — — (5 ) — (5 ) General corporate — — 1 — 1 Total 392 392 40 9 49 Plus amounts included in net periodic benefit income, excluding service cost (2) — — 12 — 12 Total $ 392 $ 392 $ 52 $ 9 $ 61 (1) Included in cost of sales for 2020 and marketing, administration and research costs for 2019 in Altria’s condensed consolidated statements of earnings. (2) Represents curtailment costs. See Note 6 . Benefit Plans .
Schedule of Restructuring Reserve by Type of Cost	The movement in the restructuring liabilities, substantially all of which were severance liabilities, related to the cost reduction program was as follows: (in millions) Balances at December 31, 2019 $ 67 Charges — Cash spent (23 ) Balances at March 31, 2020 $ 44

Investments in Equity Securit_2

Investments in Equity Securities Investments in Equity Securities (Tables)	3 Months Ended
	Mar. 31, 2020
Investments [Abstract]
Investment	Altria’s investments consisted of the following: Carrying Amount March 31, 2020 December 31, 2019 (in millions) ABI $ 18,453 $ 18,071 JUUL 4,205 4,205 Cronos (1) 1,203 1,305 Total $ 23,861 $ 23,581 (1) March 31, 2020 includes Altria’s equity method investment in Cronos ( $1,037 million ), the Cronos warrant ( $132 million ) and the Fixed-price Preemptive Rights ( $34 million ) and December 31, 2019 includes Altria’s equity method investment in Cronos ( $1,002 million ), the Cronos warrant ( $234 million ) and the Fixed -price Preemptive Rights ( $69 million ), as discussed further below.
Equity Method Investments	Earnings from equity investments accounted for under the equity method of accounting consisted of the following: For the Three Months Ended March 31, 2020 2019 (in millions) ABI $ 134 $ 86 Cronos (1) 23 — Total $ 157 $ 86 (1) Represents Altria’s share of Cronos’s earnings, which includes the change in fair value of Cronos’s derivative financial instruments associated with the issuance of additional shares. As a result of the acquisition of Cronos in March 2019 and Altria reporting its share of Cronos’s results using a one-quarter lag, no equity earnings from Altria’s investment in Cronos were recorded for the three months ended March 31, 2019.

Financial Instruments (Tables)

Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair Value Measurement Inputs and Valuation Techniques	The fair values of the Fixed-price Preemptive Rights and Cronos warrant are estimated using Black-Scholes option-pricing models, adjusted for observable inputs (which are classified in Level 1 of the fair value hierarchy), including share price, and unobservable inputs, including probability factors and weighting of expected life, volatility levels and risk-free interest rates (which are classified in Level 3 of the fair value hierarchy) based on the following assumptions at: March 31, 2020 December 31, 2019 March 31, 2020 December 31, 2019 Fixed-price Preemptive Rights Cronos Warrant Share price (1) C$7.99 C$9.97 C$7.99 C$9.97 Expected life (2) 1.60 years 1.67 years 2.93 years 3.18 years Expected volatility (3) 79.97% 81.61% 79.97% 81.61% Risk-free interest rate (4)(5) 0.38% 1.71% 0.49% 1.69% Expected dividend yield (6) —% —% —% —% (1) Based on the closing market price for Cronos common stock on the Toronto Stock Exchange on the date indicated. (2) Based on the weighted-average expected life of the Fixed-price Preemptive Rights (with a range from approximately 0.25 year to 6 years at March 31, 2020 and December 31, 2019) and the March 8, 2023 expiration date of the Cronos warrant. (3) Based on a blend of historical volatility levels of the underlying equity security and peer companies. (4) Based on the implied yield currently available on Canadian Treasury zero coupon issues (with a range from approximately 0.21% to 0.62% at March 31, 2020 and 1.66% to 1.74% at December 31, 2019) weighted for the remaining expected life of the Fixed-price Preemptive Rights. (5) Based on the implied yield currently available on Canadian Treasury zero coupon issues and the expected life of the Cronos warrant. (6) Based on Cronos’s expected dividend payments.
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation	The following table provides a reconciliation of the beginning and ending balance of the Fixed-price Preemptive Rights and Cronos warrant, which are classified in Level 3 of the fair value hierarchy: (in millions) Balance at December 31, 2019 $ 303 Pre-tax earnings (losses) recognized in net earnings (137 ) Balance at March 31, 2020 $ 166
Schedule of Derivative Liabilities at Fair Value	The fair values of Altria’s derivative financial instruments on a gross basis included on the condensed consolidated balance sheets were as follows: Fair Value of Assets Fair Value of Liabilities Balance Sheet Classification March 31, 2020 December 31, 2019 Balance Sheet Classification March 31, 2020 December 31, 2019 Derivatives designated as hedging instruments: (in millions) Foreign currency contracts Other current assets $ 55 $ 46 Other accrued liabilities $ — $ 7 Foreign currency contracts Other assets 19 — Other liabilities — 21 Total $ 74 $ 46 $ — $ 28 Derivatives not designated as hedging instruments: Cronos warrant Investments in equity securities $ 132 $ 234 Fixed-price Preemptive Rights Investments in equity securities 34 69 Total $ 166 $ 303 Total derivatives $ 240 $ 349 $ — $ 28
Pre-tax Effects of Net Investment Hedges on Accumulated Other Comprehensive Losses	The pre-tax effects of Altria’s net investment hedges on accumulated other comprehensive losses and the condensed consolidated statements of earnings were as follows: Gain (Loss) Recognized in Accumulated Other Comprehensive Losses Gain (Loss) Recognized in Net Earnings (1) For the Three Months Ended March 31, 2020 2019 2020 2019 (in millions) Foreign currency contracts $ 56 $ 23 $ 14 $ 9 Foreign currency denominated debt 77 33 — — Total $ 133 $ 56 $ 14 $ 9 (1) Related to amounts excluded from effectiveness testing. three months ended March 31, 2020 and 2019 , Altria recognized pre-tax unrealized losses, representing the changes in the fair values of the Fixed-price Preemptive Rights and Cronos warrant, as follows: For the Three Months Ended March 31, 2020 2019 (in millions) Fixed-price Preemptive Rights $ (35 ) $ (132 ) Cronos warrant (102 ) (262 ) (137 ) (394 )

Benefit Plans (Tables)

Benefit Plans (Tables)	3 Months Ended
	Mar. 31, 2020
Retirement Benefits [Abstract]
Schedule of Net Periodic Benefit (Income) Cost	Net periodic benefit (income) cost consisted of the following: For the Three Months Ended March 31, Pension Postretirement 2020 2019 2020 2019 (in millions) Service cost $ 19 $ 17 $ 4 $ 4 Interest cost 63 77 15 20 Expected return on plan assets (126 ) (145 ) (3 ) (4 ) Amortization: Net loss 27 42 3 3 Prior service cost (credit) 1 1 (7 ) (7 ) Curtailment — 7 — 5 Net periodic benefit (income) cost $ (16 ) $ (1 ) $ 12 $ 21

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Earnings Per Share	Basic and diluted earnings per share (“EPS”) were calculated using the following: For the Three Months Ended March 31, 2020 2019 (in millions) Net earnings attributable to Altria $ 1,552 $ 1,120 Less: Distributed and undistributed earnings attributable to share-based awards (2 ) (2 ) Earnings for basic and diluted EPS $ 1,550 $ 1,118 Weighted-average shares for basic and diluted EPS 1,858 1,874

Other Comprehensive Earnings__2

Other Comprehensive Earnings/Losses (Tables)	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The following tables set forth the changes in each component of accumulated other comprehensive losses, net of deferred income taxes, attributable to Altria: For the Three Months Ended March 31, 2020 Benefit Plans ABI Currency Translation Adjustments and Other Accumulated Other Comprehensive Losses (in millions) Balances, December 31, 2019 $ (2,192 ) $ (693 ) $ 21 $ (2,864 ) Other comprehensive earnings (losses) before reclassifications — 388 12 400 Deferred income taxes — (85 ) — (85 ) Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes — 303 12 315 Amounts reclassified to net earnings 28 (7 ) — 21 Deferred income taxes (7 ) 2 — (5 ) Amounts reclassified to net earnings, net of deferred income taxes 21 (5 ) — 16 Other comprehensive earnings (losses), net of deferred income taxes 21 298 (1) 12 331 Balances, March 31, 2020 $ (2,171 ) $ (395 ) $ 33 $ (2,533 ) For the Three Months Ended March 31, 2019 Benefit Plans ABI Currency Translation Adjustments and Other Accumulated Other Comprehensive Losses (in millions) Balances, December 31, 2018 $ (2,168 ) $ (374 ) $ (5 ) $ (2,547 ) Other comprehensive earnings (losses) before reclassifications — (238 ) — (238 ) Deferred income taxes — 49 — 49 Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes — (189 ) — (189 ) Amounts reclassified to net earnings 39 (12 ) — 27 Deferred income taxes (10 ) 2 — (8 ) Amounts reclassified to net earnings, net of deferred income taxes 29 (10 ) — 19 Other comprehensive earnings (losses), net of deferred income taxes 29 (199 ) (1) — (170 ) Balances, March 31, 2019 $ (2,139 ) $ (573 ) $ (5 ) $ (2,717 ) (1) Primarily reflects Altria’s share of ABI’s currency translation adjustments and the impact of Altria’s designated net investment hedges. For further discussion of designated net investment hedges, see Note 5 . Financial Instruments.
Reclassification out of Accumulated Other Comprehensive Income	The following table sets forth pre-tax amounts by component, reclassified from accumulated other comprehensive losses to net earnings: For the Three Months Ended March 31, 2020 2019 (in millions) Benefit Plans: (1) Net loss $ 34 $ 49 Prior service cost/credit (6 ) (10 ) 28 39 ABI (2) (7 ) (12 ) Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings $ 21 $ 27 (1) Amounts are included in net defined benefit plan costs. For further details, see Note 6 . Benefit Plans. (2) Amounts are included in earnings from equity investments. For further information, see Note 4 . Investments in Equity Securities.

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	Segment data were as follows: For the Three Months Ended March 31, 2020 2019 (in millions) Net revenues: Smokeable products $ 5,606 $ 4,935 Oral tobacco products 601 540 Wine 146 151 All other 6 2 Net revenues $ 6,359 $ 5,628 Earnings before income taxes: Operating companies income (loss): Smokeable products $ 2,370 $ 1,932 Oral tobacco products 414 358 Wine (379 ) 15 All other (5 ) (12 ) Amortization of intangibles (19 ) (8 ) General corporate expenses (45 ) (46 ) Corporate asset impairment and exit costs — (1 ) Operating income 2,336 2,238 Interest and other debt expense, net (275 ) (384 ) Net periodic benefit income, excluding service cost 27 1 Earnings from equity investments 157 86 Loss on Cronos-related financial instruments (137 ) (425 ) Earnings before income taxes $ 2,108 $ 1,516
Schedule of Pre-tax Tobacco and Health Litigation Items	Tobacco and Health Litigation Items - Pre-tax charges related to certain tobacco and health litigation items were recorded in Altria’s condensed consolidated statements of earnings as follows: For the Three Months Ended March 31, 2020 2019 (in millions) Smokeable products segment $ 22 $ 15 Interest and other debt expense, net 2 2 Total $ 24 $ 17

Contingencies (Tables)

Contingencies (Tables)	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Schedule of Contingencies	The table below lists the number of certain tobacco-related cases pending in the U.S. against PM USA and, in some instances, Altria as of April 27, 2020, April 22, 2019 and April 23, 2018: April 27, 2020 April 22, 2019 April 23, 2018 Individual Smoking and Health Cases (1) 109 98 102 Health Care Cost Recovery Actions (2) — 1 1 E-vapor Cases (3) 202 2 3 Other Tobacco-Related Cases (4) 4 — — (1) Includes 22 cases filed in Massachusetts and 46 non- Engle cases filed in Florida. Does not include individual smoking and health cases brought by or on behalf of plaintiffs in Florida state and federal courts following the decertification of the Engle case (these Engle progeny cases are discussed below in Smoking and Health Litigation - Engle Class Action ). Also does not include 1,472 cases brought by flight attendants seeking compensatory damages for personal injuries allegedly caused by exposure to environmental tobacco smoke (“ETS”). The flight attendants allege that they are members of an ETS smoking and health class action in Florida, which was settled in 1997 ( Broin ). The terms of the court-approved settlement in that case allowed class members to file individual lawsuits seeking compensatory damages, but prohibited them from seeking punitive damages. In March 2018, 923 of these cases were voluntarily dismissed without prejudice. (2) See Health Care Cost Recovery Litigation - Federal Government’s Lawsuit below. (3) Includes 24 class action lawsuits, 170 individual lawsuits, five state or local government lawsuits and three lawsuits filed by school districts relating to JUUL e-vapor products. JUUL is an additional named defendant in each of these lawsuits. (4) For 2019 and 2020, includes two inactive smoking and health cases alleging personal injury or seeking court-supervised programs or ongoing medical monitoring and purporting to be brought on behalf of a class of individual plaintiffs, including one case in which the aggregated claims of a number of individual plaintiffs are to be tried in a single proceeding, and two inactive class action lawsuits alleging that use of the terms “Lights” and “Ultra Lights” constitute deceptive and unfair trade practices, common law or statutory fraud, unjust enrichment, breach of warranty or violations of RICO. Currently Pending Engle Cases with Accrued Liabilities (rounded to nearest $ million) Plaintiff Verdict Date Defendant(s) Court Compensatory Damages (All Defendants) Punitive Damages (PM USA) Appeal Status Accrual (1) Berger ( Cote ) September 2014 PM USA Federal Court - Middle District of Florida $6 million $21 million The Eleventh Circuit Court of Appeals reinstated the punitive and compensatory damages awards and remanded the case to the district court. PM USA’s challenge to the punitive damages award was denied by the district court. PM USA’s appeal to the Eleventh Circuit Court of Appeals is pending. $6 million accrual in the fourth quarter of 2018 (1) Accrual amounts include interest and associated costs, if applicable. For cases with multiple defendants, if any, accrual amounts reflect the portion of compensatory damages PM USA believes it will have to pay if the case is ultimately decided in plaintiff’s favor after taking into account any portion potentially payable by the other defendant(s). Other Currently Pending Engle Cases with Verdicts Against PM USA (rounded to nearest $ million) Plaintiff Verdict Date Defendant(s) Court Compensatory Damages (1) Punitive Damages Appeal Status Duignan February 2020 (2 ) PM USA and (3) Pinellas $3 million $12 million Defendants’ post-trial motions pending. Cuddihee January 2020 PM USA Duval $3 million $0 Defendant’s post-trial motions pending. Rintoul (Caprio) November 2019 (2 ) PM USA and R.J. Reynolds Broward $9 million ($5 million PM USA) $74 million Defendants’ post-trial motion pending. Gloger November 2019 (2 ) PM USA and R.J. Reynolds Miami-Dade $15 million ($5 million PM USA) $11 million Appeal by defendants to Third District Court of Appeal pending. McCall March 2019 PM USA Broward <$1 million (<$1 million PM USA) <$1 million New trial ordered on punitive damages. Neff March 2019 PM USA and R.J. Reynolds Broward $4 million $2 million Appeals by plaintiff and defendants to Fourth District Court of Appeal pending. Frogel March 2019 PM USA Palm Beach <$1 million (<$1 million PM USA) $0 Appeals by plaintiff and defendant to Fourth District Court of Appeal pending. Other Currently Pending Engle Cases with Verdicts Against PM USA (rounded to nearest $ million) Plaintiff Verdict Date Defendant(s) Court Compensatory Damages (1) Punitive Damages Appeal Status Mahfuz February 2019 PM USA and R.J. Reynolds Broward $12 million $10 million Appeals by plaintiff and defendants to Fourth District Court of Appeal pending. Holliman February 2019 PM USA Miami-Dade $3 million $0 Defendant’s appeal to Third District Court of Appeal pending. Chadwell September 2018 PM USA Miami-Dade $2 million $0 Appeals by defendant and plaintiff to Third District Court of Appeal pending. Kaplan July 2018 PM USA and R.J. Reynolds Broward $2 million $2 million Appeals by defendants and plaintiff to Fourth District Court of Appeal pending. Landi June 2018 PM USA and R.J. Reynolds Broward $8 million $5 million Appeals by plaintiff and defendants to Fourth District Court of Appeal pending. R. Douglas November 2017 PM USA Duval <$1 million $0 Awaiting entry of final judgment by the trial court. Sommers April 2017 PM USA Miami-Dade $1 million $0 Third District Court of Appeal affirmed compensatory damages award and granted new trial on punitive damages. Defendant petitioned Florida Supreme Court for review. Santoro March 2017 PM USA, R.J. Reynolds and Liggett Group (3) Broward $2 million $0 Trial court set aside punitive damages award; appeals by plaintiff and defendants to Fourth District Court of Appeal pending. Cooper (Blackwood) September 2015 PM USA and R.J. Reynolds Broward $5 million $0 Fourth District Court of Appeal affirmed judgment and granted a new trial on punitive damages. D. Brown January 2015 PM USA Federal Court - Middle District of Florida $8 million $9 million Appeal by defendant to U.S. Court of Appeals for the Eleventh Circuit pending. Kerrivan October 2014 PM USA and R.J. Reynolds Federal Court - Middle District of Florida $16 million $16 million U.S. Court of Appeals for the Eleventh Circuit affirmed the judgment. Defendants’ motion for rehearing pending. Harris July 2014 PM USA, (3) Federal Court - Middle District of Florida $2 million (<$ 1 million PM USA) $0 Appeals by plaintiff and defendants to U.S. Court of Appeals for the Eleventh Circuit pending. (1) PM USA’s portion of the compensatory damages award is noted parenthetically where the court has ruled that comparative fault applies. (2) Plaintiff’s verdict following a retrial of an initial verdict in favor of plaintiff. (3) References to “R.J. Reynolds,” “Liggett Group” and “Lorillard” are to R.J. Reynolds Tobacco Company, Liggett Group, LLC and Lorillard Tobacco Company, respectively. Engle Cases Concluded Within Past 12 Months (1) (rounded to nearest $ million) Plaintiff Verdict Date Defendant(s) Court Accrual Date Payment Amount (if any) Payment Date Theis (2) May 2018 PM USA and Sarasota First quarter of 2020 $17 million February 2020 Alvarez Del Real September 2019 PM USA Miami-Dade Fourth quarter of 2019 <$1 million October 2019 Engle Cases Concluded Within Past 12 Months (1) (rounded to nearest $ million) Plaintiff Verdict Date Defendant(s) Court Accrual Date Payment Amount (if any) Payment Date Zingaro May 2019 PM USA and Broward Third quarter of 2019 <$1 million October 2019 Bryant December 2017 PM USA Escambia Second quarter of 2019 <$1 million July 2019 Wallace October 2017 PM USA and Brevard Second quarter of 2019 $26 million May 2019 J. Brown February 2017 PM USA and Pinellas First quarter of 2019 $4 million April 2019 L. Martin May 2017 PM USA Miami-Dade First quarter of 2019 $2 million April 2019 Danielson November 2015 PM USA Escambia First quarter of 2019 $3 million March 2019 S. Martin November 2016 PM USA and Broward First quarter of 2019 $5 million March 2019 Searcy April 2013 PM USA and Federal Court - Middle District of Florida Third quarter of 2018 $2 million March 2019 Boatright November 2014 PM USA and Liggett Group Polk Second quarter of 2018 $42 million March 2019 M. Brown (3) May 2015 PM USA Duval Second quarter of 2018 $8 million March 2019 Jordan (4) August 2015 PM USA Duval Second quarter of 2018 $11 million March 2019 Pardue December 2016 PM USA and Alachua Second and Third quarters of 2018 $11 million March 2019 McKeever February 2015 PM USA Broward Fourth quarter of 2017 $21 million March 2019 (1) In two cases in which PM USA paid the judgments more than a year ago, Naugle and Gore , plaintiffs were awarded approximately $8 million and approximately $2 million in fees and other costs, respectively. In both cases, PM USA has appealed. (2) In February 2020, the Florida Second District Court of Appeal denied PM USA’s petition for review. As a result, in the first quarter of 2020, PM USA recorded a pre-tax provision of approximately $17 million for the judgment plus interest, which was subsequently paid in the first quarter of 2020. (3) The trial court also awarded plaintiff approximately $9 million in fees, interest and costs. PM USA and plaintiff have appealed. (4) The trial court also awarded plaintiff approximately $4 million in fees and costs. PM USA and plaintiff have appealed. The changes in Altria’s accrued liability for tobacco and health litigation items, including related interest costs, for the periods specified below are as follows: For the Three Months Ended March 31, (in millions) 2020 2019 Accrued liability for tobacco and health litigation items at beginning of period (1) $ 14 $ 112 Pre-tax charges for: Tobacco and health litigation 22 (2) 15 Related interest costs 2 2 Payments (1) (28 ) (3) (109 ) Accrued liability for tobacco and health litigation items at end of period (1) $ 10 $ 20 (1) Includes amounts related to the costs of implementing the corrective communications remedy related to the Federal Government’s Lawsuit discussed below. (2) Includes approximately $7 million related to pre-trial resolution of approximately 100 tobacco and health cases. (3) Includes approximately $7 million in payments related to above-mentioned pre-trial resolution of approximately 100 tobacco and health cases and $2 million for pre-trial resolution of other tobacco and health cases that was accrued in 2019 but not paid until 2020 .

Condensed Consolidating Finan_2

Condensed Consolidating Financial Information (Tables)	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Consolidating Balance Sheet	Condensed Consolidating Balance Sheets March 31, 2020 (in millions of dollars) Altria Group, Inc. PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Assets Cash and cash equivalents $ 5,548 $ 1 $ 67 $ — $ 5,616 Receivables — 17 130 — 147 Inventories: Leaf tobacco — 508 387 — 895 Other raw materials — 123 70 — 193 Work in process — 6 461 — 467 Finished product — 87 364 — 451 — 724 1,282 — 2,006 Due from Altria Group, Inc. and subsidiaries 91 5,660 1,361 (7,112 ) — Other current assets 301 23 68 (226 ) 166 Total current assets 5,940 6,425 2,908 (7,338 ) 7,935 Property, plant and equipment, at cost — 2,970 2,133 — 5,103 Less accumulated depreciation — 2,186 920 — 3,106 — 784 1,213 — 1,997 Goodwill — — 5,177 — 5,177 Other intangible assets, net — 2 12,666 — 12,668 Investments in equity securities 18,453 — 5,408 — 23,861 Investment in consolidated subsidiaries 18,905 2,867 — (21,772 ) — Due from Altria Group, Inc. and subsidiaries 4,790 — — (4,790 ) — Other assets 71 950 567 (608 ) 980 Total Assets $ 48,159 $ 11,028 $ 27,939 $ (34,508 ) $ 52,618 Condensed Consolidating Balance Sheets (Continued) March 31, 2020 (in millions of dollars) Altria Group, Inc. PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Liabilities Short-term borrowings $ 3,000 $ — $ — $ — $ 3,000 Accounts payable 1 136 141 — 278 Accrued liabilities: Marketing — 391 76 — 467 Settlement charges — 4,410 9 — 4,419 Other 312 343 377 — 1,032 Income taxes 6 508 105 (226 ) 393 Dividends payable 1,565 — — — 1,565 Due to Altria Group, Inc. and subsidiaries 6,278 587 247 (7,112 ) — Total current liabilities 11,162 6,375 955 (7,338 ) 11,154 Long-term debt 26,971 — — — 26,971 Deferred income taxes 3,228 — 2,571 (608 ) 5,191 Accrued pension costs 196 — 231 — 427 Accrued postretirement health care costs — 1,076 722 — 1,798 Due to Altria Group, Inc. and subsidiaries — — 4,790 (4,790 ) — Other liabilities 59 90 253 — 402 Total liabilities 41,616 7,541 9,522 (12,736 ) 45,943 Contingencies Redeemable noncontrolling interest — — 38 — 38 Stockholders’ Equity Common stock 935 — 9 (9 ) 935 Additional paid-in capital 5,959 3,310 27,566 (30,876 ) 5,959 Earnings reinvested in the business 36,528 393 (7,441 ) 7,048 36,528 Accumulated other comprehensive losses (2,533 ) (216 ) (1,849 ) 2,065 (2,533 ) Cost of repurchased stock (34,346 ) — — — (34,346 ) Total stockholders’ equity attributable to Altria Group, Inc. 6,543 3,487 18,285 (21,772 ) 6,543 Noncontrolling interests — — 94 — 94 Total stockholders’ equity 6,543 3,487 18,379 (21,772 ) 6,637 Total Liabilities and Stockholders’ Equity $ 48,159 $ 11,028 $ 27,939 $ (34,508 ) $ 52,618 Condensed Consolidating Balance Sheets December 31, 2019 (in millions of dollars) Altria Group, Inc. PM USA Non- Total Consolidated Assets Cash and cash equivalents $ 2,022 $ — $ 95 $ — $ 2,117 Receivables — 30 122 — 152 Inventories: Leaf tobacco — 494 380 — 874 Other raw materials — 120 72 — 192 Work in process — 4 692 — 696 Finished product — 119 412 — 531 — 737 1,556 — 2,293 Due from Altria Group, Inc. and subsidiaries 88 4,005 1,359 (5,452 ) — Other current assets 133 64 114 (49 ) 262 Total current assets 2,243 4,836 3,246 (5,501 ) 4,824 Property, plant and equipment, at cost — 2,956 2,118 — 5,074 Less accumulated depreciation — 2,166 909 — 3,075 — 790 1,209 — 1,999 Goodwill — — 5,177 — 5,177 Other intangible assets, net — 2 12,685 — 12,687 Investments in equity securities 18,071 — 5,510 — 23,581 Investment in consolidated subsidiaries 19,312 2,831 — (22,143 ) — Due from Altria Group, Inc. and subsidiaries 4,790 — — (4,790 ) — Other assets 58 951 603 (609 ) 1,003 Total Assets $ 44,474 $ 9,410 $ 28,430 $ (33,043 ) $ 49,271 Condensed Consolidating Balance Sheets (Continued) December 31, 2019 (in millions of dollars) Altria Group, Inc. PM USA Non- Total Consolidated Liabilities Current portion of long-term debt $ 1,000 $ — $ — $ — $ 1,000 Accounts payable — 146 179 — 325 Accrued liabilities: Marketing — 320 73 — 393 Settlement charges — 3,340 6 — 3,346 Other 570 482 481 — 1,533 Income taxes 6 — 55 (49 ) 12 Dividends payable 1,565 — — — 1,565 Due to Altria Group, Inc. and subsidiaries 4,693 514 245 (5,452 ) — Total current liabilities 7,834 4,802 1,039 (5,501 ) 8,174 Long-term debt 27,042 — — — 27,042 Deferred income taxes 3,099 — 2,593 (609 ) 5,083 Accrued pension costs 197 — 276 — 473 Accrued postretirement health care costs — 1,078 719 — 1,797 Due to Altria Group, Inc. and subsidiaries — — 4,790 (4,790 ) — Other liabilities 80 87 178 — 345 Total liabilities 38,252 5,967 9,595 (10,900 ) 42,914 Contingencies Redeemable noncontrolling interest — — 38 — 38 Stockholders’ Equity Common stock 935 — 9 (9 ) 935 Additional paid-in capital 5,970 3,310 27,565 (30,875 ) 5,970 Earnings reinvested in the business 36,539 352 (6,997 ) 6,645 36,539 Accumulated other comprehensive losses (2,864 ) (219 ) (1,877 ) 2,096 (2,864 ) Cost of repurchased stock (34,358 ) — — — (34,358 ) Total stockholders’ equity attributable to Altria Group, Inc. 6,222 3,443 18,700 (22,143 ) 6,222 Noncontrolling interests — — 97 — 97 Total stockholders’ equity 6,222 3,443 18,797 (22,143 ) 6,319 Total Liabilities and Stockholders’ Equity $ 44,474 $ 9,410 $ 28,430 $ (33,043 ) $ 49,271
Condensed Consolidating Statements of Earnings and Comprehensive Earnings	Condensed Consolidating Statements of Earnings and Comprehensive Earnings For the Three Months Ended March 31, 2020 (in millions of dollars) Altria Group, Inc. PM USA Non- Total Consolidated Net revenues $ — $ 5,359 $ 1,008 $ (8 ) $ 6,359 Cost of sales — 1,532 649 (8 ) 2,173 Excise taxes on products — 1,267 46 — 1,313 Gross profit — 2,560 313 — 2,873 Marketing, administration and research costs 22 387 128 — 537 Operating income (expense) (22 ) 2,173 185 — 2,336 Interest and other debt expense (income), net 237 (18 ) 56 — 275 Net periodic benefit (income) cost, excluding service cost — (22 ) (5 ) — (27 ) Earnings from equity investments (134 ) — (23 ) — (157 ) Loss on Cronos-related financial instruments — — 137 — 137 Earnings (losses) before income taxes and equity earnings of subsidiaries (125 ) 2,213 20 — 2,108 Provision (benefit) for income taxes (32 ) 550 40 — 558 Equity earnings of subsidiaries 1,645 126 — (1,771 ) — Net earnings 1,552 1,789 (20 ) (1,771 ) 1,550 Net (earnings) losses attributable to noncontrolling interests — — 2 — 2 Net earnings attributable to Altria $ 1,552 $ 1,789 $ (18 ) $ (1,771 ) $ 1,552 Net earnings $ 1,552 $ 1,789 $ (20 ) $ (1,771 ) $ 1,550 Other comprehensive earnings (losses), net of deferred income taxes 331 3 28 (31 ) 331 Comprehensive earnings 1,883 1,792 8 (1,802 ) 1,881 Comprehensive (earnings) losses attributable to noncontrolling interests — — 2 — 2 Comprehensive earnings attributable to Altria $ 1,883 $ 1,792 $ 10 $ (1,802 ) $ 1,883 Condensed Consolidating Statements of Earnings and Comprehensive Earnings For the Three Months Ended March 31, 2019 (in millions of dollars) Altria Group, Inc. PM USA Non- Total Consolidated Net revenues $ — $ 4,725 $ 913 $ (10 ) $ 5,628 Cost of sales — 1,340 248 (10 ) 1,578 Excise taxes on products — 1,185 54 — 1,239 Gross profit — 2,200 611 — 2,811 Marketing, administration and research costs 35 384 114 — 533 Asset impairment and exit costs 1 35 4 — 40 Operating income (expense) (36 ) 1,781 493 — 2,238 Interest and other debt expense (income), net 355 (25 ) 54 — 384 Net periodic benefit (income) cost, excluding service cost 1 — (2 ) — (1 ) Earnings from equity investments (86 ) — — — (86 ) Loss on Cronos-related financial instruments — — 425 — 425 Earnings (losses) before income taxes and equity earnings of subsidiaries (306 ) 1,806 16 — 1,516 Provision (benefit) for income taxes (75 ) 459 11 — 395 Equity earnings of subsidiaries 1,351 95 — (1,446 ) — Net earnings 1,120 1,442 5 (1,446 ) 1,121 Net (earnings) losses attributable to noncontrolling interests — — (1 ) — (1 ) Net earnings attributable to Altria $ 1,120 $ 1,442 $ 4 $ (1,446 ) $ 1,120 Net earnings $ 1,120 $ 1,442 $ 5 $ (1,446 ) $ 1,121 Other comprehensive earnings (losses), net of deferred income taxes (170 ) 5 23 (28 ) (170 ) Comprehensive earnings 950 1,447 28 (1,474 ) 951 Comprehensive (earnings) losses attributable to noncontrolling interests — — (1 ) — (1 ) Comprehensive earnings attributable to Altria $ 950 $ 1,447 $ 27 $ (1,474 ) $ 950
Condensed Consolidating Statements of Cash Flows	Condensed Consolidating Statements of Cash Flows For the Three Months Ended March 31, 2020 (in millions of dollars) Altria Group, Inc. PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Cash Provided by (Used In) Operating Activities Net cash provided by (used in) operating activities $ 1,515 $ 3,351 $ 437 $ (2,174 ) $ 3,129 Cash Provided by (Used in) Investing Activities Capital expenditures — (15 ) (37 ) — (52 ) Investment in consolidated subsidiaries (1 ) — — 1 — Other, net — — — — — Net cash provided by (used in) investing activities (1 ) (15 ) (37 ) 1 (52 ) Cash Provided by (Used in) Financing Activities Proceeds from short-term borrowings 3,000 — — — 3,000 Long-term debt repaid (1,000 ) — — — (1,000 ) Dividends paid on common stock (1,563 ) — — — (1,563 ) Changes in amounts due to/from Altria Group, Inc. and subsidiaries 1,584 (1,582 ) (1 ) (1 ) — Cash dividends paid to parent — (1,748 ) (426 ) 2,174 — Other, net (9 ) — (1 ) — (10 ) Net cash provided by (used in) financing activities 2,012 (3,330 ) (428 ) 2,173 427 Cash, cash equivalents and restricted cash (1) : Increase (decrease) 3,526 6 (28 ) — 3,504 Balance at beginning of period 2,022 43 95 — 2,160 Balance at end of period $ 5,548 $ 49 $ 67 $ — $ 5,664 (1) Restricted cash consisted of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals. See Note 11 . Contingencies . Condensed Consolidating Statements of Cash Flows For the Three Months Ended March 31, 2019 (in millions of dollars) Altria Group, Inc. PM USA Non- Guarantor Subsidiaries Total Consolidating Adjustments Consolidated Cash Provided by (Used In) Operating Activities Net cash provided by (used in) operating activities $ 1,642 $ 2,520 $ 166 $ (2,039 ) $ 2,289 Cash Provided by (Used in) Investing Activities Capital expenditures — (9 ) (29 ) — (38 ) Investment in Cronos — — (1,831 ) — (1,831 ) Investment in consolidated subsidiaries (1,947 ) — — 1,947 — Other, net (3 ) — (78 ) — (81 ) Net cash provided by (used in) investing activities (1,950 ) (9 ) (1,938 ) 1,947 (1,950 ) Cash Provided by (Used in) Financing Activities Repayment of short-term borrowings (12,800 ) — — — (12,800 ) Long-term debt issued 16,265 — — — 16,265 Repurchases of common stock (151 ) — — — (151 ) Dividends paid on common stock (1,502 ) — — — (1,502 ) Changes in amounts due to/from Altria Group, Inc. and subsidiaries 657 (771 ) 2,061 (1,947 ) — Cash dividends paid to parent — (1,737 ) (302 ) 2,039 — Other (120 ) — (9 ) — (129 ) Net cash provided by (used in) financing activities 2,349 (2,508 ) 1,750 92 1,683 Cash, cash equivalents and restricted cash (1) : Increase (decrease) 2,041 3 (22 ) — 2,022 Balance at beginning of period 1,277 100 56 — 1,433 Balance at end of period $ 3,318 $ 103 $ 34 $ — $ 3,455 (1) Restricted cash consisted of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals. See Note 11 . Contingencies .

New Accounting Guidance Not Y_2

New Accounting Guidance Not Yet Adopted (Tables)	3 Months Ended
	Mar. 31, 2020
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Recent Accounting Guidance Not Yet Adopted	The following table provides a description of issued accounting guidance applicable to, but not yet adopted by, Altria: Standards Description Effective Date for Public Entity Effect on Financial Statements ASU 2019-12 Simplifying the Accounting for Income Taxes (Topic 740) The guidance removes certain exceptions for investments, intraperiod allocations and interim calculations, and adds guidance to reduce complexity in accounting for income taxes. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early application is permitted, including adoption in any interim period. Altria is in the process of evaluating the impact of this guidance on its consolidated financial statements and related disclosures. ASU 2020-01 Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 The guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early application is permitted, including adoption in any interim period. Altria is in the process of evaluating the impact of this guidance on its consolidated financial statements and related disclosures.

Background and Basis of Prese_4

Background and Basis of Presentation (Narrative) (Details) - USD ($) $ / shares in Units, shares in Millions	3 Months Ended			18 Months Ended
	Mar. 31, 2020	Sep. 30, 2019	Mar. 31, 2019	Jun. 30, 2019	Apr. 30, 2020	Dec. 31, 2019	Jul. 31, 2019	May 31, 2018	Jan. 31, 2018
ABI [Member]
Equity, Class of Treasury Stock [Line Items]
Equity method investment, ownership percentage	10.10%
JUUL [Member]
Equity, Class of Treasury Stock [Line Items]
Equity securities, ownership percentage	35.00%					35.00%
Cronos [Member]
Equity, Class of Treasury Stock [Line Items]
Equity method investment, ownership percentage	45.00%		45.00%
January 2018 Share Repurchase Program [Member]
Equity, Class of Treasury Stock [Line Items]
Planned share repurchase program								$ 2,000,000,000	$ 1,000,000,000
Repurchase of common stock (shares)			2.7	34
Average price of repurchased shares, per share (usd per share)			$ 56.34	$ 58.86
July 2019 Share Repurchase Program [Member]
Equity, Class of Treasury Stock [Line Items]
Planned share repurchase program							$ 1,000,000,000
Repurchase of common stock (shares)	0
Helix Innovations LLC [Member]
Equity, Class of Treasury Stock [Line Items]
Noncontrolling interest, ownership percentage by parent	80.00%
Business Combination, Consideration Transferred		$ 353,000,000
Noncontrolling interest, ownership percentage by noncontrolling owners	20.00%
Subsequent Event [Member] | July 2019 Share Repurchase Program [Member]
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, remaining authorized repurchase amount					$ 500,000,000

Background and Basis of Prese_5

Background and Basis of Presentation (Share Repurchase Table) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended	18 Months Ended
	Mar. 31, 2019	Jun. 30, 2019
Equity, Class of Treasury Stock [Line Items]
Aggregate cost of shares repurchased	$ 151
January 2018 Share Repurchase Program [Member]
Equity, Class of Treasury Stock [Line Items]
Total number of shares repurchased (shares)	2.7	34
Aggregate cost of shares repurchased	$ 151
Average price per share of shares repurchased (usd per share)	$ 56.34	$ 58.86

Revenues from Contracts with _2

Revenues from Contracts with Customers (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Allowance for sales discounts, goods	$ 0	$ 0
Deferred revenue	$ 219	362
Expected period for satisfaction of performance obligation	three days
Receivables	$ 147	$ 152

Asset Impairment, Exit and Im_3

Asset Impairment, Exit and Implementation Costs (Pre-tax Asset Impairment, Exit and Implementation Costs) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Restructuring Cost and Reserve [Line Items]
Asset impairment and exit costs	$ 0	$ 40
Plus amounts included in net periodic benefit income, excluding service cost, Asset Impairment and Exit Costs		12
Asset Impairment and Exit Costs		52
Total, Implementation Costs	392	9
Plus amounts included in net period benefit income, excluding service cost, Implementation Costs	0	0
Implementation Costs	392	9
Total restructuring	392	49
Plus amounts included in net periodic benefit income, excluding service cost, Total	0	12
Total	392	61
Operating Segments [Member] | Smokeable Products Segment [Member]
Restructuring Cost and Reserve [Line Items]
Asset impairment and exit costs		36
Total, Implementation Costs	0	8
Total restructuring	0	44
Operating Segments [Member] | Oral Tobacco Segment [Member]
Restructuring Cost and Reserve [Line Items]
Asset impairment and exit costs		8
Total, Implementation Costs	0	1
Total restructuring	0	9
Operating Segments [Member] | Wine Segment [Member]
Restructuring Cost and Reserve [Line Items]
Asset impairment and exit costs		0
Total, Implementation Costs	392	0
Total restructuring	392	0
Operating Segments [Member] | All Other [Member]
Restructuring Cost and Reserve [Line Items]
Asset impairment and exit costs		(5)
Total, Implementation Costs	0	0
Total restructuring	0	(5)
Corporate, Non-Segment [Member]
Restructuring Cost and Reserve [Line Items]
Asset impairment and exit costs		1
Asset Impairment and Exit Costs	0	1
Total, Implementation Costs	0	0
Total restructuring	$ 0	$ 1

Asset Impairment, Exit and Im_4

Asset Impairment, Exit and Implementation Costs (Movement in Restructuring Liabilities) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2020USD ($)
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning of period	$ 67
Charges	0
Cash spent	(23)
Restructuring reserve, end of period	$ 44

Asset Impairment, Exit and Im_5

Asset Impairment, Exit and Implementation Costs (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2020
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 392	$ 61
Wine Business Strategic Reset [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	392
Inventory Write-Off [Member] | Wine Business Strategic Reset [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	292
Purchase Commitment [Member] | Wine Business Strategic Reset [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 100
Fulfillment term	5 years
Forecast [Member] | Wine Business Strategic Reset [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges			$ 25

Investments in Equity Securit_3

Investments in Equity Securities (Summary of Investments) (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Investments [Line Items]
Investments	$ 23,861	$ 23,581
ABI [Member]
Investments [Line Items]
Investments in equity securities	18,453	18,071
JUUL [Member]
Investments [Line Items]
Equity securities without readily determinable fair value, amount	4,205	4,205
Cronos [Member]
Investments [Line Items]
Investments in equity securities	1,203	1,305
Equity Contract, Warrant [Member] | Cronos [Member]
Investments [Line Items]
Derivative asset, fair value, gross asset	132	234
Equity Contract, Preemptive Rights [Member] | Cronos [Member]
Investments [Line Items]
Derivative asset, fair value, gross asset	34	69
Common Stock [Member] | Cronos [Member]
Investments [Line Items]
Investments in equity securities	$ 1,037	$ 1,002

Investments in Equity Securit_4

Investments in Equity Securities (Earnings in Equity Securities) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Schedule of Equity Method Investments [Line Items]
Earnings from equity investments	$ 157	$ 86
ABI [Member]
Schedule of Equity Method Investments [Line Items]
Earnings from equity investments	134	86
Cronos Group Inc. [Member]
Schedule of Equity Method Investments [Line Items]
Earnings from equity investments	$ 23	$ 0

Investments in Equity Securit_5

Investments in Equity Securities (Investment in ABI Narrative) (Details) - ABI [Member] shares in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2020USD ($)shares	Dec. 31, 2019USD ($)	Mar. 31, 2020€ / shares	Dec. 31, 2019€ / shares
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage	10.10%
Number of restricted shares owned (in shares) | shares	185
Number of ordinary shares owned (in shares) | shares	12
Investments in equity securities | $	$ 18,453,000,000	$ 18,071,000,000
Difference between carrying amount and fair value, percentage (approximately)	52.00%	11.00%
Equity method investment, impairment | $	$ 0	$ 0
Derivative instrument, number of shares hedged (in shares) | shares	100
Derivative instrument, shares hedged, price per share (in eur per share) | € / shares			€ 40.47	€ 72.71
Fair Value, Inputs, Level 1 [Member]
Schedule of Equity Method Investments [Line Items]
Fair value of equity investment | $	$ 8,800,000,000	$ 16,100,000,000

Investments in Equity Securit_6

Investments in Equity Securities (Investment in JUUL Narrative) (Details)	Jan. 28, 2020director	Dec. 31, 2018USD ($)	Dec. 31, 2019USD ($)	Mar. 31, 2020USD ($)director
Schedule of Equity Method Investments [Line Items]
Equity securities without readily determinable fair value, upward price adjustment, cumulative amount | $				$ 0
JUUL [Member]
Schedule of Equity Method Investments [Line Items]
Payments to acquire equity securities | $		$ 12,800,000,000
Equity securities, ownership percentage			35.00%	35.00%
Equity securities without readily determinable fair value, impairment loss, annual amount | $			$ 8,600,000,000
Equity securities without readily determinable fair value, amount | $			$ 4,205,000,000	$ 4,205,000,000
Equity securities without readily determinable fair value, no litigation period	1 year
Equity securities without readily determinable fair value, non-compete release trigger period	12 months
Equity securities without readily determinable fair value, non-compete release trigger percentage of investment carrying value	10.00%
Equity securities without readily determinable fair value, quantitative assessment adjustment, annual amount | $		$ 12,800,000,000
Equity securities without readily determinable fair value, number of board members				7
Equity securities without readily determinable fair value, number of board members upon share conversion	9
Equity securities without readily determinable fair value, number of independent board members upon share conversion	3
Equity securities without readily determinable fair value, number of board members appointed by investor upon share conversion	1
Equity securities without readily determinable fair value, number of board members appointed by investee stockholders upon share conversion	2
Equity securities without readily determinable fair value, number of investor nominating committee designees upon share conversion	1
Equity securities without readily determinable fair value, number of directors designated by investor upon share conversion	2
Equity securities without readily determinable fair value, number of nominating committee directors designated by investee upon share conversion	3
Equity securities without readily determinable fair value, number of oversight committee directors designated by investor upon share conversion	2
Equity securities without readily determinable fair value, number of oversight committee chair directors designated by investor upon share conversion	1

Investments in Equity Securit_7

Investments in Equity Securities (Investment in Cronos Narrative) (Details) - Cronos Group Inc. [Member] $ / shares in Units, shares in Millions, $ in Billions	Mar. 31, 2019USD ($)shares	Mar. 31, 2019CAD ($)	Mar. 07, 2019CAD ($)	Mar. 31, 2020USD ($)directorboard_membershares	Mar. 31, 2020CAD ($)	Sep. 30, 2019	Dec. 31, 2019USD ($)	Mar. 31, 2019$ / shares
Investments [Line Items]
Number of ordinary shares owned (approximately) (in shares) | shares	149.8
Ownership percentage (approximately)	45.00%			45.00%
Equity method investments, purchase price	$ 1,800,000,000	$ 2.4	$ 2.4
Equity method investment, warrant exercised, ownership percentage (approximately)	55.00%	55.00%
Payments to acquire equity method investments	$ 400,000,000
Payments for deferred tax liability	300,000,000
Number of directors nominated | director				4
Equity method investment, number of independent directors nominated | director				1
Number of members on the Board of Directors | board_member				7
Equity method investments				$ 1,203,000,000			$ 1,305,000,000
Equity method investment, difference between carrying amount and fair value, percentage (approximately)						(14.00%)
Equity Contract, Preemptive Rights [Member]
Investments [Line Items]
Equity method investment, shares purchased, (CAD per share) | $ / shares								$ 16.25
Equity method investment, number of shares eligible for purchase (in shares) | shares				37
Payments for derivative instrument, investing activities	$ 500,000,000
Equity method investment, aggregate exercise price				$ 400,000,000	$ 0.6
Equity Contract, Warrant [Member]
Investments [Line Items]
Equity method investment, shares purchased, (CAD per share) | $ / shares								$ 19
Equity method investment, number of shares eligible for purchase (in shares) | shares				78
Equity method investment, percentage of shares eligible for purchase	10.00%
Payments for derivative instrument, investing activities	$ 1,200,000,000
Equity method investment, aggregate exercise price				$ 1,100,000,000	$ 1.5
Common Stock [Member]
Investments [Line Items]
Equity method investments				1,037,000,000			1,002,000,000
Equity method investment, impairment				0
Fair Value, Inputs, Level 1 [Member]
Investments [Line Items]
Fair value of equity investment				$ 900,000,000			$ 1,200,000,000

Financial Instruments (Narrativ

Financial Instruments (Narrative) (Details) $ in Billions	Mar. 31, 2019USD ($)	Mar. 31, 2019CAD ($)	Mar. 07, 2019CAD ($)	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2019USD ($)	Mar. 07, 2019USD ($)	Mar. 07, 2019CAD ($)
Derivative [Line Items]
Short-term borrowings				$ 3,000,000,000		$ 0
Derivative, gain (loss) on derivative, net				(137,000,000)	$ (425,000,000)
Not Designated as Hedging Instrument [Member] | Forward Contracts [Member]
Derivative [Line Items]
Derivative asset, notional amount							$ 1,800,000,000	$ 2.4
Derivative, gain (loss) on derivative, net					$ 31,000,000
Cronos Group Inc. [Member]
Derivative [Line Items]
Equity method investments, purchase price	$ 1,800,000,000	$ 2.4	$ 2.4
Foreign Currency Denominated Debt [Member]
Derivative [Line Items]
Debt instrument, fair value disclosure				4,595,000,000		5,057,000,000
Long-term debt				4,666,000,000		4,741,000,000
Net Investment Hedging [Member] | Foreign currency contracts [Member]
Derivative [Line Items]
Derivative, notional amount				2,246,000,000		2,246,000,000
Reported Value Measurement [Member]
Derivative [Line Items]
Long-term debt, fair value				27,000,000,000		28,000,000,000
Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value Measurement [Member]
Derivative [Line Items]
Long-term debt, fair value				$ 28,300,000,000		$ 30,700,000,000

Financial Instruments (Fair Val

Financial Instruments (Fair Value Using Black-Scholes Option-Pricing Model) (Details)	Mar. 31, 2020year	Dec. 31, 2019year
Share price [Member] | Fixed-price Preemptive Rights [Member]
Derivative [Line Items]
Derivative asset, measurement input	7.99	9.97
Share price [Member] | Cronos Warrant [Member]
Derivative [Line Items]
Derivative asset, measurement input	7.99	9.97
Expected Life [Member] | Fixed-price Preemptive Rights [Member]
Derivative [Line Items]
Derivative asset, measurement input	1.60	1.67
Expected Life [Member] | Cronos Warrant [Member]
Derivative [Line Items]
Derivative asset, measurement input	2.93	3.18
Expected Volatility [Member] | Fixed-price Preemptive Rights [Member]
Derivative [Line Items]
Derivative asset, measurement input	0.7997	0.8161
Expected Volatility [Member] | Cronos Warrant [Member]
Derivative [Line Items]
Derivative asset, measurement input	0.7997	0.8161
Risk Free Interest Rate [Member] | Fixed-price Preemptive Rights [Member]
Derivative [Line Items]
Derivative asset, measurement input	0.0038	0.0171
Risk Free Interest Rate [Member] | Fixed-price Preemptive Rights [Member] | Minimum [Member]
Derivative [Line Items]
Derivative asset, measurement input	0.0021	0.0166
Risk Free Interest Rate [Member] | Fixed-price Preemptive Rights [Member] | Maximum [Member]
Derivative [Line Items]
Derivative asset, measurement input	0.0062	0.0174
Risk Free Interest Rate [Member] | Cronos Warrant [Member]
Derivative [Line Items]
Derivative asset, measurement input	0.0049	0.0169
Expected Dividend Yield [Member] | Fixed-price Preemptive Rights [Member]
Derivative [Line Items]
Derivative asset, measurement input	0	0
Expected Dividend Yield [Member] | Cronos Warrant [Member]
Derivative [Line Items]
Derivative asset, measurement input	0	0
Weighted Average Expected Term [Member] | Fixed-price Preemptive Rights [Member] | Minimum [Member]
Derivative [Line Items]
Derivative asset, measurement input	0.25
Weighted Average Expected Term [Member] | Fixed-price Preemptive Rights [Member] | Maximum [Member]
Derivative [Line Items]
Derivative asset, measurement input	6

Financial Instruments (Beginnin

Financial Instruments (Beginning and Ending Balances of Fixed-price Preemptive Rights and Warrants) (Details) - Fair Value, Inputs, Level 3 [Member] - Equity Contract [Member] $ in Millions	3 Months Ended
	Mar. 31, 2020USD ($)
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Balance at begging of period	$ 303
Pre-tax earnings (losses) recognized in net earnings	(137)
Balance at end of period	$ 166

Financial Instruments (Fair V_2

Financial Instruments (Fair Value Derivative Financial Instruments) (Details) - Net Investment Hedging [Member] - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Derivatives, Fair Value [Line Items]
Fair Value of Assets	$ 240	$ 349
Fair Value of Liabilities	0	28
Foreign currency contracts [Member] | Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Fair Value of Assets	74	46
Fair Value of Liabilities	0	28
Foreign currency contracts [Member] | Designated as Hedging Instrument [Member] | Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Fair Value of Assets	55	46
Foreign currency contracts [Member] | Designated as Hedging Instrument [Member] | Other Assets [Member]
Derivatives, Fair Value [Line Items]
Fair Value of Assets	19	0
Foreign currency contracts [Member] | Designated as Hedging Instrument [Member] | Other Accrued Liabilities [Member]
Derivatives, Fair Value [Line Items]
Fair Value of Liabilities	0	7
Foreign currency contracts [Member] | Designated as Hedging Instrument [Member] | Other Liabilities [Member]
Derivatives, Fair Value [Line Items]
Fair Value of Liabilities	0	21
Equity Contract [Member] | Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Fair Value of Assets	166	303
Cronos Warrant [Member] | Not Designated as Hedging Instrument [Member] | Investments In Equity Securities [Member]
Derivatives, Fair Value [Line Items]
Fair Value of Assets	132	234
Fixed-price Preemptive Rights [Member] | Not Designated as Hedging Instrument [Member] | Investments In Equity Securities [Member]
Derivatives, Fair Value [Line Items]
Fair Value of Assets	$ 34	$ 69

Financial Instruments (Pre-tax

Financial Instruments (Pre-tax Unrealized Gains (Losses)) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Derivative [Line Items]
Unrealized gain (loss) on derivatives	$ (137)	$ (394)
Fixed-price Preemptive Rights [Member]
Derivative [Line Items]
Unrealized gain (loss) on derivatives	(35)	(132)
Cronos Warrant [Member]
Derivative [Line Items]
Unrealized gain (loss) on derivatives	$ (102)	$ (262)

Financial Instruments (Effects

Financial Instruments (Effects of Net Investment Hedges on Accumulated Other Comprehensive Losses) (Details) - Net Investment Hedging [Member] - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in Accumulated Other Comprehensive Losses	$ 133	$ 56
Gain (Loss) Recognized in Net Earnings	14	9
Foreign currency contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in Accumulated Other Comprehensive Losses	56	23
Gain (Loss) Recognized in Net Earnings	14	9
Foreign currency denominated debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in Accumulated Other Comprehensive Losses	77	33
Gain (Loss) Recognized in Net Earnings	$ 0	$ 0

Benefit Plans (Schedule Of Comp

Benefit Plans (Schedule Of Components Of Net Periodic Benefit Cost (Income)) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Pension [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 19	$ 17
Interest cost	63	77
Expected return on plan assets	(126)	(145)
Amortization:
Net loss	27	42
Prior service cost (credit)	1	1
Curtailment	0	7
Net periodic benefit (income) cost	(16)	(1)
Postretirement [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	4	4
Interest cost	15	20
Expected return on plan assets	(3)	(4)
Amortization:
Net loss	3	3
Prior service cost (credit)	(7)	(7)
Curtailment	0	5
Net periodic benefit (income) cost	$ 12	$ 21

Benefit Plans (Narrative) (Deta

Benefit Plans (Narrative) (Details)	3 Months Ended
	Mar. 31, 2020USD ($)
Pension [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, plan assets, contributions by employer	$ 4,000,000
Pension [Member] | Maximum [Member]
Defined Benefit Plan Disclosure [Line Items]
Anticipated additional employer contributions	25,000,000
Postretirement [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, plan assets, contributions by employer	0
Postretirement [Member] | Maximum [Member]
Defined Benefit Plan Disclosure [Line Items]
Anticipated additional employer contributions	$ 60,000,000

Earnings Per Share (Basic and D

Earnings Per Share (Basic and Diluted Earnings Per Share) (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Net earnings attributable to Altria	$ 1,552	$ 1,120
Less: Distributed and undistributed earnings attributable to share-based awards	(2)	(2)
Earnings for basic and diluted EPS	$ 1,550	$ 1,118
Weighted-average shares for basic and diluted EPS (in shares)	1,858	1,874

Other Comprehensive Earnings__3

Other Comprehensive Earnings/Losses (Changes in Each Component of Accumulated Other Comprehensive Losses) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance	$ 6,319	$ 14,789
Other comprehensive earnings (losses), net of deferred income taxes	331	(170)
Ending balance	6,637	14,081
Accumulated Other Comprehensive Losses [Member]
Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance	(2,864)	(2,547)
Other comprehensive earnings (losses) before reclassifications	400	(238)
Deferred income taxes	(85)	49
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes	315	(189)
Amounts reclassified to net earnings	21	27
Deferred income taxes	(5)	(8)
Amounts reclassified to net earnings, net of deferred income taxes	16	19
Other comprehensive earnings (losses), net of deferred income taxes	331	(170)
Ending balance	(2,533)	(2,717)
Benefit Plans [Member]
Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance	(2,192)	(2,168)
Other comprehensive earnings (losses) before reclassifications	0	0
Deferred income taxes	0	0
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes	0	0
Amounts reclassified to net earnings	28	39
Deferred income taxes	(7)	(10)
Amounts reclassified to net earnings, net of deferred income taxes	21	29
Other comprehensive earnings (losses), net of deferred income taxes	21	29
Ending balance	(2,171)	(2,139)
ABI [Member]
Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance	(693)	(374)
Other comprehensive earnings (losses) before reclassifications	388	(238)
Deferred income taxes	(85)	49
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes	303	(189)
Amounts reclassified to net earnings	(7)	(12)
Deferred income taxes	2	2
Amounts reclassified to net earnings, net of deferred income taxes	(5)	(10)
Other comprehensive earnings (losses), net of deferred income taxes	298	(199)
Ending balance	(395)	(573)
Currency Translation Adjustments and Other [Member]
Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance	21	(5)
Other comprehensive earnings (losses) before reclassifications	12	0
Deferred income taxes	0	0
Other comprehensive earnings (losses) before reclassifications, net of deferred income taxes	12	0
Amounts reclassified to net earnings	0	0
Deferred income taxes	0	0
Amounts reclassified to net earnings, net of deferred income taxes	0	0
Other comprehensive earnings (losses), net of deferred income taxes	12	0
Ending balance	$ 33	$ (5)

Other Comprehensive Earnings__4

Other Comprehensive Earnings/Losses (Reclassifications) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net periodic benefit income, excluding service cost	$ (27)	$ (1)
ABI	(157)	(86)
Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings	(1,550)	(1,121)
Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
ABI	(7)	(12)
Pre-tax amounts reclassified from accumulated other comprehensive losses to net earnings	21	27
Benefit Plans [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net periodic benefit income, excluding service cost	28	39
Net loss [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net periodic benefit income, excluding service cost	34	49
Prior service cost/credit [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net periodic benefit income, excluding service cost	$ (6)	$ (10)

Segment Reporting (Segment Data

Segment Reporting (Segment Data Schedule) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Segment Reporting Information [Line Items]
Net revenues	$ 6,359	$ 5,628
Operating income	2,336	2,238
Corporate asset impairment and exit costs		(52)
Interest and other debt expense, net	(275)	(384)
Net periodic benefit income, excluding service cost	27	1
Earnings from equity investments	157	86
Loss on Cronos-related financial instruments	(137)	(425)
Earnings (losses) before income taxes and equity earnings of subsidiaries	2,108	1,516
Smokeable Products Segment [Member]
Segment Reporting Information [Line Items]
Net revenues	5,606	4,935
Oral Tobacco Segment [Member]
Segment Reporting Information [Line Items]
Net revenues	601	540
Wine Segment [Member]
Segment Reporting Information [Line Items]
Net revenues	146	151
All Other [Member]
Segment Reporting Information [Line Items]
Net revenues	6	2
Operating Segments [Member] | Smokeable Products Segment [Member]
Segment Reporting Information [Line Items]
Operating income	2,370	1,932
Operating Segments [Member] | Oral Tobacco Segment [Member]
Segment Reporting Information [Line Items]
Operating income	414	358
Operating Segments [Member] | Wine Segment [Member]
Segment Reporting Information [Line Items]
Operating income	(379)	15
Operating Segments [Member] | All Other [Member]
Segment Reporting Information [Line Items]
Operating income	(5)	(12)
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Amortization of intangibles	(19)	(8)
General corporate [Member]
Segment Reporting Information [Line Items]
General corporate expenses	(45)	(46)
Corporate asset impairment and exit costs	$ 0	$ (1)

Segment Reporting (Schedule of

Segment Reporting (Schedule of Tobacco and Health Litigation Items) (Details) - Tobacco and Health Litigation Cases [Member] - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items]
Provision related to litigation recorded	$ 24	$ 17
Segment Reconciling Items [Member]
Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items]
Provision related to litigation recorded	2	2
PM USA [Member] | Operating Segments [Member] | Smokeable Products Segment [Member]
Schedule of Pre-tax Tobacco and Health Litigation Charges [Line Items]
Provision related to litigation recorded	$ 22	$ 15

Debt (Narrative) (Details)

Debt (Narrative) (Details)	3 Months Ended
	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2019USD ($)	Aug. 01, 2018Extension
Debt Instrument [Line Items]
Short-term borrowings	$ 3,000,000,000		$ 0
Face amount			0
Debt instrument, covenant, consolidated EBITDA to interest expense ratio, minimum	4
Debt instrument, consolidated EBITDA to interest expense ratio	9
Interest payable, short-term borrowings	$ 1,000,000
Long-term debt repaid	1,000,000,000	$ 0
Accrued interest on long-term debt	270,000,000		$ 470,000,000
Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt repaid	$ 1,000,000,000
Revolving Credit Facility [Member] | Line of Credit [Member] | Revolving Credit Facility Due August 2023 [Member]
Debt Instrument [Line Items]
Debt instrument, number of extensions | Extension				2
Debt instrument, expected repayment period	1 year
Debt instrument, extension term	1 year
Debt instrument, interest rate during period	2.23%
Line of Credit [Member] | Revolving Credit Facility [Member] | Revolving Credit Facility Due August 2023 [Member]
Debt Instrument [Line Items]
Face amount	$ 3,000,000,000
Debt instrument, term	5 years
London Interbank Offered Rate (LIBOR) [Member] | Revolving Credit Facility [Member] | Line of Credit [Member] | Revolving Credit Facility Due August 2023 [Member]
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	1.00%

Contingencies (General Informat

Contingencies (General Information) (Details)	Mar. 31, 2020state
Commitments and Contingencies Disclosure [Abstract]
Number of states that cap bond or require no bond	47

Contingencies (Schedule of Pend

Contingencies (Schedule of Pending Cases) (Details)	Apr. 27, 2020caselawsuitclaim	Mar. 31, 2018case	Apr. 30, 2020lawsuit	Apr. 22, 2019case	Apr. 23, 2018case
Individual Smoking and Health Cases [Member]
Loss Contingencies [Line Items]
Number of cases pending				98	102
ETS Smoking and Health Case, Flight Attendants [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of claims dismissed		923
Health Care Cost Recovery Actions [Member]
Loss Contingencies [Line Items]
Number of cases pending				1	1
E-vapor Litigation [Member]
Loss Contingencies [Line Items]
Number of cases pending				2	3
Other Tabacco-Related Cases [Member]
Loss Contingencies [Line Items]
Number of cases pending				0	0
Loss contingency, number of inactive cases				2
Subsequent Event [Member]
Loss Contingencies [Line Items]
Loss contingency, class action lawsuit | lawsuit			3
Subsequent Event [Member] | Individual Smoking and Health Cases [Member]
Loss Contingencies [Line Items]
Number of cases pending	109
Subsequent Event [Member] | Individual Smoking and Health Cases [Member] | Pending Litigation [Member] | Massachusetts [Member]
Loss Contingencies [Line Items]
Number of cases pending	22
Subsequent Event [Member] | Individual Smoking and Health Cases [Member] | Pending Litigation [Member] | Florida [Member]
Loss Contingencies [Line Items]
Number of cases pending	46
Subsequent Event [Member] | ETS Smoking and Health Case, Flight Attendants [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of cases	1,472
Subsequent Event [Member] | Health Care Cost Recovery Actions [Member]
Loss Contingencies [Line Items]
Number of cases pending	0
Subsequent Event [Member] | E-vapor Litigation [Member]
Loss Contingencies [Line Items]
Number of cases pending	202
Loss contingency, class action lawsuit | lawsuit	24
Number of cases set for trial | claim	0
Subsequent Event [Member] | E-vapor Litigation [Member] | Pending Individual Lawsuits [Member]
Loss Contingencies [Line Items]
Number of cases pending | claim	170
Subsequent Event [Member] | E-vapor Litigation [Member] | Pending Lawsuits Filed By State Or Local Governments [Member]
Loss Contingencies [Line Items]
Number of cases pending | claim	5
Subsequent Event [Member] | E-vapor Litigation [Member] | Pending Lawsuit Filed By School District [Member]
Loss Contingencies [Line Items]
Number of cases pending | claim	3
Subsequent Event [Member] | Other Tabacco-Related Cases [Member]
Loss Contingencies [Line Items]
Number of cases pending	4
Loss contingency, number of inactive cases	2
Loss contingency, number of cases tried in a single proceeding	1
Loss contingency, number of inactive class action lawsuits	2
PM USA [Member] | Subsequent Event [Member] | Engle Progeny Cases [Member]
Loss Contingencies [Line Items]
Number of cases set for trial	2
PM USA [Member] | Subsequent Event [Member] | Individual Smoking and Health Cases [Member]
Loss Contingencies [Line Items]
Number of cases set for trial	0

Contingencies (Overview of Altr

Contingencies (Overview of Altria and/or PM USA Tobacco-Related Litigation Narrative) (Details) - case	Apr. 27, 2020	Apr. 27, 2020	Apr. 22, 2019	Apr. 23, 2018
Other Tabacco-Related Cases [Member]
Loss Contingencies [Line Items]
Loss contingency, number of inactive cases			2
Number of cases pending			0	0
Health Care Cost Recovery Actions [Member]
Loss Contingencies [Line Items]
Number of cases pending			1	1
Individual Smoking and Health Cases [Member]
Loss Contingencies [Line Items]
Number of cases pending			98	102
Subsequent Event [Member] | Other Tabacco-Related Cases [Member]
Loss Contingencies [Line Items]
Loss contingency, number of inactive cases	2	2
Number of cases pending	4	4
Subsequent Event [Member] | Health Care Cost Recovery Actions [Member]
Loss Contingencies [Line Items]
Number of cases pending	0	0
Subsequent Event [Member] | Individual Smoking and Health Cases [Member]
Loss Contingencies [Line Items]
Number of cases pending	109	109
Subsequent Event [Member] | PM USA [Member] | Health Care Cost Recovery Actions [Member] | Canada [Member]
Loss Contingencies [Line Items]
Number of cases pending	10	10
Subsequent Event [Member] | PM USA [Member] | Engle Progeny Cases [Member]
Loss Contingencies [Line Items]
Number of cases set for trial	2	2
Number of verdicts returned	134
Number of favorable verdicts	47
Number of unfavorable verdicts	78
Subsequent Event [Member] | PM USA [Member] | Individual Smoking and Health Cases [Member]
Loss Contingencies [Line Items]
Number of cases set for trial	0	0
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member]
Loss Contingencies [Line Items]
Number of verdicts returned		69
Number of favorable verdicts		44
Number of unfavorable verdicts		25
Number of claims resolved		20
Number of verdicts reversed		1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Alaska [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | California [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		7
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Connecticut [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Florida [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		10
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Louisiana [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Massachusetts [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		4
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Mississippi [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Missouri [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		4
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | New Hampshire [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | New Jersey [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | New York [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		5
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Ohio [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		2
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Pennsylvania [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Rhode Island [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		1
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | Tennessee [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		2
Subsequent Event [Member] | PM USA [Member] | Non Engle Progeny Cases [Member] | West Virginia [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts		2
Subsequent Event [Member] | Philip Morris USA and Altria Group [Member] | Health Care Cost Recovery Actions [Member] | Canada [Member]
Loss Contingencies [Line Items]
Number of cases pending	8	8
Subsequent Event [Member] | Philip Morris USA and Altria Group [Member] | Smoking and Health Class Actions and Aggregated Claims Litigation [Member] | Canada [Member]
Loss Contingencies [Line Items]
Number of cases pending	7	7

Contingencies (Judgments Paid a

Contingencies (Judgments Paid and Provisions for Tobacco and Health Litigation) (Details) $ in Millions	3 Months Ended		186 Months Ended
	Mar. 31, 2020USD ($)case	Mar. 31, 2019USD ($)	Mar. 31, 2020USD ($)case
Loss Contingency Accrual [Roll Forward]
Accrued liability for tobacco and health litigation items at beginning of period	$ 14	$ 112
Payments	(28)	(109)
Accrued liability for tobacco and health litigation items at end of period	10	20	$ 10
Pre-Trial Resolution [Member]
Loss Contingency Accrual [Roll Forward]
Payments	(7)
Accrued liability for tobacco and health litigation items at end of period	2		2
Interest Expense Related to Litigation [Member]
Loss Contingency Accrual [Roll Forward]
Provision related to litigation recorded	2	2
Tobacco and Health Judgment [Member]
Loss Contingencies [Line Items]
Judgments paid (approximately)			748
Litigation settlement interest expense (income)			$ 216
Tobacco and Health Judgment [Member] | Pre-Trial Resolution [Member]
Loss Contingency Accrual [Roll Forward]
Provision related to litigation recorded	$ 7
Loss contingency, number of pre-trial resolution cases | case	100		100
Tobacco and Health Judgment [Member] | Litigation Cases Results [Member]
Loss Contingency Accrual [Roll Forward]
Provision related to litigation recorded	$ 22	$ 15
Engle Progeny Cases [Member]
Loss Contingencies [Line Items]
Judgments paid (approximately)			$ 327
Litigation settlement interest expense (income)			54
Assets [Member] | Pending Litigation [Member] | PM USA [Member]
Loss Contingency Accrual [Roll Forward]
Security posted for appeal of judgments	$ 48		$ 48

Contingencies (Non-Engle Progen

Contingencies (Non-Engle Progeny Litigation) (Details) - USD ($) $ in Millions	Feb. 29, 2020	Sep. 30, 2019	Aug. 31, 2019	Oct. 31, 2017
Non-Engle Progeny Smoking And Health Case, Principe [Member]
Loss Contingencies [Line Items]
Compensatory damages awarded	$ 11
Non-Engle Progeny Smoking and Health Case, Greene [Member]
Loss Contingencies [Line Items]
Compensatory damages awarded		$ 10
Non-Engle Progeny Smoking and Health Case, Laramie [Member]
Loss Contingencies [Line Items]
Compensatory damages awarded			$ 11
Punitive damages awarded			$ 10
Non-Engle Progeny Smoking and Health Case, Gentile [Member]
Loss Contingencies [Line Items]
Compensatory damages awarded				$ 7.1
Non-Engle Progeny Smoking and Health Case, Gentile [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Compensatory damages awarded				$ 5.3
Compensatory damages award, allocation percentage				75.00%

Contingencies (Engle Class Acti

Contingencies (Engle Class Action And Engle Progeny Trial Results) (Details)	Apr. 27, 2020USD ($)caseplantiff	Jul. 31, 2006	Jan. 31, 2008case	Jul. 31, 2000USD ($)
Engle Progeny Cases [Member]
Loss Contingencies [Line Items]
Punitive damages awarded | $				$ 145,000,000,000
Engle Progeny Cases [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Punitive damages awarded | $				$ 74,000,000,000
Period for decertified class members could file individual actions		1 year
Engle Progeny Cases, State [Member]
Loss Contingencies [Line Items]
Number of cases pending			9,300
Subsequent Event [Member] | Engle Progeny Cases [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Number of verdicts returned	134
Number of unfavorable verdicts	78
Number of claims with unfavorable verdicts pending/reversed	4
Number of favorable verdicts	47
Subsequent Event [Member] | Engle Progeny Cases, State [Member]
Loss Contingencies [Line Items]
Number of cases pending	1,500
Number of plaintiffs | plantiff	1,900
Subsequent Event [Member] | Engle Progeny Cases, State [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts	42
Subsequent Event [Member] | Engle Progeny Cases, Federal [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Number of cases pending	4
Subsequent Event [Member] | Engle Progeny Cases, D Cohen, Collar, Chacon [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Number of verdicts reversed	4
Subsequent Event [Member] | Engle Progeny Cases, Reider and Banks [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Zero damages verdicts	2
Damages awarded, value | $	$ 0
Subsequent Event [Member] | Engle Progeny Cases, Weingart and Hancock [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Damages awarded, value | $	$ 0
Zero damages verdict modified	2
Subsequent Event [Member] | Engle Progeny Cases, Pollari [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts	1
Subsequent Event [Member] | Engle Progeny Cases, Gloger, Rintoul and Duignam [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts	3
Subsequent Event [Member] | Engle Progeny Cases, Freeman [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Number of favorable verdicts	1

Contingencies (Engle Progeny Ca

Contingencies (Engle Progeny Cases Trial Results - Pending and Concluded) (Details) - USD ($) $ in Millions

3 Months Ended

6 Months Ended

Mar. 31, 2020

Dec. 31, 2019

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Dec. 31, 2017

Sep. 30, 2018

Feb. 29, 2020

Jan. 31, 2020

Nov. 30, 2019

Feb. 28, 2019

Jul. 31, 2018

Nov. 30, 2017

Apr. 30, 2017

Mar. 31, 2017

Sep. 30, 2015

Jan. 31, 2015

Oct. 31, 2014

Sep. 30, 2014

Jul. 31, 2014

PM USA [Member]

Loss Contingencies [Line Items]

Pre-tax charges (gain) included in net earning

$ 17

Engle Progeny Cases, Berger [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 6

Provision related to litigation recorded

$ 6

Engle Progeny Cases, Berger [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 21

Engle Progeny Cases, Duignan [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 3

Engle Progeny Cases, Duignan [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 12

Engle Progeny Cases, Cuddihee [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 3

Engle Progeny Cases, Cuddihee [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 0

Engle Progeny Cases, Rintoul [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 9

Engle Progeny Cases, Rintoul [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

5

Punitive damages awarded

74

Engle Progeny Cases, Gloger [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

15

Engle Progeny Cases, Gloger [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

5

Punitive damages awarded

$ 11

Engle Progeny Cases, McCall [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 1

Engle Progeny Cases, McCall [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

1

Punitive damages awarded

1

Engle Progeny Cases, Neff [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

4

Punitive damages awarded

2

Engle Progeny Cases, Frogel [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

1

Engle Progeny Cases, Frogel [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

1

Punitive damages awarded

0

Engle Progeny Cases, Mahfuz [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 12

Punitive damages awarded

10

Engle Progeny Cases, Holliman [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

3

Engle Progeny Cases, Holliman [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 0

Engle Progeny Cases, Chadwell [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 2

$ 2

Engle Progeny Cases, Chadwell [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

0

0

Engle Progeny Cases, Kaplan [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 2

Punitive damages awarded

$ 2

Engle Progeny Cases, Landi [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 8

Engle Progeny Cases, Landi [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

5

Engle Progeny Cases, R. Douglas [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 1

Engle Progeny Cases, R. Douglas [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 0

Engle Progeny Cases, Sommers [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 1

Engle Progeny Cases, Sommers [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 0

Engle Progeny Cases, Santoro [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 2

Engle Progeny Cases, Santoro [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 0

Engle Progeny Cases, Cooper [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 5

Engle Progeny Cases, Cooper [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

1

Punitive damages awarded

$ 0

Engle Progeny Cases, D. Brown [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 8

Punitive damages awarded

$ 9

Engle Progeny Cases, Kerrivan [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 16

Engle Progeny Cases, Kerrivan [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Punitive damages awarded

$ 16

Engle Progeny Cases, Harris [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

$ 2

Engle Progeny Cases, Harris [Member] | Pending Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Compensatory damages awarded

1

Punitive damages awarded

$ 0

Engle Progeny Cases, Theis [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

17

Engle Progeny Cases, Alvarez del Real [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

$ 1

Engle Progeny Cases, Zingaro [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

$ 1

Engle Progeny Cases, Bryant [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

$ 1

Engle Progeny Cases, Wallace [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

$ 26

Engle Progeny Cases, J. Brown [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

4

Engle Progeny Cases, L. Martin [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

2

Engle Progeny Cases, Danielson [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

3

Engle Progeny Cases, S. Martin [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

$ 5

Engle Progeny Cases, Searcy [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

$ 2

Engle Progeny Cases, Boatright [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

0

Engle Progeny Cases, M. Brown [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

9

Engle Progeny Cases, M. Brown [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

8

Engle Progeny Cases, Jordan [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

4

Engle Progeny Cases, Jordan [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

$ 11

Engle Progeny Cases, Pardue [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

$ 11

Engle Progeny Cases, McKeever [Member] | Settled Litigation [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

$ 21

Engle Progeny Cases, Naugle [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

8

Engle Progeny Cases, Gore [Member] | PM USA [Member]

Loss Contingencies [Line Items]

Damages awarded, value

$ 2

Contingencies (Florida Bond Sta

Contingencies (Florida Bond Statute) (Details) $ in Millions	Jun. 30, 2009USD ($)
Florida [Member] | Engle Progeny Cases, State [Member]
Loss Contingencies [Line Items]
Maximum bond for all defendants	$ 200

Contingencies (Other Smoking an

Contingencies (Other Smoking and Health Class Actions) (Details) - Smoking and Health Class Actions and Aggregated Claims Litigation [Member] $ in Billions	1 Months Ended	287 Months Ended
	Mar. 31, 2019CAD ($)rulingmanufacture	Mar. 31, 2020case	Apr. 27, 2020case
PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		61
Arkansas [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
California [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Delaware [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
District of Columbia [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		2
Florida [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		2
Illinois [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		3
Iowa [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Kansas [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Louisiana [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Maryland [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Michigan [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Minnesota [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Nevada [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		29
New Jersey [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		6
New York [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		2
Ohio [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Oklahoma [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Oregon [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Pennsylvania [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Puerto Rico [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
South Carolina [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Texas [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Wisconsin [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Class not certified		1
Canada [Member] | Canadian Tobacco Manufacturers [Member]
Loss Contingencies [Line Items]
Number of manufacturers | manufacture	3
Number of verdicts upheld | ruling	2
Amount awarded to other party | $	$ 13
Subsequent Event [Member] | Canada [Member] | Philip Morris USA and Altria Group [Member]
Loss Contingencies [Line Items]
Number of cases pending			7
Subsequent Event [Member] | British Columbia and Saskatchewan [Member] | Philip Morris USA and Altria Group [Member]
Loss Contingencies [Line Items]
Number of cases pending			2

Contingencies (Health Care Cost

Contingencies (Health Care Cost Recovery Litigation) (Details) $ in Millions	1 Months Ended	3 Months Ended
	Nov. 30, 1998USD ($)state	Mar. 31, 2020USD ($)case	Mar. 31, 2019USD ($)manufacture	Apr. 22, 2019case	Apr. 23, 2018case
Health Care Cost Recovery Actions [Member]
Loss Contingencies [Line Items]
Number of cases pending | case				1	1
Number of states with settled litigation | state	46
State settlement agreements annual payments	$ 9,400
State settlement agreements attorney fees annual cap	$ 500
Litigation settlement		$ 1,100	$ 900
Threatened Litigation [Member] | Canada [Member] | Health Care Cost Recovery Actions [Member]
Loss Contingencies [Line Items]
Number of cases pending | case		10
Canadian Tobacco Manufacturers [Member] | Canada [Member] | Smoking and Health Class Actions and Aggregated Claims Litigation [Member]
Loss Contingencies [Line Items]
Number of manufacturers | manufacture			3

Contingencies (NPM Adjustment D

Contingencies (NPM Adjustment Disputes - Settlement with 20 States and Territories and Settlement with New York) (Details) $ in Millions	1 Months Ended						3 Months Ended			12 Months Ended
	Apr. 30, 2020USD ($)	Apr. 30, 2019USD ($)	Apr. 30, 2018USD ($)	Oct. 31, 2017USD ($)state	Sep. 30, 2013USD ($)state	Nov. 30, 1998state	Mar. 31, 2020USD ($)stateclaim	Mar. 31, 2019USD ($)	Mar. 31, 2018state	Dec. 31, 2018USD ($)settlement_development	Dec. 31, 2017USD ($)
Health Care Cost Recovery Actions [Member]
Loss Contingencies [Line Items]
Number of states with settled litigation | state						46
PM USA [Member] | Health Care Cost Recovery Actions [Member]
Loss Contingencies [Line Items]
Loss contingency, reduction to cost of sales								$ 52		$ 209	$ 39
Loss contingency, credits to offset payments							$ 43
Loss contingency, settlement agreement, payment period							9 years
PM USA [Member] | Health Care Cost Recovery Actions [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Loss contingency, number of states with settled litigation including New York, subsequent expansion | state							36
Settlement agreements, number | claim							2
Number of states with settled litigation | state							37
PM USA [Member] | Health Care Cost Recovery Actions, 2003-2015 NPM Adjustments [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Loss contingency, number of states with settled litigation including New York, subsequent expansion | state				26
​Proceeds from legal settlements				$ 740
Loss contingency, number of settlement developments | settlement_development										2
PM USA [Member] | Health Care Cost Recovery Actions, 2004-2017 [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Loss contingency, number of additional states added | state							10		10
Loss contingency, number of additional states extended with settled litigation | state							9
Payments received from litigation settlement		$ 121	$ 68							$ 248
PM USA [Member] | Health Care Cost Recovery Actions, 2003 NPM Adjustment [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Number of states with settled litigation | state					2
PM USA [Member] | Health Care Cost Recovery Actions, 2003 NPM Adjustment [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Loss contingency, number of states | state					15
Number of states without defense | state					6
Loss contingency, number of disputes outstanding | state					2
PM USA [Member] | Health Care Cost Recovery Actions, 2003 NPM Adjustment [Member] | Pending Litigation [Member] | Cost of Sales [Member]
Loss Contingencies [Line Items]
Loss contingency, reduction to cost of sales					$ 74
PM USA [Member] | Health Care Cost Recovery Actions, 2004 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain							$ 388
PM USA [Member] | Health Care Cost Recovery Actions, 2005 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain							181
PM USA [Member] | Health Care Cost Recovery Actions, 2006 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain							154
PM USA [Member] | Health Care Cost Recovery Actions, 2007 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain							185
PM USA [Member] | Health Care Cost Recovery Actions, 2008 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain							250
PM USA [Member] | Health Care Cost Recovery Actions, 2009 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain							211
PM USA [Member] | Health Care Cost Recovery Actions, 2010 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain							218
PM USA [Member] | Health Care Cost Recovery Actions, 2011 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain							166
PM USA [Member] | Health Care Cost Recovery Actions, 2012 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain							214
PM USA [Member] | Health Care Cost Recovery Actions, 2013 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain							224
PM USA [Member] | Health Care Cost Recovery Actions, 2014 NPM Adjustment [Member]
Loss Contingencies [Line Items]
Estimate of possible gain							258
PM USA [Member] | Health Care Cost Recovery Actions, 2015 NPM Adjustments [Member]
Loss Contingencies [Line Items]
Estimate of possible gain							313
PM USA [Member] | Health Care Cost Recovery Actions, 2016 NPM Adjustments [Member]
Loss Contingencies [Line Items]
Estimate of possible gain							305
PM USA [Member] | Health Care Cost Recovery Actions, 2017 NPM Adjustments [Member]
Loss Contingencies [Line Items]
Estimate of possible gain							297
PM USA [Member] | Health Care Cost Recovery Actions, 2018 NPM Adjustments [Member]
Loss Contingencies [Line Items]
Estimate of possible gain							340
PM USA [Member] | Health Care Cost Recovery Actions, 2019 NPM Adjustments [Member]
Loss Contingencies [Line Items]
Estimate of possible gain							441
New York [Member] | PM USA [Member] | Health Care Cost Recovery Actions, Transition Years 2004-2017 [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
​Proceeds from legal settlements							$ 317
Maryland, Missouri, New Mexico and Pennsylvania [Member] | PM USA [Member] | Health Care Cost Recovery Actions, 2003 NPM Adjustment [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Loss contingency, number of states remaining | state					4
Subsequent Event [Member] | PM USA [Member] | Health Care Cost Recovery Actions, 2004-2017 [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Payments received from litigation settlement	$ 47

Contingencies (Other Disputes U

Contingencies (Other Disputes Under the State Settlement Agreements) (Details) $ in Millions	1 Months Ended
	Aug. 31, 2018USD ($)
PM USA [Member] | Other Disputes Under the State Settlement Agreements [Member]
Loss Contingencies [Line Items]
Amount ordered to be paid from other party	$ 9.8

Contingencies (Federal Governme

Contingencies (Federal Government's Lawsuit) (Details) - Federal Governments Lawsuit [Member] - USD ($) $ in Millions	1 Months Ended	3 Months Ended	12 Months Ended
	Aug. 31, 2006	Dec. 31, 2019	Dec. 31, 2014
Loss Contingencies [Line Items]
Disclosure period	10 years
Implementation of Corrective Communications [Member]
Loss Contingencies [Line Items]
Provision related to litigation recorded		$ 5	$ 31

Contingencies (E-vapor Product

Contingencies (E-vapor Product Litigation) (Details) - E-vapor Litigation [Member]	Apr. 27, 2020caseclaim	Apr. 22, 2019case	Apr. 23, 2018case
Loss Contingencies [Line Items]
Number of cases pending | case		2	3
Subsequent Event [Member]
Loss Contingencies [Line Items]
Number of cases pending | case	202
Number of cases set for trial | claim	0
Pending Individual Lawsuits [Member] | Subsequent Event [Member]
Loss Contingencies [Line Items]
Number of cases pending | claim	170

Contingencies (Lights_Ultra Lig

Contingencies (Lights/Ultra Lights Cases) (Details) - Subsequent Event [Member]	Apr. 27, 2020casecourt
Lights Ultra Lights Class Actions [Member]
Loss Contingencies [Line Items]
Number of cases pending | case	2
Lights [Member]
Loss Contingencies [Line Items]
Claims not certified, number | case	23
Number of cases pending | court	2
Lights [Member] | PM USA [Member]
Loss Contingencies [Line Items]
Number of state courts | court	21

Contingencies (UST Litigations

Contingencies (UST Litigations Narrative) (Details)	3 Months Ended
	Dec. 31, 2019shareholder	Apr. 27, 2020claim
Loss Contingencies [Line Items]
Loss contingency, number of shareholders filing class action lawsuits | shareholder	2
Pending Individual Lawsuits [Member] | Subsequent Event [Member] | UST Litigation [Member]
Loss Contingencies [Line Items]
Claims filed, number | claim		1

Contingencies (Antitrust Litiga

Contingencies (Antitrust Litigation) (Details) - lawsuit	Apr. 30, 2020	Mar. 31, 2020	Dec. 31, 2019
JUUL [Member]
Loss Contingencies [Line Items]
Equity securities, ownership percentage		35.00%	35.00%
Subsequent Event [Member]
Loss Contingencies [Line Items]
Loss contingency, class action lawsuit	3

Contingencies (Guarantees and O

Contingencies (Guarantees and Other Similar Matters Narrative) (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Loss Contingencies [Line Items]
Contingent liability related to performance surety bonds	$ 27,000,000
Redeemable noncontrolling interest	38,000,000	$ 38,000,000
Letter of Credit [Member]
Loss Contingencies [Line Items]
Credit line available under the agreement	50,000,000
Revolving Credit Facility [Member] | Credit Agreement [Member]
Loss Contingencies [Line Items]
Credit line available under the agreement	$ 3,000,000,000

Condensed Consolidating Finan_3

Condensed Consolidating Financial Information (Condensed Consolidating Balance Sheets) (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018
Assets
Cash and cash equivalents	$ 5,616,000,000	$ 2,117,000,000
Receivables	147,000,000	152,000,000
Inventories:
Leaf tobacco	895,000,000	874,000,000
Other raw materials	193,000,000	192,000,000
Work in process	467,000,000	696,000,000
Finished product	451,000,000	531,000,000
Inventory, net	2,006,000,000	2,293,000,000
Due from Altria Group, Inc. and subsidiaries	0	0
Other current assets	166,000,000	262,000,000
Total current assets	7,935,000,000	4,824,000,000
Property, plant and equipment, at cost	5,103,000,000	5,074,000,000
Less accumulated depreciation	3,106,000,000	3,075,000,000
Property, plant and equipment, net	1,997,000,000	1,999,000,000
Goodwill	5,177,000,000	5,177,000,000
Other intangible assets, net	12,668,000,000	12,687,000,000
Investments in equity securities	23,861,000,000	23,581,000,000
Investment in consolidated subsidiaries	0	0
Due from Altria Group, Inc. and subsidiaries	0	0
Other assets	980,000,000	1,003,000,000
Total Assets	52,618,000,000	49,271,000,000
Liabilities
Short-term borrowings	3,000,000,000	0
Current portion of long-term debt	0	1,000,000,000
Accounts payable	278,000,000	325,000,000
Accrued liabilities:
Marketing	467,000,000	393,000,000
Settlement charges	4,419,000,000	3,346,000,000
Other	1,032,000,000	1,533,000,000
Income taxes	393,000,000	12,000,000
Dividends payable	1,565,000,000	1,565,000,000
Due to Altria Group, Inc. and subsidiaries	0	0
Total current liabilities	11,154,000,000	8,174,000,000
Long-term debt	26,971,000,000	27,042,000,000
Deferred income taxes	5,191,000,000	5,083,000,000
Accrued pension costs	427,000,000	473,000,000
Accrued postretirement health care costs	1,798,000,000	1,797,000,000
Due to Altria Group, Inc. and subsidiaries	0	0
Other liabilities	402,000,000	345,000,000
Total liabilities	45,943,000,000	42,914,000,000
Contingencies
Redeemable noncontrolling interest	38,000,000	38,000,000
Stockholders’ Equity
Common stock	935,000,000	935,000,000
Additional paid-in capital	5,959,000,000	5,970,000,000
Earnings reinvested in the business	36,528,000,000	36,539,000,000
Accumulated other comprehensive losses	(2,533,000,000)	(2,864,000,000)
Cost of repurchased stock	(34,346,000,000)	(34,358,000,000)
Total stockholders’ equity attributable to Altria	6,543,000,000	6,222,000,000
Noncontrolling interests	94,000,000	97,000,000
Total stockholders’ equity	6,637,000,000	6,319,000,000	$ 14,081,000,000	$ 14,789,000,000
Total Liabilities and Stockholders’ Equity	52,618,000,000	49,271,000,000
Reportable Legal Entities [Member] | Altria Group, Inc. [Member]
Assets
Cash and cash equivalents	5,548,000,000	2,022,000,000
Receivables	0	0
Inventories:
Leaf tobacco	0	0
Other raw materials	0	0
Work in process	0	0
Finished product	0	0
Inventory, net	0	0
Due from Altria Group, Inc. and subsidiaries	91,000,000	88,000,000
Other current assets	301,000,000	133,000,000
Total current assets	5,940,000,000	2,243,000,000
Property, plant and equipment, at cost	0	0
Less accumulated depreciation	0	0
Property, plant and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Investments in equity securities	18,453,000,000	18,071,000,000
Investment in consolidated subsidiaries	18,905,000,000	19,312,000,000
Due from Altria Group, Inc. and subsidiaries	4,790,000,000	4,790,000,000
Other assets	71,000,000	58,000,000
Total Assets	48,159,000,000	44,474,000,000
Liabilities
Short-term borrowings	3,000,000,000
Current portion of long-term debt		1,000,000,000
Accounts payable	1,000,000	0
Accrued liabilities:
Marketing	0	0
Settlement charges	0	0
Other	312,000,000	570,000,000
Income taxes	6,000,000	6,000,000
Dividends payable	1,565,000,000	1,565,000,000
Due to Altria Group, Inc. and subsidiaries	6,278,000,000	4,693,000,000
Total current liabilities	11,162,000,000	7,834,000,000
Long-term debt	26,971,000,000	27,042,000,000
Deferred income taxes	3,228,000,000	3,099,000,000
Accrued pension costs	196,000,000	197,000,000
Accrued postretirement health care costs	0	0
Due to Altria Group, Inc. and subsidiaries	0	0
Other liabilities	59,000,000	80,000,000
Total liabilities	41,616,000,000	38,252,000,000
Contingencies
Redeemable noncontrolling interest	0	0
Stockholders’ Equity
Common stock	935,000,000	935,000,000
Additional paid-in capital	5,959,000,000	5,970,000,000
Earnings reinvested in the business	36,528,000,000	36,539,000,000
Accumulated other comprehensive losses	(2,533,000,000)	(2,864,000,000)
Cost of repurchased stock	(34,346,000,000)	(34,358,000,000)
Total stockholders’ equity attributable to Altria	6,543,000,000	6,222,000,000
Noncontrolling interests	0	0
Total stockholders’ equity	6,543,000,000	6,222,000,000
Total Liabilities and Stockholders’ Equity	48,159,000,000	44,474,000,000
Reportable Legal Entities [Member] | PM USA [Member]
Assets
Cash and cash equivalents	1,000,000	0
Receivables	17,000,000	30,000,000
Inventories:
Leaf tobacco	508,000,000	494,000,000
Other raw materials	123,000,000	120,000,000
Work in process	6,000,000	4,000,000
Finished product	87,000,000	119,000,000
Inventory, net	724,000,000	737,000,000
Due from Altria Group, Inc. and subsidiaries	5,660,000,000	4,005,000,000
Other current assets	23,000,000	64,000,000
Total current assets	6,425,000,000	4,836,000,000
Property, plant and equipment, at cost	2,970,000,000	2,956,000,000
Less accumulated depreciation	2,186,000,000	2,166,000,000
Property, plant and equipment, net	784,000,000	790,000,000
Goodwill	0	0
Other intangible assets, net	2,000,000	2,000,000
Investments in equity securities	0	0
Investment in consolidated subsidiaries	2,867,000,000	2,831,000,000
Due from Altria Group, Inc. and subsidiaries	0	0
Other assets	950,000,000	951,000,000
Total Assets	11,028,000,000	9,410,000,000
Liabilities
Short-term borrowings	0
Current portion of long-term debt		0
Accounts payable	136,000,000	146,000,000
Accrued liabilities:
Marketing	391,000,000	320,000,000
Settlement charges	4,410,000,000	3,340,000,000
Other	343,000,000	482,000,000
Income taxes	508,000,000	0
Dividends payable	0	0
Due to Altria Group, Inc. and subsidiaries	587,000,000	514,000,000
Total current liabilities	6,375,000,000	4,802,000,000
Long-term debt	0	0
Deferred income taxes	0	0
Accrued pension costs	0	0
Accrued postretirement health care costs	1,076,000,000	1,078,000,000
Due to Altria Group, Inc. and subsidiaries	0	0
Other liabilities	90,000,000	87,000,000
Total liabilities	7,541,000,000	5,967,000,000
Contingencies
Redeemable noncontrolling interest	0	0
Stockholders’ Equity
Common stock	0	0
Additional paid-in capital	3,310,000,000	3,310,000,000
Earnings reinvested in the business	393,000,000	352,000,000
Accumulated other comprehensive losses	(216,000,000)	(219,000,000)
Cost of repurchased stock	0	0
Total stockholders’ equity attributable to Altria	3,487,000,000	3,443,000,000
Noncontrolling interests	0	0
Total stockholders’ equity	3,487,000,000	3,443,000,000
Total Liabilities and Stockholders’ Equity	11,028,000,000	9,410,000,000
Reportable Legal Entities [Member] | Non-Guarantor Subsidiaries [Member]
Assets
Cash and cash equivalents	67,000,000	95,000,000
Receivables	130,000,000	122,000,000
Inventories:
Leaf tobacco	387,000,000	380,000,000
Other raw materials	70,000,000	72,000,000
Work in process	461,000,000	692,000,000
Finished product	364,000,000	412,000,000
Inventory, net	1,282,000,000	1,556,000,000
Due from Altria Group, Inc. and subsidiaries	1,361,000,000	1,359,000,000
Other current assets	68,000,000	114,000,000
Total current assets	2,908,000,000	3,246,000,000
Property, plant and equipment, at cost	2,133,000,000	2,118,000,000
Less accumulated depreciation	920,000,000	909,000,000
Property, plant and equipment, net	1,213,000,000	1,209,000,000
Goodwill	5,177,000,000	5,177,000,000
Other intangible assets, net	12,666,000,000	12,685,000,000
Investments in equity securities	5,408,000,000	5,510,000,000
Investment in consolidated subsidiaries	0	0
Due from Altria Group, Inc. and subsidiaries	0	0
Other assets	567,000,000	603,000,000
Total Assets	27,939,000,000	28,430,000,000
Liabilities
Short-term borrowings	0
Current portion of long-term debt		0
Accounts payable	141,000,000	179,000,000
Accrued liabilities:
Marketing	76,000,000	73,000,000
Settlement charges	9,000,000	6,000,000
Other	377,000,000	481,000,000
Income taxes	105,000,000	55,000,000
Dividends payable	0	0
Due to Altria Group, Inc. and subsidiaries	247,000,000	245,000,000
Total current liabilities	955,000,000	1,039,000,000
Long-term debt	0	0
Deferred income taxes	2,571,000,000	2,593,000,000
Accrued pension costs	231,000,000	276,000,000
Accrued postretirement health care costs	722,000,000	719,000,000
Due to Altria Group, Inc. and subsidiaries	4,790,000,000	4,790,000,000
Other liabilities	253,000,000	178,000,000
Total liabilities	9,522,000,000	9,595,000,000
Contingencies
Redeemable noncontrolling interest	38,000,000	38,000,000
Stockholders’ Equity
Common stock	9,000,000	9,000,000
Additional paid-in capital	27,566,000,000	27,565,000,000
Earnings reinvested in the business	(7,441,000,000)	(6,997,000,000)
Accumulated other comprehensive losses	(1,849,000,000)	(1,877,000,000)
Cost of repurchased stock	0	0
Total stockholders’ equity attributable to Altria	18,285,000,000	18,700,000,000
Noncontrolling interests	94,000,000	97,000,000
Total stockholders’ equity	18,379,000,000	18,797,000,000
Total Liabilities and Stockholders’ Equity	27,939,000,000	28,430,000,000
Total Consolidating Adjustments [Member]
Assets
Cash and cash equivalents	0	0
Receivables	0	0
Inventories:
Leaf tobacco	0	0
Other raw materials	0	0
Work in process	0	0
Finished product	0	0
Inventory, net	0	0
Due from Altria Group, Inc. and subsidiaries	(7,112,000,000)	(5,452,000,000)
Other current assets	(226,000,000)	(49,000,000)
Total current assets	(7,338,000,000)	(5,501,000,000)
Property, plant and equipment, at cost	0	0
Less accumulated depreciation	0	0
Property, plant and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Investments in equity securities	0	0
Investment in consolidated subsidiaries	(21,772,000,000)	(22,143,000,000)
Due from Altria Group, Inc. and subsidiaries	(4,790,000,000)	(4,790,000,000)
Other assets	(608,000,000)	(609,000,000)
Total Assets	(34,508,000,000)	(33,043,000,000)
Liabilities
Short-term borrowings	0
Current portion of long-term debt		0
Accounts payable	0	0
Accrued liabilities:
Marketing	0	0
Settlement charges	0	0
Other	0	0
Income taxes	(226,000,000)	(49,000,000)
Dividends payable	0	0
Due to Altria Group, Inc. and subsidiaries	(7,112,000,000)	(5,452,000,000)
Total current liabilities	(7,338,000,000)	(5,501,000,000)
Long-term debt	0	0
Deferred income taxes	(608,000,000)	(609,000,000)
Accrued pension costs	0	0
Accrued postretirement health care costs	0	0
Due to Altria Group, Inc. and subsidiaries	(4,790,000,000)	(4,790,000,000)
Other liabilities	0	0
Total liabilities	(12,736,000,000)	(10,900,000,000)
Contingencies
Redeemable noncontrolling interest	0	0
Stockholders’ Equity
Common stock	(9,000,000)	(9,000,000)
Additional paid-in capital	(30,876,000,000)	(30,875,000,000)
Earnings reinvested in the business	7,048,000,000	6,645,000,000
Accumulated other comprehensive losses	2,065,000,000	2,096,000,000
Cost of repurchased stock	0	0
Total stockholders’ equity attributable to Altria	(21,772,000,000)	(22,143,000,000)
Noncontrolling interests	0	0
Total stockholders’ equity	(21,772,000,000)	(22,143,000,000)
Total Liabilities and Stockholders’ Equity	$ (34,508,000,000)	$ (33,043,000,000)

Condensed Consolidating Finan_4

Condensed Consolidating Financial Information (Condensed Consolidating Statements of Earnings and Comprehensive Earnings) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Condensed Income Statements, Captions [Line Items]
Net revenues	$ 6,359	$ 5,628
Cost of sales	2,173	1,578
Excise taxes on products	1,313	1,239
Gross profit	2,873	2,811
Marketing, administration and research costs	537	533
Asset impairment and exit costs	0	40
Operating income (expense)	2,336	2,238
Interest and other debt expense (income), net	275	384
Net periodic benefit (income) cost, excluding service cost	(27)	(1)
Earnings from equity investments	(157)	(86)
Loss on Cronos-related financial instruments	137	425
Earnings (losses) before income taxes and equity earnings of subsidiaries	2,108	1,516
Provision (benefit) for income taxes	558	395
Equity earnings of subsidiaries	0	0
Net earnings	1,550	1,121
Net (earnings) losses attributable to noncontrolling interests	2	(1)
Net earnings attributable to Altria	1,552	1,120
Net earnings	1,550	1,121
Other comprehensive earnings (losses), net of deferred income taxes	331	(170)
Comprehensive earnings	1,881	951
Comprehensive earnings attributable to noncontrolling interests	2	(1)
Comprehensive earnings attributable to Altria	1,883	950
Reportable Legal Entities [Member] | Altria Group, Inc. [Member]
Condensed Income Statements, Captions [Line Items]
Net revenues	0	0
Cost of sales	0	0
Excise taxes on products	0	0
Gross profit	0	0
Marketing, administration and research costs	22	35
Asset impairment and exit costs		1
Operating income (expense)	(22)	(36)
Interest and other debt expense (income), net	237	355
Net periodic benefit (income) cost, excluding service cost	0	1
Earnings from equity investments	(134)	(86)
Loss on Cronos-related financial instruments	0	0
Earnings (losses) before income taxes and equity earnings of subsidiaries	(125)	(306)
Provision (benefit) for income taxes	(32)	(75)
Equity earnings of subsidiaries	1,645	1,351
Net earnings	1,552	1,120
Net (earnings) losses attributable to noncontrolling interests	0	0
Net earnings attributable to Altria	1,552	1,120
Net earnings	1,552	1,120
Other comprehensive earnings (losses), net of deferred income taxes	331	(170)
Comprehensive earnings	1,883	950
Comprehensive earnings attributable to noncontrolling interests	0	0
Comprehensive earnings attributable to Altria	1,883	950
Reportable Legal Entities [Member] | PM USA [Member]
Condensed Income Statements, Captions [Line Items]
Net revenues	5,359	4,725
Cost of sales	1,532	1,340
Excise taxes on products	1,267	1,185
Gross profit	2,560	2,200
Marketing, administration and research costs	387	384
Asset impairment and exit costs		35
Operating income (expense)	2,173	1,781
Interest and other debt expense (income), net	(18)	(25)
Net periodic benefit (income) cost, excluding service cost	(22)	0
Earnings from equity investments	0	0
Loss on Cronos-related financial instruments	0	0
Earnings (losses) before income taxes and equity earnings of subsidiaries	2,213	1,806
Provision (benefit) for income taxes	550	459
Equity earnings of subsidiaries	126	95
Net earnings	1,789	1,442
Net (earnings) losses attributable to noncontrolling interests	0	0
Net earnings attributable to Altria	1,789	1,442
Net earnings	1,789	1,442
Other comprehensive earnings (losses), net of deferred income taxes	3	5
Comprehensive earnings	1,792	1,447
Comprehensive earnings attributable to noncontrolling interests	0	0
Comprehensive earnings attributable to Altria	1,792	1,447
Reportable Legal Entities [Member] | Non-Guarantor Subsidiaries [Member]
Condensed Income Statements, Captions [Line Items]
Net revenues	1,008	913
Cost of sales	649	248
Excise taxes on products	46	54
Gross profit	313	611
Marketing, administration and research costs	128	114
Asset impairment and exit costs		4
Operating income (expense)	185	493
Interest and other debt expense (income), net	56	54
Net periodic benefit (income) cost, excluding service cost	(5)	(2)
Earnings from equity investments	(23)	0
Loss on Cronos-related financial instruments	137	425
Earnings (losses) before income taxes and equity earnings of subsidiaries	20	16
Provision (benefit) for income taxes	40	11
Equity earnings of subsidiaries	0	0
Net earnings	(20)	5
Net (earnings) losses attributable to noncontrolling interests	2	(1)
Net earnings attributable to Altria	(18)	4
Net earnings	(20)	5
Other comprehensive earnings (losses), net of deferred income taxes	28	23
Comprehensive earnings	8	28
Comprehensive earnings attributable to noncontrolling interests	2	(1)
Comprehensive earnings attributable to Altria	10	27
Total Consolidating Adjustments [Member]
Condensed Income Statements, Captions [Line Items]
Net revenues	(8)	(10)
Cost of sales	(8)	(10)
Excise taxes on products	0	0
Gross profit	0	0
Marketing, administration and research costs	0	0
Asset impairment and exit costs		0
Operating income (expense)	0	0
Interest and other debt expense (income), net	0	0
Net periodic benefit (income) cost, excluding service cost	0	0
Earnings from equity investments	0	0
Loss on Cronos-related financial instruments	0	0
Earnings (losses) before income taxes and equity earnings of subsidiaries	0	0
Provision (benefit) for income taxes	0	0
Equity earnings of subsidiaries	(1,771)	(1,446)
Net earnings	(1,771)	(1,446)
Net (earnings) losses attributable to noncontrolling interests	0	0
Net earnings attributable to Altria	(1,771)	(1,446)
Net earnings	(1,771)	(1,446)
Other comprehensive earnings (losses), net of deferred income taxes	(31)	(28)
Comprehensive earnings	(1,802)	(1,474)
Comprehensive earnings attributable to noncontrolling interests	0	0
Comprehensive earnings attributable to Altria	$ (1,802)	$ (1,474)

Condensed Consolidating Finan_5

Condensed Consolidating Financial Information (Condensed Consolidating Statements of Cash Flows) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash Provided by (Used In) Operating Activities
Net cash provided by (used in) operating activities	$ 3,129	$ 2,289
Cash Provided by (Used in) Investing Activities
Capital expenditures	(52)	(38)
Investment in Cronos	0	(1,831)
Investment in consolidated subsidiaries	0	0
Other, net	0	(81)
Net cash provided by (used in) investing activities	(52)	(1,950)
Cash Provided by (Used in) Financing Activities
Proceeds from short-term borrowings	3,000	0
Repayment of short-term borrowings	0	(12,800)
Long-term debt issued	0	16,265
Long-term debt repaid	(1,000)	0
Repurchases of common stock	0	(151)
Dividends paid on common stock	(1,563)	(1,502)
Changes in amounts due to/from Altria Group, Inc. and subsidiaries	0	0
Cash dividends paid to parent	0	0
Other, net	(10)	(129)
Net cash provided by (used in) financing activities	427	1,683
Cash, cash equivalents and restricted cash:
Increase (decrease)	3,504	2,022
Balance at beginning of period	2,160	1,433
Balance at end of period	5,664	3,455
Reportable Legal Entities [Member] | Altria Group, Inc. [Member]
Cash Provided by (Used In) Operating Activities
Net cash provided by (used in) operating activities	1,515	1,642
Cash Provided by (Used in) Investing Activities
Capital expenditures	0	0
Investment in Cronos		0
Investment in consolidated subsidiaries	(1)	(1,947)
Other, net	0	(3)
Net cash provided by (used in) investing activities	(1)	(1,950)
Cash Provided by (Used in) Financing Activities
Proceeds from short-term borrowings	3,000
Repayment of short-term borrowings		(12,800)
Long-term debt issued		16,265
Long-term debt repaid	(1,000)
Repurchases of common stock		(151)
Dividends paid on common stock	(1,563)	(1,502)
Changes in amounts due to/from Altria Group, Inc. and subsidiaries	1,584	657
Cash dividends paid to parent	0	0
Other, net	(9)	(120)
Net cash provided by (used in) financing activities	2,012	2,349
Cash, cash equivalents and restricted cash:
Increase (decrease)	3,526	2,041
Balance at beginning of period	2,022	1,277
Balance at end of period	5,548	3,318
Reportable Legal Entities [Member] | PM USA [Member]
Cash Provided by (Used In) Operating Activities
Net cash provided by (used in) operating activities	3,351	2,520
Cash Provided by (Used in) Investing Activities
Capital expenditures	(15)	(9)
Investment in Cronos		0
Investment in consolidated subsidiaries	0	0
Other, net	0	0
Net cash provided by (used in) investing activities	(15)	(9)
Cash Provided by (Used in) Financing Activities
Proceeds from short-term borrowings	0
Repayment of short-term borrowings		0
Long-term debt issued		0
Long-term debt repaid	0
Repurchases of common stock		0
Dividends paid on common stock	0	0
Changes in amounts due to/from Altria Group, Inc. and subsidiaries	(1,582)	(771)
Cash dividends paid to parent	(1,748)	(1,737)
Other, net	0	0
Net cash provided by (used in) financing activities	(3,330)	(2,508)
Cash, cash equivalents and restricted cash:
Increase (decrease)	6	3
Balance at beginning of period	43	100
Balance at end of period	49	103
Reportable Legal Entities [Member] | Non-Guarantor Subsidiaries [Member]
Cash Provided by (Used In) Operating Activities
Net cash provided by (used in) operating activities	437	166
Cash Provided by (Used in) Investing Activities
Capital expenditures	(37)	(29)
Investment in Cronos		(1,831)
Investment in consolidated subsidiaries	0	0
Other, net	0	(78)
Net cash provided by (used in) investing activities	(37)	(1,938)
Cash Provided by (Used in) Financing Activities
Proceeds from short-term borrowings	0
Repayment of short-term borrowings		0
Long-term debt issued		0
Long-term debt repaid	0
Repurchases of common stock		0
Dividends paid on common stock	0	0
Changes in amounts due to/from Altria Group, Inc. and subsidiaries	(1)	2,061
Cash dividends paid to parent	(426)	(302)
Other, net	(1)	(9)
Net cash provided by (used in) financing activities	(428)	1,750
Cash, cash equivalents and restricted cash:
Increase (decrease)	(28)	(22)
Balance at beginning of period	95	56
Balance at end of period	67	34
Total Consolidating Adjustments [Member]
Cash Provided by (Used In) Operating Activities
Net cash provided by (used in) operating activities	(2,174)	(2,039)
Cash Provided by (Used in) Investing Activities
Capital expenditures	0	0
Investment in Cronos		0
Investment in consolidated subsidiaries	1	1,947
Other, net	0	0
Net cash provided by (used in) investing activities	1	1,947
Cash Provided by (Used in) Financing Activities
Proceeds from short-term borrowings	0
Repayment of short-term borrowings		0
Long-term debt issued		0
Long-term debt repaid	0
Repurchases of common stock		0
Dividends paid on common stock	0	0
Changes in amounts due to/from Altria Group, Inc. and subsidiaries	(1)	(1,947)
Cash dividends paid to parent	2,174	2,039
Other, net	0	0
Net cash provided by (used in) financing activities	2,173	92
Cash, cash equivalents and restricted cash:
Increase (decrease)	0	0
Balance at beginning of period	0	0
Balance at end of period	$ 0	$ 0

Uncategorized Items - a2020form

Label	Element	Value	[1]
Restricted Cash, Noncurrent	us-gaap_RestrictedCashNoncurrent	$ 45,000,000
Restricted Cash, Noncurrent	us-gaap_RestrictedCashNoncurrent	43,000,000
Restricted Cash, Current	us-gaap_RestrictedCashCurrent	3,000,000
Restricted Cash, Current	us-gaap_RestrictedCashCurrent	$ 0
[1]	Restricted cash consisted of cash deposits collateralizing appeal bonds posted by PM USA to obtain stays of judgments pending appeals. See Note 11 . Contingencies .